Anti-SARS-CoV-2 Antigen Antibodies and Related Compositions and Methods
Patent Information
- Application Number
- JP2023526126
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-05-18
- Filing Date
- 2021-10-29
- Publication Date
- 2024-11-05
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
There is a need for effective treatments for the prevention and treatment of SARS-CoV-2 infection and COVID-19, as current therapies like remdesivir have shown limited efficacy in clinical trials.
Development of antibodies that specifically bind to SARS-CoV-2 antigens, including nucleic acids encoding variable chain polypeptides of these antibodies, and their use in pharmaceutical compositions for therapeutic administration.
The antibodies demonstrate strong binding and neutralization capabilities against SARS-CoV-2, including resistance to viral variants, and when administered, prevent significant weight loss and reduce viral RNA copies in infected individuals.
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
Technical field
[0001] (Cross reference to related applications) This application is filed in U.S. Provisional Patent Application No. 63 / 190,097, filed on May 18, 2021, and U.S. Provisional Patent Application No. 63 / 112,096, filed on November 10, 2020. U.S. Provisional Patent Application No. 63 / 108,791, filed on October 30, 2020, and U.S. Provisional Patent Application No. 63 / 108,158, filed on October 30, 2020. Incorporated herein by reference in its entirety.
[0002] Introduction Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), a new coronavirus, is the cause of the respiratory disease designated as novel coronavirus infection or COVID-19 in 2019. It was first identified in December. COVID-19, a new clinical syndrome, is a respiratory syndrome with varying degrees of severity, ranging from mild upper respiratory tract disease to severe interstitial pneumonia and acute respiratory distress syndrome, exacerbated by thrombosis in the pulmonary microcirculation. characterized by Its clinical evolution is characterized by three major stages: the initial infection stage, the pulmonary disease stage, and the hyperinflammatory stage, with clinical features ranging from mild or asymptomatic to acute respiratory distress syndrome and multiple organ failure. .
[0003] SARS-CoV-2 is a positive-sense single-stranded RNA virus that belongs to the β-coronavirus family, along with SARS and MERS. The SARS-CoV-2 genome contains five genes encoding four structural proteins - spike (S), envelope (E), membrane (M), and nucleocapsid (N) - and 16 nonstructural proteins. . Viral entry into human cells is mediated by the interaction between the S-glycoprotein and the Angiotensin-Converting Enzyme 2 (ACE2) receptor. ACE2 is a metalloprotease that lowers blood pressure by catalyzing the hydrolysis of angiotensin II. ACE2 enzyme activity is not associated with or required for SARS-CoV-2 entry into host cells.
[0004] Several investigational drugs and drugs approved for other indications are currently being evaluated in clinical trials for the treatment of COVID-19 and related complications. Data from randomized controlled trials, prospective and retrospective observational cohorts, and case series studies are rapidly emerging. Remdesivir (GS-5734), an inhibitor of viral RNA-dependent RNA polymerase, has in vitro inhibitory activity against SARS-CoV-1 and Middle East respiratory syndrome (MERS-CoV). -It was early identified as a promising treatment candidate for COVID-19 due to its ability to inhibit CoV-2. The U.S. Food and Drug Administration (FDA) recently approved remdesivir for the treatment of COVID-19 patients who require hospitalization. However, in a study of more than 11,000 people in 30 countries sponsored by the World Health Organization, remdesivir was shown to be effective against hospitalized COVID-19 patients, as shown by overall mortality, initiation of mechanical ventilation, and length of hospital stay. It was found to have little or no effect. Therefore, there remains a need for effective treatments for the prevention and treatment of SARS-CoV-2 infection and COVID-19. [Summary of the invention]
[0005] Antibodies that specifically bind to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigens are provided. Nucleic acids encoding one or both of the variable chain polypeptides of the antibodies of the present disclosure are also provided, and cells containing such nucleic acids are also provided. In some cases, compositions comprising antibodies of the present disclosure are also provided, including pharmaceutical compositions. Also provided are methods of making and using the antibodies of the disclosure. In certain embodiments, methods are provided that include administering to an individual in need thereof a therapeutically effective amount of an antibody of the present disclosure. [Brief explanation of drawings]
[0006]
Figure 1
[0007] Before describing the antibodies, compositions, and methods of the present disclosure in more detail, it is important to note that the antibodies, compositions, and methods are not limited to the particular embodiments described, as such may, of course, vary. I hope you understand that. The terminology used herein is for the purpose of describing particular embodiments only, and is not limiting, as the scope of the antibodies, compositions, and methods is limited only by the appended claims. It should also be understood that this is not intended to be the case.
[0008] When a range of values is provided, each intervening value between the upper and lower limits of that range, and any other stated or intervening values within that stated range, shall be used unless the context clearly dictates otherwise. It is understood that up to one tenth of the lower limit is encompassed within the antibodies, compositions, and methods. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges and within the antibodies, compositions, and methods, subject to any specifically excluded limits within the stated ranges. It is also included in Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the antibodies, compositions, and methods.
[0009] Certain ranges are presented herein with numerical values preceded by the term "about." The term "about" is used herein to provide literal support to the exact number that it precedes, as well as to a number that is near or approximates the number that it precedes. In determining whether a number is near or approximates a specifically enumerated number, the unenumerated number that is near or approximates the number in the context in which it is presented. , may be a number providing substantial equivalence to a specifically recited number.
[0010] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which antibodies, compositions, and methods belong. Although any antibodies, compositions, and methods similar or equivalent to those described herein can also be used in the practice or testing of antibodies, compositions, and methods, representative Antibodies, compositions, and methods are described herein.
[0011] All publications and patents cited herein are herein incorporated by reference to the same extent as if each individual publication or patent was specifically and individually indicated to be incorporated by reference. , publications are incorporated herein by reference to disclose and describe the materials and / or methods cited. The citation of any publication is for its disclosure prior to the filing date, and the publication date provided may differ from the actual publication date, which may need to be independently confirmed, and is therefore Nothing herein shall be construed as an admission that the antibodies, compositions, and methods of the invention are not entitled to antedate such publication.
[0012] As used in this specification and the appended claims, the singular forms "a," "an," and "the" do not clearly dictate otherwise. Note that this includes multiple referents. It is further noted that the claims may be drafted to exclude optional elements. Accordingly, this description does not reflect the use of exclusive terms such as "solely" or "only" or the use of "negative" limitations in connection with the recitation of claim elements. is intended to serve as an antecedent of.
[0013] It is also understood that, for clarity, certain features of antibodies, compositions, and methods that are described in the context of separate embodiments may also be provided in combination in a single embodiment. . Conversely, various features of antibodies, compositions, and methods that are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination. . All combinations of embodiments are specifically encompassed by this disclosure, to the extent that such combinations encompass operable processes and / or compositions, as if each and every combination were individually and expressly disclosed. disclosed herein. In addition, all subcombinations recited in the embodiments describing such variables are also specifically encompassed by the antibodies, compositions, and methods of the invention, and each and every such subcombination includes: Disclosed herein as if individually and expressly disclosed herein.
[0014] As will be apparent to those skilled in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein departs from the scope or spirit of the antibodies, compositions, and methods of the invention. have distinct components and features that can be easily separated from or easily combined with features of any of the other embodiments without . Any recited method may be performed in the recited order of events or in any other order that is logically possible.
[0015] antibody As summarized above, the present disclosure provides anti-SARS-CoV-2 antigen antibodies. According to some embodiments, the antibodies of the present disclosure are directed to the S1 subunit of the SARS-CoV-2 spike (S) protein, the receptor-binding domain of the S1 subunit of the SARS-CoV-2 spike protein. domain, RBD), SARS-CoV-2 spike (S) protein trimer, S2 subunit of SARS-CoV-2 spike protein, SARS-CoV-2 envelope (E) protein, SARS-CoV-2 membrane (M ) proteins, and SARS-CoV-2 antigens, such as the SARS-CoV-2 nucleocapsid (N) protein. Details regarding the structure of the SARS-CoV-2 spike protein can be found, for example, in Lan et al. (2020) Nature 581:215-220, Huang et al. (2020) Acta Pharmacologica Sinica 41:1141-1149, Schaub et al. ( 2021) Nature Protocols doi.org / 10.1038 / s41596-021-00623-0, Juraszek et al. incorporated herein by. In certain embodiments, the anti-SARS-CoV-2 antigen antibodies of the present disclosure are SARS-CoV-2 virus neutralizing antibodies. As used herein, a "neutralizing" antibody is an antibody that binds to the SARS-CoV-2 virus and interferes with its ability to infect cells.
[0016] In certain embodiments, the antibodies of the present disclosure specifically bind to a SARS-CoV-2 antigen, and for binding to a SARS-CoV-2 antigen are herein referred to as antibodies 508, 767, 935, 937, 941, 980, 1085, 1213, 1227, 1231, 1238, 1439, 1589, 1671, 1679, 1814, 1815, 1823, 1826, 1851, 1856, 1859, 1864, 1867, 1870, 1871, 1872, 1888, 191 5, 1959,1963,1969,1984,2019,2020,2024,2025,2050,2075,2080,2432,2564,2598,2606,2619,2646,2706,2729,2788,2793,2794,2854,2866,2 892, Complementary of one, two, three, four, five, or all six of one or more of the anti-SARS-CoV-2 antibodies designated 3086, 3091, 3995, 4042, and 4441 Competes with antibodies that have sex-determining regions (CDRs). In some embodiments, such antibodies are herein defined as antibodies 508, 767, 935, 937, 941, 980, 1085, 1213, 1227, 1231, 1238, 1439, 1589, 1671, 1679, 1814, 1815,1823,1826,1851,1856,1859,1864,1867,1870,1871,1872,1888,1915,1959,1963,1969,1984,2019,2020,2024,2025,2050,2075,2080,2 432, One, two, three of the antibodies designated 2564, 2598, 2606, 2619, 2646, 2706, 2729, 2788, 2793, 2794, 2854, 2866, 2892, 3086, 3091, 3995, 4042, and 4441 Contains one, four, five, or all six CDRs. In some embodiments, such antibodies have a variable heavy chain (V H ) polypeptide and / or variable light chain (V L) polypeptides, herein defined as antibodies 508, 767, 935, 937, 941, 980, 1085, 1213, 1227, 1231, 1238, 1439, 1589, 1671, 1679, 1814, 1815, 1823, 1826, 1851,1856,1859,1864,1867,1870,1871,1872,1888,1915,1959,1963,1969,1984,2019,2020,2024,2025,2050,2075,2080,2432,2564,2598,2 606, V of antibodies designated 2619, 2646, 2706, 2729, 2788, 2793, 2794, 2854, 2866, 2892, 3086, 3091, 3995, 4042, and 4441 H and / or V L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more , 97% or more, 98% or more, 99% or more, or 100% identity H ) polypeptide and / or variable light chain (V L ) containing polypeptides.
[0017] Antibodies herein 508, 767, 935, 937, 941, 980, 1085, 1213, 1227, 1231, 1238, 1439, 1589, 1671, 1679, 1814, 1815, 1823, 1826, 1851, 1856, 1859, 1864 , 1867, 1870, 1871, 1872, 1888, 1915, 1959, 1963, 1969, 1984, 2019, 2020, 2024, 2025, 2050, 2075, 2080, 2432, 2564, 2598, 2606, 2619, 2646, 2706, 2729 , 2788, 2793, 2794, 2854, 2866, 2892, 3086, 3091, 3995, 4042, and 4441 have a lack of free cysteine, non-canonical glycosylation sites, sites of undesired post-translational modification, and They were selected from over 300,000 identified and over 3,000 synthesized antibodies with desirable manufacturing characteristics, such as biophysical properties that affect stability. Further selection is the ability to bind and neutralize the SARS-CoV-2 virus strongly, the ability to neutralize and / or retain binding to the variant, the diversity of epitopes, and the diversity of neutralization mechanisms. Contained.
[0018] As demonstrated in the experimental section herein, the epitopes of RBD-binding antibodies may be separated and these antibodies grouped into three classes or epitope bins. These antibodies are non-competitive and inhibit ACE2 binding. When administered in combination (see, e.g., in vivo studies and data in the Experimental section and Figures), the combination of antibodies exhibits comparable efficacy compared to a single type of antibody administered alone. demonstrated and reduced the impact of viral variants.
[0019] Antibodies of the present disclosure that bind to the S2 domain of the spike protein represent unique binding epitopes on the spike protein. These antibodies do not compete with RBD binding antibodies. The in vivo studies presented herein demonstrate that the combination of RBD- and S2-binding antibodies exhibits comparable efficacy and, as a combination, reduces the impact of viral variants.
[0020] The amino acid sequence of the S2 domain of the spike protein is much more conserved than the RBD domain [Shah et. All, Fr. Immunology 2021] and is therefore a novel and attractive protein that is likely to be resistant to viral variants. Represents an epitope. S2-binding antibodies also neutralize SARs-CoV (2003) (see experimental section below) and can neutralize other coronaviruses of the Betacoronaviridae family, as evidenced by binding. .
[0021] Furthermore, S2-binding antibodies present a unique mechanism of virus neutralization compared to RBD-binding antibodies. S2-binding antibodies do not inhibit RBD from binding to ACE2, but rather neutralize the virus by binding to the HR1 / fusion peptide region within the S2 domain. Effector functions are conserved in these antibodies and may contribute to additional mechanisms of neutralization and efficacy.
[0022] Antibodies 508, 767, 935, 937, 941, 980, 1085, 1213, 1227, 1231, 1238, 1439, 1589, 1671, 1679, 1814, 1815, 1823, 1826, 1851, 1856, 1859, 1864, 1867, 1870 , 1871, 1872, 1888, 1915, 1959, 1963, 1969, 1984, 2019, 2020, 2024, 2025, 2050, 2075, 2080, 2432, 2564, 2598, 2606, 2619, 2646, 2706, 2729, 2788, 2793 , 2794, 2854, 2866, 2892, 3086, 3091, 3995, 4042, and 4441 V H Polypeptide and V L The amino acid sequence of the polypeptide is provided in Table 1 below. CDR sequences defined according to IMGT are underlined.
[0023] [Table 1-1]
[0024] [Table 1-2]
[0025] [Table 1-3]
[0026] [Table 1-4]
[0027] [Table 1-5]
[0028] [Table 1-6]
[0029] [Table 1-7]
[0030] [Table 1-8]
[0031] [Table 1-9]
[0032] According to some embodiments, the antibodies of the present disclosure specifically bind to SARS-CoV-2 antigens, and for binding to SARS-CoV-2 antigens, antibodies designated herein as antibody 508 or competes with an antibody that contains one, two, three, four, five, or all six CDRs of. CDR sequences can be defined according to IMGT. In certain embodiments, the SARS-CoV-2 antigen is the receptor binding domain (RBD) of the S1 subunit of the SARS-CoV-2 spike protein. In certain embodiments, such antibodies are V of antibody designated herein as antibody 508. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity H Polypeptide, V of the antibody designated herein as antibody 508 L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity L polypeptides, or both. According to some embodiments, such an antibody is a V of antibody designated herein as antibody 508. H polypeptide, V L V compared to the corresponding framework region or regions of the polypeptide, or both. H polypeptide, V L One or more amino acid substitutions (eg, one or more conservative amino acid substitutions) in one or more framework regions of the polypeptide, or both.
[0033] According to some embodiments, an antibody of the present disclosure specifically binds to a SARS-CoV-2 antigen, and for binding to a SARS-CoV-2 antigen, the antibody designated herein as antibody 767 or competes with an antibody that contains one, two, three, four, five, or all six CDRs of. CDR sequences can be defined according to IMGT. In certain embodiments, the SARS-CoV-2 antigen is the receptor binding domain (RBD) of the S1 subunit of the SARS-CoV-2 spike protein. In certain embodiments, such antibodies are V of antibody designated herein as antibody 767. H70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity H Polypeptide, V of the antibody designated herein as antibody 767 L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity L polypeptides, or both. According to some embodiments, such antibodies are V of antibody designated herein as antibody 767. H polypeptide, V L V compared to the corresponding framework region or regions of the polypeptide, or both. H polypeptide, V L One or more amino acid substitutions (eg, one or more conservative amino acid substitutions) in one or more framework regions of the polypeptide, or both.
[0034] According to some embodiments, the antibodies of the present disclosure specifically bind to SARS-CoV-2 antigens, and for binding to SARS-CoV-2 antigens, antibodies designated herein as antibody 935 or competes with an antibody that contains one, two, three, four, five, or all six CDRs of. CDR sequences can be defined according to IMGT. In certain embodiments, the SARS-CoV-2 antigen is the receptor binding domain (RBD) of the S1 subunit of the SARS-CoV-2 spike protein. In certain embodiments, such antibodies are V of antibody designated herein as antibody 935. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity H Polypeptide, V of the antibody designated herein as antibody 935 L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity L polypeptides, or both. According to some embodiments, such antibodies are V of antibody designated herein as antibody 935. H polypeptide, V L V compared to the corresponding framework region or regions of the polypeptide, or both. H polypeptide, V L One or more amino acid substitutions (eg, one or more conservative amino acid substitutions) in one or more framework regions of the polypeptide, or both.
[0035] According to some embodiments, the antibodies of the present disclosure specifically bind to SARS-CoV-2 antigens, and for binding to SARS-CoV-2 antigens, antibodies designated herein as antibody 937 or competes with an antibody that contains one, two, three, four, five, or all six CDRs of. CDR sequences can be defined according to IMGT. In certain embodiments, the SARS-CoV-2 antigen is the receptor binding domain (RBD) of the S1 subunit of the SARS-CoV-2 spike protein. In certain embodiments, such antibodies are V of antibody designated herein as antibody 937. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity H Polypeptide, V of the antibody designated herein as antibody 937 L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity L polypeptides, or both. According to some embodiments, such an antibody is a V of antibody designated herein as antibody 937. H polypeptide, V L V compared to the corresponding framework region or regions of the polypeptide, or both. H polypeptide, V L One or more amino acid substitutions (eg, one or more conservative amino acid substitutions) in one or more framework regions of the polypeptide, or both.
[0036] According to some embodiments, the antibodies of the present disclosure specifically bind to SARS-CoV-2 antigens, and for binding to SARS-CoV-2 antigens, antibodies designated herein as antibody 941 or competes with an antibody that contains one, two, three, four, five, or all six CDRs of. CDR sequences can be defined according to IMGT. In certain embodiments, the SARS-CoV-2 antigen is the receptor binding domain (RBD) of the S1 subunit of the SARS-CoV-2 spike protein. In certain embodiments, such antibodies are V of antibody designated herein as antibody 941. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity H Polypeptide, V of the antibody designated herein as antibody 941 L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity L polypeptides, or both. According to some embodiments, such antibodies are V of antibody designated herein as antibody 941. H polypeptide, V L V compared to the corresponding framework region or regions of the polypeptide, or both. H polypeptide, V L One or more amino acid substitutions (eg, one or more conservative amino acid substitutions) in one or more framework regions of the polypeptide, or both.
[0037] According to some embodiments, the antibodies of the present disclosure specifically bind to SARS-CoV-2 antigens, and for binding to SARS-CoV-2 antigens, antibodies designated herein as antibody 980 or competes with an antibody that contains one, two, three, four, five, or all six CDRs of. CDR sequences can be defined according to IMGT. In certain embodiments, the SARS-CoV-2 antigen is the receptor binding domain (RBD, eg, class III) of the S1 subunit of the SARS-CoV-2 spike protein. In certain embodiments, such antibodies are V of antibody designated herein as antibody 980. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity H Polypeptide, V of the antibody designated herein as antibody 980 L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity L polypeptides, or both. According to some embodiments, such an antibody is a V of antibody designated herein as antibody 980. H polypeptide, V L V compared to the corresponding framework region or regions of the polypeptide, or both. H polypeptide, V L One or more amino acid substitutions (eg, one or more conservative amino acid substitutions) in one or more framework regions of the polypeptide, or both.
[0038] According to some embodiments, the antibodies of the present disclosure specifically bind to SARS-CoV-2 antigens, and for binding to SARS-CoV-2 antigens, antibodies designated herein as antibody 1085 or competes with an antibody that contains one, two, three, four, five, or all six CDRs of. CDR sequences can be defined according to IMGT. In certain embodiments, such antibodies are V of antibody designated herein as antibody 1085. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity H polypeptide, V of the antibody designated herein as antibody 1085 L70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity L polypeptides, or both. According to some embodiments, such an antibody is a V of antibody designated herein as antibody 1085. H polypeptide, V L V compared to the corresponding framework region or regions of the polypeptide, or both. H polypeptide, V L One or more amino acid substitutions (eg, one or more conservative amino acid substitutions) in one or more framework regions of the polypeptide, or both.
[0039] According to some embodiments, the antibodies of the present disclosure specifically bind to SARS-CoV-2 antigens, and for binding to SARS-CoV-2 antigens, antibodies designated herein as antibody 1213 or competes with an antibody that contains one, two, three, four, five, or all six CDRs of. CDR sequences can be defined according to IMGT. In certain embodiments, the SARS-CoV-2 antigen is the receptor binding domain (RBD) of the S1 subunit of the SARS-CoV-2 spike protein. In certain embodiments, such antibodies are V of antibody designated herein as antibody 1213. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity H polypeptide, V of the antibody designated herein as antibody 1213 L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity L polypeptides, or both. According to some embodiments, such antibodies are V of antibody designated herein as antibody 1213. H polypeptide, V L V compared to the corresponding framework region or regions of the polypeptide, or both. H polypeptide, V L One or more amino acid substitutions (eg, one or more conservative amino acid substitutions) in one or more framework regions of the polypeptide, or both.
[0040] According to some embodiments, the antibodies of the present disclosure specifically bind to SARS-CoV-2 antigens, and for binding to SARS-CoV-2 antigens, antibodies designated herein as antibody 1227 or competes with an antibody that contains one, two, three, four, five, or all six CDRs of. CDR sequences can be defined according to IMGT. In certain embodiments, the SARS-CoV-2 antigen is the receptor binding domain (RBD) of the S1 subunit of the SARS-CoV-2 spike protein. In certain embodiments, such antibodies are V of antibody designated herein as antibody 1227. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity H Polypeptide, V of the antibody designated herein as antibody 1227 L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity L polypeptides, or both. According to some embodiments, such antibodies are V of antibody designated herein as antibody 1227. H polypeptide, V L V compared to the corresponding framework region or regions of the polypeptide, or both. H polypeptide, V L One or more amino acid substitutions (eg, one or more conservative amino acid substitutions) in one or more framework regions of the polypeptide, or both.
[0041] According to some embodiments, the antibodies of the present disclosure specifically bind to SARS-CoV-2 antigens, and for binding to SARS-CoV-2 antigens, antibodies designated herein as antibody 1231 or competes with an antibody that contains one, two, three, four, five, or all six CDRs of. CDR sequences can be defined according to IMGT. In certain embodiments, the SARS-CoV-2 antigen is the receptor binding domain (RBD) of the S1 subunit of the SARS-CoV-2 spike protein. In certain embodiments, such antibodies are V of antibody designated herein as antibody 1231. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity H polypeptide, V of the antibody designated herein as antibody 1231 L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity L polypeptides, or both. According to some embodiments, such an antibody is a V of antibody designated herein as antibody 1231. H polypeptide, V L V compared to the corresponding framework region or regions of the polypeptide, or both. H polypeptide, V L One or more amino acid substitutions (eg, one or more conservative amino acid substitutions) in one or more framework regions of the polypeptide, or both.
[0042] According to some embodiments, the antibodies of the present disclosure specifically bind to SARS-CoV-2 antigens, and for binding to SARS-CoV-2 antigens, antibodies designated herein as antibody 1238 or competes with an antibody that contains one, two, three, four, five, or all six CDRs of. CDR sequences can be defined according to IMGT. In certain embodiments, the SARS-CoV-2 antigen is the S1 subunit of the SARS-CoV-2 spike (S) protein. In certain embodiments, such antibodies are V of antibody designated herein as antibody 1238. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity H polypeptide, V of the antibody designated herein as antibody 1238 L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity L polypeptides, or both. According to some embodiments, such antibodies are V of antibody designated herein as antibody 1238. H polypeptide, V L V compared to the corresponding framework region or regions of the polypeptide, or both. H polypeptide, V L One or more amino acid substitutions (eg, one or more conservative amino acid substitutions) in one or more framework regions of the polypeptide, or both.
[0043] According to some embodiments, the antibodies of the present disclosure specifically bind to SARS-CoV-2 antigens, and for binding to SARS-CoV-2 antigens, antibodies designated herein as antibody 1439 or competes with an antibody that contains one, two, three, four, five, or all six CDRs of. CDR sequences can be defined according to IMGT. In certain embodiments, the SARS-CoV-2 antigen is the receptor binding domain (RBD) of the S1 subunit of the SARS-CoV-2 spike protein. In certain embodiments, such antibodies are V of antibody designated herein as antibody 1439. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity H polypeptide, V of the antibody designated herein as antibody 1439 L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity Lpolypeptides, or both. According to some embodiments, such antibodies are V of antibody designated herein as antibody 1439. H polypeptide, V L V compared to the corresponding framework region or regions of the polypeptide, or both. H polypeptide, V L One or more amino acid substitutions (eg, one or more conservative amino acid substitutions) in one or more framework regions of the polypeptide, or both.
[0044] According to some embodiments, the antibodies of the present disclosure specifically bind to SARS-CoV-2 antigens, and for binding to SARS-CoV-2 antigens, antibodies designated herein as antibody 1589 or competes with an antibody that contains one, two, three, four, five, or all six CDRs of. CDR sequences can be defined according to IMGT. In certain embodiments, the SARS-CoV-2 antigen is the receptor binding domain (RBD, eg, class I) of the S1 subunit of the SARS-CoV-2 spike protein. In certain embodiments, such antibodies are V of antibody designated herein as antibody 1589. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity H polypeptide, V of the antibody designated herein as antibody 1589 L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity L polypeptides, or both. According to some embodiments, such antibodies are similar to the V of antibody designated herein as antibody 1589. H polypeptide, V L V compared to the corresponding framework region or regions of the polypeptide, or both. H polypeptide, V L One or more amino acid substitutions (eg, one or more conservative amino acid substitutions) in one or more framework regions of the polypeptide, or both.
[0045] According to some embodiments, the antibodies of the present disclosure specifically bind to SARS-CoV-2 antigens, and for binding to SARS-CoV-2 antigens, antibodies designated herein as antibody 1671 or competes with an antibody that contains one, two, three, four, five, or all six CDRs of. CDR sequences can be defined according to IMGT. In certain embodiments, the SARS-CoV-2 antigen is the S1 subunit of the SARS-CoV-2 spike (S) protein. In certain embodiments, such antibodies are V of antibody designated herein as antibody 1671. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity H Polypeptide, V of the antibody designated herein as antibody 1671 L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity L polypeptides, or both. According to some embodiments, such antibodies are similar to the V of antibody designated herein as antibody 1671. H polypeptide, V L V compared to the corresponding framework region or regions of the polypeptide, or both. H polypeptide, V L One or more amino acid substitutions (eg, one or more conservative amino acid substitutions) in one or more framework regions of the polypeptide, or both.
[0046] According to some embodiments, the antibodies of the present disclosure specifically bind to SARS-CoV-2 antigens, and for binding to SARS-CoV-2 antigens, antibodies designated herein as antibody 1679 or competes with an antibody that contains one, two, three, four, five, or all six CDRs of. CDR sequences can be defined according to IMGT. In certain embodiments, the SARS-CoV-2 antigen is the receptor binding domain (RBD) of the S1 subunit of the SARS-CoV-2 spike protein. In certain embodiments, such antibodies are V of antibody designated herein as antibody 1679. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity H polypeptide, V of the antibody designated herein as antibody 1679 L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity L polypeptides, or both. According to some embodiments, such antibodies are V of antibody designated herein as antibody 1679. H polypeptide, V L V compared to the corresponding framework region or regions of the polypeptide, or both. H polypeptide, V L One or more amino acid substitutions (eg, one or more conservative amino acid substitutions) in one or more framework regions of the polypeptide, or both.
[0047] According to some embodiments, the antibodies of the present disclosure specifically bind to SARS-CoV-2 antigens, and for binding to SARS-CoV-2 antigens, antibodies designated herein as antibody 1814 or competes with an antibody that contains one, two, three, four, five, or all six CDRs of. CDR sequences can be defined according to IMGT. In certain embodiments, the SARS-CoV-2 antigen is the S2 subunit of the SARS-CoV-2 spike (S) protein. In certain embodiments, such antibodies are V of antibody designated herein as antibody 1814. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity H Polypeptide, V of the antibody designated herein as antibody 1814 L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity L polypeptides, or both. According to some embodiments, such antibodies are similar to the V of antibody designated herein as antibody 1814. H polypeptide, V L V compared to the corresponding framework region or regions of the polypeptide, or both. H polypeptide, V L One or more amino acid substitutions (eg, one or more conservative amino acid substitutions) in one or more framework regions of the polypeptide, or both.
[0048] According to some embodiments, the antibodies of the present disclosure specifically bind to SARS-CoV-2 antigens, and for binding to SARS-CoV-2 antigens, antibodies designated herein as antibody 1815 or competes with an antibody that contains one, two, three, four, five, or all six CDRs of. CDR sequences can be defined according to IMGT. In certain embodiments, the SARS-CoV-2 antigen is the S2 subunit of the SARS-CoV-2 spike (S) protein. In certain embodiments, such antibodies are V of antibody designated herein as antibody 1815. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity H polypeptide, V of the antibody designated herein as antibody 1815 L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity L polypeptides, or both. According to some embodiments, such antibodies are V of antibody designated herein as antibody 1815. H polypeptide, V L V compared to the corresponding framework region or regions of the polypeptide, or both. H polypeptide, V LOne or more amino acid substitutions (eg, one or more conservative amino acid substitutions) in one or more framework regions of the polypeptide, or both.
[0049] According to some embodiments, the antibodies of the present disclosure specifically bind to SARS-CoV-2 antigens, and for binding to SARS-CoV-2 antigens, antibodies designated herein as antibody 1823 or competes with an antibody that contains one, two, three, four, five, or all six CDRs of. CDR sequences can be defined according to IMGT. In certain embodiments, the SARS-CoV-2 antigen is the S2 subunit of the SARS-CoV-2 spike (S) protein. In certain embodiments, such antibodies are V of antibody designated herein as antibody 1823. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity H Polypeptide, V of the antibody designated herein as antibody 1823 L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity L polypeptides, or both. According to some embodiments, such antibodies are similar to the V of antibody designated herein as antibody 1823. H polypeptide, V L V compared to the corresponding framework region or regions of the polypeptide, or both. H polypeptide, V L One or more amino acid substitutions (eg, one or more conservative amino acid substitutions) in one or more framework regions of the polypeptide, or both.
[0050] According to some embodiments, the antibodies of the present disclosure specifically bind to SARS-CoV-2 antigens, and for binding to SARS-CoV-2 antigens, antibodies designated herein as antibody 1826 or competes with an antibody that contains one, two, three, four, five, or all six CDRs of. CDR sequences can be defined according to IMGT. In certain embodiments, the SARS-CoV-2 antigen is the S2 subunit of the SARS-CoV-2 spike (S) protein. In certain embodiments, such antibodies are V of antibody designated herein as antibody 1826. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity H polypeptide, V of the antibody designated herein as antibody 1826 L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity L polypeptides, or both. According to some embodiments, such antibodies are V of antibody designated herein as antibody 1826. H polypeptide, V L V compared to the corresponding framework region or regions of the polypeptide, or both. H polypeptide, V L One or more amino acid substitutions (eg, one or more conservative amino acid substitutions) in one or more framework regions of the polypeptide, or both.
[0051] According to some embodiments, the antibodies of the present disclosure specifically bind to SARS-CoV-2 antigens, and for binding to SARS-CoV-2 antigens, antibodies designated herein as antibody 1851 or competes with an antibody that contains one, two, three, four, five, or all six CDRs of. CDR sequences can be defined according to IMGT. In certain embodiments, the SARS-CoV-2 antigen is the S2 subunit of the SARS-CoV-2 spike (S) protein. In certain embodiments, such antibodies are V of antibody designated herein as antibody 1851. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity H Polypeptide, V of the antibody designated herein as antibody 1851 L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity L polypeptides, or both. According to some embodiments, such antibodies are similar to the V of antibody designated herein as antibody 1851. H polypeptide, V L V compared to the corresponding framework region or regions of the polypeptide, or both. H polypeptide, V L One or more amino acid substitutions (eg, one or more conservative amino acid substitutions) in one or more framework regions of the polypeptide, or both.
[0052] According to some embodiments, the antibodies of the present disclosure specifically bind to SARS-CoV-2 antigens, and for binding to SARS-CoV-2 antigens, antibodies designated herein as antibody 1856 or competes with an antibody that contains one, two, three, four, five, or all six CDRs of. CDR sequences can be defined according to IMGT. In certain embodiments, the SARS-CoV-2 antigen is the S2 subunit of the SARS-CoV-2 spike (S) protein. In certain embodiments, such antibodies are V of antibody designated herein as antibody 1856. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity H polypeptide, V of the antibody designated herein as antibody 1856 L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity L polypeptides, or both. According to some embodiments, such antibodies are V of antibody designated herein as antibody 1856. H polypeptide, V L V compared to the corresponding framework region or regions of the polypeptide, or both. H polypeptide, V L One or more amino acid substitutions (eg, one or more conservative amino acid substitutions) in one or more framework regions of the polypeptide, or both.
[0053] According to some embodiments, the antibodies of the present disclosure specifically bind to SARS-CoV-2 antigens, and for binding to SARS-CoV-2 antigens, antibodies designated herein as antibody 1859 or competes with an antibody that contains one, two, three, four, five, or all six CDRs of. CDR sequences can be defined according to IMGT. In certain embodiments, the SARS-CoV-2 antigen is the S2 subunit of the SARS-CoV-2 spike (S) protein. In certain embodiments, such antibodies are V of antibody designated herein as antibody 1859. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity H polypeptide, V of the antibody designated herein as antibody 1859 L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity L polypeptides, or both. According to some embodiments, such antibodies are similar to the V of antibody designated herein as antibody 1859. H polypeptide, V L V compared to the corresponding framework region or regions of the polypeptide, or both. H polypeptide, V L One or more amino acid substitutions (eg, one or more conservative amino acid substitutions) in one or more framework regions of the polypeptide, or both.
[0054] According to some embodiments, the antibodies of the present disclosure specifically bind to SARS-CoV-2 antigens, and for binding to SARS-CoV-2 antigens, antibodies designated herein as antibody 1864 or competes with an antibody that contains one, two, three, four, five, or all six CDRs of. CDR sequences can be defined according to IMGT. In certain embodiments, the SARS-CoV-2 antigen is the S2 subunit of the SARS-CoV-2 spike (S) protein. In certain embodiments, such antibodies are V of antibody designated herein as antibody 1864. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity H Polypeptide, V of the antibody designated herein as antibody 1864 L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity L polypeptides, or both. According to some embodiments, such antibodies are similar to the V of antibody designated herein as antibody 1864. H polypeptide, V L V compared to the corresponding framework region or regions of the polypeptide, or both. H polypeptide, V L One or more amino acid substitutions (eg, one or more conservative amino acid substitutions) in one or more framework regions of the polypeptide, or both.
[0055] According to some embodiments, the antibodies of the present disclosure specifically bind to SARS-CoV-2 antigens, and for binding to SARS-CoV-2 antigens, antibodies designated herein as antibody 1867 or competes with an antibody that contains one, two, three, four, five, or all six CDRs of. CDR sequences can be defined according to IMGT. In certain embodiments, the SARS-CoV-2 antigen is the S2 subunit of the SARS-CoV-2 spike (S) protein. In certain embodiments, such antibodies are V of antibody designated herein as antibody 1867. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity H Polypeptide, V of the antibody designated herein as antibody 1867 L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity L polypeptides, or both. According to some embodiments, such antibodies are V of antibody designated herein as antibody 1867. H polypeptide, V L V compared to the corresponding framework region or regions of the polypeptide, or both. H polypeptide, V L One or more amino acid substitutions (eg, one or more conservative amino acid substitutions) in one or more framework regions of the polypeptide, or both.
[0056] According to some embodiments, the antibodies of the present disclosure specifically bind to a SARS-CoV-2 antigen, and for binding to a SARS-CoV-2 antigen, the antibody designated herein as antibody 1870 or competes with an antibody that contains one, two, three, four, five, or all six CDRs of. CDR sequences can be defined according to IMGT. In certain embodiments, the SARS-CoV-2 antigen is the S2 subunit of the SARS-CoV-2 spike (S) protein. In certain embodiments, such antibodies are V of antibody designated herein as antibody 1870. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity H Polypeptide, V of the antibody designated herein as antibody 1870 L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity L polypeptides, or both. According to some embodiments, such an antibody is a V of antibody designated herein as antibody 1870. H polypeptide, V L V compared to the corresponding framework region or regions of the polypeptide, or both. H polypeptide, V L One or more amino acid substitutions (eg, one or more conservative amino acid substitutions) in one or more framework regions of the polypeptide, or both.
[0057] According to some embodiments, the antibodies of the present disclosure specifically bind to SARS-CoV-2 antigen, and for binding to SARS-CoV-2 antigen, the antibody designated herein as antibody 1871 or competes with an antibody that contains one, two, three, four, five, or all six CDRs of. CDR sequences can be defined according to IMGT. In certain embodiments, the SARS-CoV-2 antigen is the S2 subunit of the SARS-CoV-2 spike (S) protein. In certain embodiments, such antibodies are V of antibody designated herein as antibody 1871. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity H polypeptide, V of the antibody designated herein as antibody 1871 L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity L polypeptides, or both. According to some embodiments, such antibodies are similar to the V of antibody designated herein as antibody 1871. H polypeptide, V L V compared to the corresponding framework region or regions of the polypeptide, or both. H polypeptide, V L One or more amino acid substitutions (eg, one or more conservative amino acid substitutions) in one or more framework regions of the polypeptide, or both.
[0058] According to some embodiments, the antibodies of the present disclosure specifically bind to a SARS-CoV-2 antigen, and for binding to a SARS-CoV-2 antigen, the antibody designated herein as antibody 1872 or competes with an antibody that contains one, two, three, four, five, or all six CDRs of. CDR sequences can be defined according to IMGT. In certain embodiments, the SARS-CoV-2 antigen is the S2 subunit of the SARS-CoV-2 spike (S) protein. In certain embodiments, such antibodies are V of antibody designated herein as antibody 1872. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity H Polypeptide, V of the antibody designated herein as antibody 1872 L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity L polypeptides, or both. According to some embodiments, such antibodies are similar to the V of antibody designated herein as antibody 1872. H polypeptide, V L V compared to the corresponding framework region or regions of the polypeptide, or both. H polypeptide, V L One or more amino acid substitutions (eg, one or more conservative amino acid substitutions) in one or more framework regions of the polypeptide, or both.
[0059] According to some embodiments, the antibodies of the present disclosure specifically bind to SARS-CoV-2 antigens, and for binding to SARS-CoV-2 antigens, antibodies designated herein as antibody 1888 or competes with an antibody that contains one, two, three, four, five, or all six CDRs of. CDR sequences can be defined according to IMGT. In certain embodiments, the SARS-CoV-2 antigen is the S2 subunit of the SARS-CoV-2 spike (S) protein. In certain embodiments, such antibodies are V of antibody designated herein as antibody 1888. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity H Polypeptide, V of the antibody designated herein as antibody 1888 L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity L polypeptides, or both. According to some embodiments, such antibodies are V of antibody designated herein as antibody 1888. H polypeptide, V L V compared to the corresponding framework region or regions of the polypeptide, or both. H polypeptide, V L One or more amino acid substitutions (eg, one or more conservative amino acid substitutions) in one or more framework regions of the polypeptide, or both.
[0060] According to some embodiments, the antibodies of the present disclosure specifically bind to SARS-CoV-2 antigens, and for binding to SARS-CoV-2 antigens, antibodies designated herein as antibody 1915 or competes with an antibody that contains one, two, three, four, five, or all six CDRs of. CDR sequences can be defined according to IMGT. In certain embodiments, such antibodies are V of antibody designated herein as antibody 1915. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity H polypeptide, V of the antibody designated herein as antibody 1915 L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity L polypeptides, or both. According to some embodiments, such antibodies are V of antibody designated herein as antibody 1915. H polypeptide, V L V compared to the corresponding framework region or regions of the polypeptide, or both. H polypeptide, V L One or more amino acid substitutions (eg, one or more conservative amino acid substitutions) in one or more framework regions of the polypeptide, or both.
[0061] According to some embodiments, the antibodies of the present disclosure specifically bind to SARS-CoV-2 antigens, and for binding to SARS-CoV-2 antigens, antibodies designated herein as antibody 1959 or competes with an antibody that contains one, two, three, four, five, or all six CDRs of. CDR sequences can be defined according to IMGT. In certain embodiments, such antibodies are V of antibody designated herein as antibody 1959. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity H polypeptide, V of the antibody designated herein as antibody 1959 L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity L polypeptides, or both. According to some embodiments, such antibodies are V of antibody designated herein as antibody 1959. H polypeptide, V L V compared to the corresponding framework region or regions of the polypeptide, or both. H polypeptide, V L One or more amino acid substitutions (eg, one or more conservative amino acid substitutions) in one or more framework regions of the polypeptide, or both.
[0062] According to some embodiments, the antibodies of the present disclosure specifically bind to SARS-CoV-2 antigens, and for binding to SARS-CoV-2 antigens, antibodies designated herein as antibody 1963 or competes with an antibody that contains one, two, three, four, five, or all six CDRs of. CDR sequences can be defined according to IMGT. In certain embodiments, the SARS-CoV-2 antigen is the S2 subunit of the SARS-CoV-2 spike (S) protein. In certain embodiments, such antibodies are V of antibody designated herein as antibody 1963. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity H polypeptide, V of the antibody designated herein as antibody 1963 L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity L polypeptides, or both. According to some embodiments, such antibodies are V of antibody designated herein as antibody 1963. H polypeptide, V L V compared to the corresponding framework region or regions of the polypeptide, or both. H polypeptide, V L One or more amino acid substitutions (eg, one or more conservative amino acid substitutions) in one or more framework regions of the polypeptide, or both.
[0063] According to some embodiments, the antibodies of the present disclosure specifically bind to SARS-CoV-2 antigens, and for binding to SARS-CoV-2 antigens, antibodies designated herein as antibody 1969 or competes with an antibody that contains one, two, three, four, five, or all six CDRs of. CDR sequences can be defined according to IMGT. In certain embodiments, the SARS-CoV-2 antigen is the S2 subunit of the SARS-CoV-2 spike (S) protein. In certain embodiments, such antibodies are V of antibody designated herein as antibody 1969. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity H Polypeptide, V of the antibody designated herein as antibody 1969 L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity L polypeptides, or both. According to some embodiments, such antibodies are V of antibody designated herein as antibody 1969. H polypeptide, V L V compared to the corresponding framework region or regions of the polypeptide, or both. H polypeptide, V L One or more amino acid substitutions (eg, one or more conservative amino acid substitutions) in one or more framework regions of the polypeptide, or both.
[0064] According to some embodiments, the antibodies of the present disclosure specifically bind to a SARS-CoV-2 antigen, and for binding to a SARS-CoV-2 antigen, the antibody designated herein as antibody 1984 or competes with an antibody that contains one, two, three, four, five, or all six CDRs of. CDR sequences can be defined according to IMGT. In certain embodiments, the SARS-CoV-2 antigen is the receptor binding domain (RBD, eg, class I) of the S1 subunit of the SARS-CoV-2 spike protein. In certain embodiments, such antibodies are V of antibody designated herein as antibody 1984. H70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity H polypeptide, V of the antibody designated herein as antibody 1984 L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity L polypeptides, or both. According to some embodiments, such antibodies are V of antibody designated herein as antibody 1984. H polypeptide, V L V compared to the corresponding framework region or regions of the polypeptide, or both. H polypeptide, V L One or more amino acid substitutions (eg, one or more conservative amino acid substitutions) in one or more framework regions of the polypeptide, or both.
[0065] According to some embodiments, the antibodies of the present disclosure specifically bind to SARS-CoV-2 antigens, and for binding to SARS-CoV-2 antigens, antibodies designated herein as antibody 2019 or competes with an antibody that contains one, two, three, four, five, or all six CDRs of. CDR sequences can be defined according to IMGT. In certain embodiments, the SARS-CoV-2 antigen is SARS-CoV-2 spike (S) protein trimer. In certain embodiments, such antibodies are V of antibody designated herein as antibody 2019. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity H Polypeptide, V of the antibody designated herein as antibody 2019 L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity L polypeptides, or both. According to some embodiments, such an antibody is a V of antibody designated herein as antibody 2019. H polypeptide, V L V compared to the corresponding framework region or regions of the polypeptide, or both. H polypeptide, V L One or more amino acid substitutions (eg, one or more conservative amino acid substitutions) in one or more framework regions of the polypeptide, or both.
[0066] According to some embodiments, the antibodies of the present disclosure specifically bind to a SARS-CoV-2 antigen, and for binding to a SARS-CoV-2 antigen, the antibody designated herein as antibody 2020 or competes with an antibody that contains one, two, three, four, five, or all six CDRs of. CDR sequences can be defined according to IMGT. In certain embodiments, the SARS-CoV-2 antigen is the receptor binding domain (RBD, eg, class II) of the S1 subunit of the SARS-CoV-2 spike protein. In certain embodiments, such antibodies are V of antibody designated herein as antibody 2020. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity H Polypeptide, V of the antibody designated herein as antibody 2020 L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity L polypeptides, or both. According to some embodiments, such antibodies are V H polypeptide, V L V compared to the corresponding framework region or regions of the polypeptide, or both. H polypeptide, V L One or more amino acid substitutions (eg, one or more conservative amino acid substitutions) in one or more framework regions of the polypeptide, or both.
[0067] According to some embodiments, the antibodies of the present disclosure specifically bind to a SARS-CoV-2 antigen, and for binding to a SARS-CoV-2 antigen, the antibody designated herein as antibody 2024 or competes with an antibody that contains one, two, three, four, five, or all six CDRs of. CDR sequences can be defined according to IMGT. In certain embodiments, the SARS-CoV-2 antigen is SARS-CoV-2 spike (S) protein trimer. In certain embodiments, such antibodies are V of antibody designated herein as antibody 2024. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity H polypeptide, V of the antibody designated herein as antibody 2024 L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity L polypeptides, or both. According to some embodiments, such an antibody is a V of antibody designated herein as antibody 2024. H polypeptide, V L V compared to the corresponding framework region or regions of the polypeptide, or both. H polypeptide, V L One or more amino acid substitutions (eg, one or more conservative amino acid substitutions) in one or more framework regions of the polypeptide, or both.
[0068] According to some embodiments, the antibodies of the present disclosure specifically bind to SARS-CoV-2 antigens, and for binding to SARS-CoV-2 antigens, antibodies designated herein as antibody 2025 or competes with an antibody that contains one, two, three, four, five, or all six CDRs of. CDR sequences can be defined according to IMGT. In certain embodiments, the SARS-CoV-2 antigen is the receptor binding domain (RBD, eg, class II) of the S1 subunit of the SARS-CoV-2 spike protein. In certain embodiments, such antibodies are V of antibody designated herein as antibody 2025. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity H polypeptide, V of the antibody designated herein as antibody 2025 L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity L polypeptides, or both. According to some embodiments, such an antibody is a V of antibody designated herein as antibody 2025. H polypeptide, V L V compared to the corresponding framework region or regions of the polypeptide, or both. H polypeptide, V L One or more amino acid substitutions (eg, one or more conservative amino acid substitutions) in one or more framework regions of the polypeptide, or both.
[0069] According to some embodiments, the antibodies of the present disclosure specifically bind to SARS-CoV-2 antigens, and for binding to SARS-CoV-2 antigens, antibodies designated herein as antibody 2050 or competes with an antibody that contains one, two, three, four, five, or all six CDRs of. CDR sequences can be defined according to IMGT. In certain embodiments, the SARS-CoV-2 antigen is the receptor binding domain (RBD, eg, class II) of the S1 subunit of the SARS-CoV-2 spike protein. In certain embodiments, such antibodies are V of antibody designated herein as antibody 2050. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity Hpolypeptide, V of the antibody designated herein as antibody 2050 L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity L polypeptides, or both. According to some embodiments, such an antibody is a V of antibody designated herein as antibody 2050. H polypeptide, V L V compared to the corresponding framework region or regions of the polypeptide, or both. H polypeptide, V L One or more amino acid substitutions (eg, one or more conservative amino acid substitutions) in one or more framework regions of the polypeptide, or both.
[0070] According to some embodiments, the antibodies of the present disclosure specifically bind to SARS-CoV-2 antigens, and for binding to SARS-CoV-2 antigens, antibodies designated herein as antibody 2075 or competes with an antibody that contains one, two, three, four, five, or all six CDRs of. CDR sequences can be defined according to IMGT. In certain embodiments, the SARS-CoV-2 antigen is the receptor binding domain (RBD, eg, class II) of the S1 subunit of the SARS-CoV-2 spike protein. In certain embodiments, such antibodies are V of antibody designated herein as antibody 2075. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity H polypeptide, V of the antibody designated herein as antibody 2075 L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity L polypeptides, or both. According to some embodiments, such antibodies are V of antibody designated herein as antibody 2075. H polypeptide, V L V compared to the corresponding framework region or regions of the polypeptide, or both. H polypeptide, V L One or more amino acid substitutions (eg, one or more conservative amino acid substitutions) in one or more framework regions of the polypeptide, or both.
[0071] According to some embodiments, the antibodies of the present disclosure specifically bind to SARS-CoV-2 antigens, and for binding to SARS-CoV-2 antigens, antibodies designated herein as antibody 2080 or competes with an antibody that contains one, two, three, four, five, or all six CDRs of. CDR sequences can be defined according to IMGT. In certain embodiments, the SARS-CoV-2 antigen is the S1 subunit of the SARS-CoV-2 spike (S) protein. In certain embodiments, such antibodies are V of antibody designated herein as antibody 2080. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity H Polypeptide, V of the antibody designated herein as antibody 2080 L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity L polypeptides, or both. According to some embodiments, such an antibody is a V of antibody designated herein as antibody 2080. H polypeptide, V L V compared to the corresponding framework region or regions of the polypeptide, or both. H polypeptide, V L One or more amino acid substitutions (eg, one or more conservative amino acid substitutions) in one or more framework regions of the polypeptide, or both.
[0072] According to some embodiments, the antibodies of the present disclosure specifically bind to SARS-CoV-2 antigens, and for binding to SARS-CoV-2 antigens, antibodies designated herein as antibody 2432 or competes with an antibody that contains one, two, three, four, five, or all six CDRs of. CDR sequences can be defined according to IMGT. In certain embodiments, the SARS-CoV-2 antigen is the SARS-CoV-2 spike (S) protein trimer. In certain embodiments, such antibodies are similar to the V of antibody designated herein as antibody 2432. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity H polypeptide, V of the antibody designated herein as antibody 2432 L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity L polypeptides, or both. According to some embodiments, such an antibody is a V of antibody designated herein as antibody 2432. H polypeptide, V L V compared to the corresponding framework region or regions of the polypeptide, or both. H polypeptide, V L One or more amino acid substitutions (eg, one or more conservative amino acid substitutions) in one or more framework regions of the polypeptide, or both.
[0073] According to some embodiments, the antibodies of the present disclosure specifically bind to SARS-CoV-2 antigens, and for binding to SARS-CoV-2 antigens, antibodies designated herein as antibody 2564 or competes with an antibody that contains one, two, three, four, five, or all six CDRs of. CDR sequences can be defined according to IMGT. In certain embodiments, the SARS-CoV-2 antigen is the receptor binding domain (RBD, eg, class 1) of the S1 subunit of the SARS-CoV-2 spike protein. In certain embodiments, such antibodies are V of antibody designated herein as antibody 2564. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity H polypeptide, V of the antibody designated herein as antibody 2564 L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity L polypeptides, or both. According to some embodiments, such antibodies are V of antibody designated herein as antibody 2564. H polypeptide, V L V compared to the corresponding framework region or regions of the polypeptide, or both. H polypeptide, V L One or more amino acid substitutions (eg, one or more conservative amino acid substitutions) in one or more framework regions of the polypeptide, or both.
[0074] According to some embodiments, the antibodies of the present disclosure specifically bind to SARS-CoV-2 antigens, and for binding to SARS-CoV-2 antigens, antibodies designated herein as antibody 2598 or competes with an antibody that contains one, two, three, four, five, or all six CDRs of. CDR sequences can be defined according to IMGT. In certain embodiments, the SARS-CoV-2 antigen is the S1 subunit of the SARS-CoV-2 spike (S) protein. In certain embodiments, such antibodies are V of antibody designated herein as antibody 2598. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity H polypeptide, V of the antibody designated herein as antibody 2598 L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity Lpolypeptides, or both. According to some embodiments, such antibodies are similar to the V of antibody designated herein as antibody 2598. H polypeptide, V L V compared to the corresponding framework region or regions of the polypeptide, or both. H polypeptide, V L One or more amino acid substitutions (eg, one or more conservative amino acid substitutions) in one or more framework regions of the polypeptide, or both.
[0075] According to some embodiments, the antibodies of the present disclosure specifically bind to SARS-CoV-2 antigens, and for binding to SARS-CoV-2 antigens, antibodies designated herein as antibody 2606 or competes with an antibody that contains one, two, three, four, five, or all six CDRs of. CDR sequences can be defined according to IMGT. In certain embodiments, the SARS-CoV-2 antigen is the SARS-CoV-2 spike (S) protein trimer. In certain embodiments, such antibodies are V of antibody designated herein as antibody 2606. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity H Polypeptide, V of the antibody designated herein as antibody 2606 L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity L polypeptides, or both. According to some embodiments, such antibodies are V of antibody designated herein as antibody 2606. H polypeptide, V L V compared to the corresponding framework region or regions of the polypeptide, or both. H polypeptide, V L One or more amino acid substitutions (eg, one or more conservative amino acid substitutions) in one or more framework regions of the polypeptide, or both.
[0076] According to some embodiments, the antibodies of the present disclosure specifically bind to SARS-CoV-2 antigens, and for binding to SARS-CoV-2 antigens, antibodies designated herein as antibody 2619 or competes with an antibody that contains one, two, three, four, five, or all six CDRs of. CDR sequences can be defined according to IMGT. In certain embodiments, the SARS-CoV-2 antigen is the receptor binding domain (RBD, eg, class III) of the S1 subunit of the SARS-CoV-2 spike protein. In certain embodiments, such antibodies are V of antibody designated herein as antibody 2619. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity H Polypeptide, V of the antibody designated herein as antibody 2619 L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity L polypeptides, or both. According to some embodiments, such antibodies are similar to the V of antibody designated herein as antibody 2619. H polypeptide, V L V compared to the corresponding framework region or regions of the polypeptide, or both. H polypeptide, V L One or more amino acid substitutions (eg, one or more conservative amino acid substitutions) in one or more framework regions of the polypeptide, or both.
[0077] According to some embodiments, the antibodies of the present disclosure specifically bind to SARS-CoV-2 antigens, and for binding to SARS-CoV-2 antigens, antibodies designated herein as antibody 2646 or competes with an antibody that contains one, two, three, four, five, or all six CDRs of. CDR sequences can be defined according to IMGT. In certain embodiments, the SARS-CoV-2 antigen is the S1 subunit of the SARS-CoV-2 spike (S) protein. In certain embodiments, such antibodies are V of antibody designated herein as antibody 2646. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity H Polypeptide, V of the antibody designated herein as antibody 2646 L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity L polypeptides, or both. According to some embodiments, such antibodies are V of antibody designated herein as antibody 2646. H polypeptide, V L V compared to the corresponding framework region or regions of the polypeptide, or both. H polypeptide, V L One or more amino acid substitutions (eg, one or more conservative amino acid substitutions) in one or more framework regions of the polypeptide, or both.
[0078] According to some embodiments, the antibodies of the present disclosure specifically bind to SARS-CoV-2 antigens, and for binding to SARS-CoV-2 antigens, antibodies designated herein as antibody 2706 or competes with an antibody that contains one, two, three, four, five, or all six CDRs of. CDR sequences can be defined according to IMGT. In certain embodiments, the SARS-CoV-2 antigen is the receptor binding domain (RBD, eg, class III) of the S1 subunit of the SARS-CoV-2 spike protein. In certain embodiments, such antibodies are V of antibody designated herein as antibody 2706. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity H Polypeptide, V of the antibody designated herein as antibody 2706 L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity L polypeptides, or both. According to some embodiments, such an antibody is a V of antibody designated herein as antibody 2706. H polypeptide, V L V compared to the corresponding framework region or regions of the polypeptide, or both. H polypeptide, V L One or more amino acid substitutions (eg, one or more conservative amino acid substitutions) in one or more framework regions of the polypeptide, or both.
[0079] According to some embodiments, the antibodies of the present disclosure specifically bind to SARS-CoV-2 antigens, and for binding to SARS-CoV-2 antigens, antibodies designated herein as antibody 2729 or competes with an antibody that contains one, two, three, four, five, or all six CDRs of. CDR sequences can be defined according to IMGT. In certain embodiments, the SARS-CoV-2 antigen is the receptor binding domain (RBD, eg, class III) of the S1 subunit of the SARS-CoV-2 spike protein. In certain embodiments, such antibodies are V of antibody designated herein as antibody 2729. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity H Polypeptide, V of the antibody designated herein as antibody 2729 L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity L polypeptides, or both. According to some embodiments, such antibodies are V of antibody designated herein as antibody 2729. H polypeptide, V L V compared to the corresponding framework region or regions of the polypeptide, or both. Hpolypeptide, V L One or more amino acid substitutions (eg, one or more conservative amino acid substitutions) in one or more framework regions of the polypeptide, or both.
[0080] According to some embodiments, the antibodies of the present disclosure specifically bind to a SARS-CoV-2 antigen, and for binding to a SARS-CoV-2 antigen, the antibody designated herein as antibody 2788 or competes with an antibody that contains one, two, three, four, five, or all six CDRs of. CDR sequences can be defined according to IMGT. In certain embodiments, the SARS-CoV-2 antigen is the S1 subunit of the SARS-CoV-2 spike (S) protein. In certain embodiments, such antibodies are V of antibody designated herein as antibody 2788. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity H Polypeptide, V of the antibody designated herein as antibody 2788 L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity L polypeptides, or both. According to some embodiments, such antibodies are V of antibody designated herein as antibody 2788. H polypeptide, V L V compared to the corresponding framework region or regions of the polypeptide, or both. H polypeptide, V L One or more amino acid substitutions (eg, one or more conservative amino acid substitutions) in one or more framework regions of the polypeptide, or both.
[0081] According to some embodiments, the antibodies of the present disclosure specifically bind to a SARS-CoV-2 antigen, and for binding to a SARS-CoV-2 antigen, the antibody designated herein as antibody 2793 or competes with an antibody that contains one, two, three, four, five, or all six CDRs of. CDR sequences can be defined according to IMGT. In certain embodiments, the SARS-CoV-2 antigen is the S1 subunit of the SARS-CoV-2 spike (S) protein. In certain embodiments, such antibodies are V of antibody designated herein as antibody 2793. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity H Polypeptide, V of the antibody designated herein as antibody 2793 L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity L polypeptides, or both. According to some embodiments, such antibodies are V of antibody designated herein as antibody 2793. H polypeptide, V L V compared to the corresponding framework region or regions of the polypeptide, or both. H polypeptide, V L One or more amino acid substitutions (eg, one or more conservative amino acid substitutions) in one or more framework regions of the polypeptide, or both.
[0082] According to some embodiments, the antibodies of the present disclosure specifically bind to SARS-CoV-2 antigens, and for binding to SARS-CoV-2 antigens, antibodies designated herein as antibody 2794 or competes with an antibody that contains one, two, three, four, five, or all six CDRs of. CDR sequences can be defined according to IMGT. In certain embodiments, the SARS-CoV-2 antigen is the receptor binding domain (RBD, eg, class I) of the S1 subunit of the SARS-CoV-2 spike protein. In certain embodiments, such antibodies are V of antibody designated herein as antibody 2794. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity H polypeptide, V of the antibody designated herein as antibody 2794 L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity L polypeptides, or both. According to some embodiments, such antibodies are V of antibody designated herein as antibody 2794. H polypeptide, V L V compared to the corresponding framework region or regions of the polypeptide, or both. H polypeptide, V L One or more amino acid substitutions (eg, one or more conservative amino acid substitutions) in one or more framework regions of the polypeptide, or both.
[0083] According to some embodiments, the antibodies of the present disclosure specifically bind to SARS-CoV-2 antigens, and for binding to SARS-CoV-2 antigens, antibodies designated herein as antibody 2854 or competes with an antibody that contains one, two, three, four, five, or all six CDRs of. CDR sequences can be defined according to IMGT. In certain embodiments, the SARS-CoV-2 antigen is the SARS-CoV-2 spike (S) protein trimer. In certain embodiments, such antibodies are V of antibody designated herein as antibody 2854. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity H Polypeptide, V of the antibody designated herein as antibody 2854 L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity L polypeptides, or both. According to some embodiments, such antibodies are V of antibody designated herein as antibody 2854. H polypeptide, V L V compared to the corresponding framework region or regions of the polypeptide, or both. H polypeptide, V L One or more amino acid substitutions (eg, one or more conservative amino acid substitutions) in one or more framework regions of the polypeptide, or both.
[0084] According to some embodiments, the antibodies of the present disclosure specifically bind to SARS-CoV-2 antigens, and for binding to SARS-CoV-2 antigens, antibodies designated herein as antibody 2866 or competes with an antibody that contains one, two, three, four, five, or all six CDRs of. CDR sequences can be defined according to IMGT. In certain embodiments, the SARS-CoV-2 antigen is the SARS-CoV-2 spike (S) protein trimer. In certain embodiments, such antibodies are V of antibody designated herein as antibody 2866. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity H Polypeptide, V of the antibody designated herein as antibody 2866 L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity L polypeptides, or both. According to some embodiments, such antibodies are V of antibody designated herein as antibody 2866. H polypeptide, V L V compared to the corresponding framework region or regions of the polypeptide, or both. H polypeptide, V L One or more amino acid substitutions (eg, one or more conservative amino acid substitutions) in one or more framework regions of the polypeptide, or both.
[0085] According to some embodiments, the antibodies of the present disclosure specifically bind to a SARS-CoV-2 antigen, and for binding to a SARS-CoV-2 antigen, the antibody designated herein as antibody 2892 or competes with an antibody that contains one, two, three, four, five, or all six CDRs of. CDR sequences can be defined according to IMGT. In certain embodiments, the SARS-CoV-2 antigen is the receptor binding domain (RBD, eg, class I) of the S1 subunit of the SARS-CoV-2 spike protein. In certain embodiments, such antibodies are V of antibody designated herein as antibody 2892. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity H polypeptide, V of the antibody designated herein as antibody 2892 L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity L polypeptides, or both. According to some embodiments, such an antibody is a V of antibody designated herein as antibody 2892. H polypeptide, V L V compared to the corresponding framework region or regions of the polypeptide, or both. H polypeptide, V L One or more amino acid substitutions (eg, one or more conservative amino acid substitutions) in one or more framework regions of the polypeptide, or both.
[0086] According to some embodiments, the antibodies of the present disclosure specifically bind to SARS-CoV-2 antigens, and for binding to SARS-CoV-2 antigens, antibodies designated herein as antibody 3086 or competes with an antibody that contains one, two, three, four, five, or all six CDRs of. CDR sequences can be defined according to IMGT. In certain embodiments, the SARS-CoV-2 antigen is the receptor binding domain (RBD, eg, class I) of the S1 subunit of the SARS-CoV-2 spike protein. In certain embodiments, such antibodies are V of antibody designated herein as antibody 3086. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity H Polypeptide, V of the antibody designated herein as antibody 3086 L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity L polypeptides, or both. According to some embodiments, such antibodies are V of antibody designated herein as antibody 3086. H polypeptide, V L V compared to the corresponding framework region or regions of the polypeptide, or both. H polypeptide, V L One or more amino acid substitutions (eg, one or more conservative amino acid substitutions) in one or more framework regions of the polypeptide, or both.
[0087] According to some embodiments, the antibodies of the present disclosure specifically bind to SARS-CoV-2 antigens, and for binding to SARS-CoV-2 antigens, antibodies designated herein as antibody 3091 or competes with an antibody that contains one, two, three, four, five, or all six CDRs of. CDR sequences can be defined according to IMGT. In certain embodiments, the SARS-CoV-2 antigen is the receptor binding domain (RBD, eg, class I) of the S1 subunit of the SARS-CoV-2 spike protein. In certain embodiments, such antibodies are V of antibody designated herein as antibody 3091. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity H polypeptide, V of the antibody designated herein as antibody 3091 L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity L polypeptides, or both. According to some embodiments, such an antibody is a V of antibody designated herein as antibody 3091. H polypeptide, V L V compared to the corresponding framework region or regions of the polypeptide, or both. H polypeptide, V L One or more amino acid substitutions (eg, one or more conservative amino acid substitutions) in one or more framework regions of the polypeptide, or both.
[0088] According to some embodiments, the antibodies of the present disclosure specifically bind to SARS-CoV-2 antigens, and for binding to SARS-CoV-2 antigens, antibodies designated herein as antibody 3995 or competes with an antibody that contains one, two, three, four, five, or all six CDRs of. CDR sequences can be defined according to IMGT. In certain embodiments, the SARS-CoV-2 antigen is the receptor binding domain (RBD, eg, class III) of the S1 subunit of the SARS-CoV-2 spike protein. In certain embodiments, such antibodies are V of antibody designated herein as antibody 3995. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity H polypeptide, V of the antibody designated herein as antibody 3995 L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity L polypeptides, or both. According to some embodiments, such an antibody is a V of antibody designated herein as antibody 3995. H polypeptide, V L V compared to the corresponding framework region or regions of the polypeptide, or both. H polypeptide, V L One or more amino acid substitutions (eg, one or more conservative amino acid substitutions) in one or more framework regions of the polypeptide, or both.
[0089] According to some embodiments, the antibodies of the present disclosure specifically bind to SARS-CoV-2 antigens, and for binding to SARS-CoV-2 antigens, antibodies designated herein as antibody 4042 or competes with an antibody that contains one, two, three, four, five, or all six CDRs of. CDR sequences can be defined according to IMGT. In certain embodiments, the SARS-CoV-2 antigen is the receptor binding domain (RBD, eg, class III) of the S1 subunit of the SARS-CoV-2 spike protein. In certain embodiments, such antibodies are V of antibody designated herein as antibody 4042. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity H Polypeptide, V of the antibody designated herein as antibody 4042 L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity L polypeptides, or both. According to some embodiments, such antibodies are V of antibody designated herein as antibody 4042. H polypeptide, V L V compared to the corresponding framework region or regions of the polypeptide, or both. H polypeptide, V L One or more amino acid substitutions (eg, one or more conservative amino acid substitutions) in one or more framework regions of the polypeptide, or both.
[0090] According to some embodiments, the antibodies of the present disclosure specifically bind to SARS-CoV-2 antigens, and for binding to SARS-CoV-2 antigens, antibodies designated herein as antibody 4441 or competes with an antibody that contains one, two, three, four, five, or all six CDRs of. CDR sequences can be defined according to IMGT. In certain embodiments, the SARS-CoV-2 antigen is the receptor binding domain (RBD, eg, class III) of the S1 subunit of the SARS-CoV-2 spike protein. In certain embodiments, such antibodies are V of antibody designated herein as antibody 4441. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity H Polypeptide, V of the antibody designated herein as antibody 4441 L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, V containing an amino acid sequence with 97% or more, 98% or more, 99% or more, or 100% identity L polypeptides, or both. According to some embodiments, such antibodies are V of antibody designated herein as antibody 4441. H polypeptide, V L V compared to the corresponding framework region or regions of the polypeptide, or both. H polypeptide, V L One or more amino acid substitutions (eg, one or more conservative amino acid substitutions) in one or more framework regions of the polypeptide, or both.
[0091] In certain embodiments, CDRs are defined according to the IMGT numbering system. According to some embodiments, CDRs are defined according to the Kabat numbering system.
[0092] In certain embodiments, V as listed in Table 1 H and / or V L Antibody variants having one or more amino acid substitutions to the amino acid sequence are provided. Sites of interest for substitutional mutagenesis include one or more CDRs and / or one or more framework regions (FRs). Conservative substitutions are shown in the table below under the heading "Preferred Substitutions". More substantial changes are provided in the table below under the heading "Exemplary Substitutions" and are further described below with reference to amino acid side chain classes. Amino acid substitutions may be introduced into antibodies of interest and the products screened for desired activities, e.g., retained / improved antigen binding, reduced immunogenicity, improved developability, improved manufacturability, etc. good.
[0093] [Table 2]
[0094] Amino acids can be grouped according to common side chain properties. (1) Hydrophobicity: norleucine, Met, Ala, Val, Leu, Ile, (2) Neutral hydrophilicity: Cys, Ser, Thr, Asn, Gln, (3) Acidic: Asp, Glu, (4) Basic: His, Lys, Arg, (5) Residues that affect chain orientation: Gly, Pro, (6) Aromatic: Trp, Tyr, Phe.
[0095] Non-conservative substitutions involve exchanging elements of one of these classes with another.
[0096] Any suitable technique for determining whether a first antibody competes with a second antibody for binding to a SARS-CoV-2 antigen can be used. Non-limiting examples of such techniques include competitive ELISA, competitive SARS-CoV-2 antigen binding assays, and the like.
[0097] Methods are available for measuring the affinity of anti-SARS-CoV-2 antigen antibodies for SARS-CoV-2 antigen using direct binding assays or competitive binding assays. In direct binding assays, candidate anti-SARS-CoV-2 antigen antibodies conjugated to fluorophores or radioisotopes, or candidate anti-SARS-CoV-2 antigens containing an N-terminal epitope tag or a C-terminal epitope tag for detection by labeled antibodies. Using CoV-2 antigen-antibody, the equilibrium binding constant (K D ) may be measured. If a label or tag is not feasible or desired, the amount of unlabeled candidate anti-SARS-CoV-2 antigen antibody such that 50% of the maximum signal of the labeled competitor is detectable using a competitive binding assay. is the half-maximal inhibitory concentration (IC 50 ) can be determined. Then the measured IC 50 value to K D value can be calculated. Ligand depletion is more pronounced when measuring high-affinity interactions over a lower concentration range and by decreasing the amount of SARS-CoV-2 (or its antigen) added in the experiment or by increasing the binding reaction volume. This can be avoided or minimized by
[0098] Amino acid sequences of SARS-CoV-2 antigens that can be used to determine whether an antibody of the present disclosure competes with a second antibody for binding to a SARS-CoV-2 antigen are provided in Table 2 below. provided.
[0099] [Table 3]
[0100] The term "antibody" refers to antibodies or immunoglobulins of any isotype (e.g., IgG (e.g., IgG1, IgG2, IgG3, or IgG4), IgE, IgD, IgA, IgM, etc.), whole antibodies (e.g., tetrameric and then two dimers of a heavy chain polypeptide and a light chain polypeptide), single chain antibodies (e.g. scFv), single chain Fv (scFv), Fab, (Fab') 2 , (scFv’) 2 Fragments of antibodies that retain specific binding to cell surface molecules of target cells (e.g., whole antibodies or fragments of single chain antibodies), chimeric antibodies, monoclonal antibodies, including, but not limited to, bispecific antibodies, and bispecific antibodies. , human antibodies, humanized antibodies (e.g., humanized whole antibodies, humanized half antibodies, or humanized antibody fragments, e.g., humanized scFv), and fusion proteins comprising an antigen-binding portion of an antibody and a non-antibody protein. obtain. In some embodiments, the antibody is selected from IgG, Fv, single chain antibody, scFv, Fab, F(ab')2, or Fab'. Antibodies can be detectably labeled, for example, with in vivo imaging agents, radioactive isotopes, enzymes that produce detectable products, fluorescent proteins, and the like. The antibody can be further conjugated to other moieties, such as a member of a specific binding pair, eg, biotin (a member of a biotin-avidin specific binding pair).
[0101] The immunoglobulin light or heavy chain variable region is composed of "framework" regions (FR) interrupted by three hypervariable regions, also called "complementarity determining regions" or "CDRs." Framework regions and CDR ranges can be defined based on databases known in the art. For example, "Sequences of Proteins of Immunological Interest," E. Kabat et al., Sequences of proteins of immunological interest, 4th ed. U.S. Dept. Health and Human Services, Public Health Services, Bethesda, MD (1987), Lefranc et al. .IMGT, the international ImMunoGeneTics information system(R).Nucl.Acids Res.2005,33:D593-D597(www.imgt.org / textes / IMGTScientificChart / ), and / or V Base at vbase.mrc-cpe. See cam.ac.uk / ). The sequences of the framework regions of different light or heavy chains are relatively conserved within species. The framework regions of antibodies, ie, the combined framework regions of the component light and heavy chains, serve to position and align the CDRs. CDRs are primarily responsible for binding antigens to epitopes.
[0102] Any anti-SARS-CoV-2 antigen antibody of this disclosure may be a monoclonal antibody. As used herein, the term "monoclonal antibody" refers to an antibody composition having a homogeneous population of antibodies. The term is not limited by the manner in which it is made. The term refers to whole immunoglobulin molecules as well as Fab molecules, F(ab’) 2 fragments, Fv fragments, single chain fragment variables (scFv), fusion proteins comprising antigen-binding portions of antibodies and non-antibody proteins, and other molecules that exhibit the immunological binding properties of the parent monoclonal antibody molecule. do. Methods of making monoclonal antibodies are known in the art and are described more fully below.
[0103] Any anti-SARS-CoV-2 antigen antibodies of this disclosure may be recombinant or modified antibodies, such as chimeric antibodies, deimmunized antibodies, and / or in vitro generated antibodies. As used herein, the term "recombinant" or "modified" antibody refers to (i) an antibody expressed from one or more recombinant expression vectors transfected into a host cell; (ii) a recombinant combinatorial antibody; (iii) antibodies isolated from an animal (e.g., a mouse) that is transgenic for human immunoglobulin genes; or (iv) other DNA sequences of human immunoglobulin gene sequences. Any antibody prepared, expressed, produced, or isolated by recombinant means, including antibodies prepared, expressed, produced, or isolated by any other means, including splicing into is intended to include. Such recombinant antibodies include, for example, chimeric antibodies, deimmunized antibodies, and / or in vitro generated antibodies.
[0104] Any anti-SARS-CoV-2 antigen antibody of this disclosure may be isolated. "Isolated" means that the antibody has been separated from all or some of the components that naturally accompany it. "Isolated" also refers to the state of an antibody that has been separated from all or some of its attendant components during manufacture, eg, chemical synthesis, recombinant expression, culture media, and the like.
[0105] Any anti-SARS-CoV-2 antigen antibodies of the present disclosure (e.g., human anti-SARS-CoV-2 antigen antibodies) are naturally produced, e.g., produced in an animal (e.g., produced in a human) It may include a degree and / or pattern of glycosylation that is different from that of the antibody. For example, an anti-SARS-CoV-2 antigen antibody of the present disclosure may be a recombinant antibody (e.g., a monoclonal antibody) expressed from one or more recombinant expression vectors transfected into a host cell, and expressed Recombinant anti-SARS-CoV-2 antigen antibodies produced when produced naturally, e.g., when produced in an animal in response to a SARS-CoV-2 virus infection (e.g. The antibody may contain a different degree of glycosylation, a different glycosylation pattern, or both, as compared to the degree of glycosylation and / or the glycosylation pattern of the antibody (when produced in humans in response to an antibody).
[0106] In some embodiments, the anti-SARS-CoV-2 antigen antibodies of the present disclosure include a heavy chain that includes an Fc region, where the Fc region H - i.e., the Fc region is heterologous to the Fc region and V H Anti-SARS-CoV-2 antigen antibodies produced in animals in response to a SARS-CoV-2 virus infection are different from the anti-SARS-CoV-2 antigen antibodies that do not occur naturally, e.g. the amino acid sequence (e.g., one or more amino acid substitutions, deletions and / or insertions), one or more post-translational modifications (e.g., one or more amino acid substitutions, deletions and / or insertions); Including.
[0107] In certain embodiments, one or more amino acid modifications may be introduced into the Fc region of an antibody provided herein, thereby generating an Fc region variant. An Fc region variant can include a mouse Fc region sequence (eg, IgG1, IgG2a, or IgG2b) that includes an amino acid modification (eg, substitution) at one or more amino acid positions. Fc region variants are human Fc region sequences (e.g., human IgG1, IgG2, IgG3, or IgG4 Fc regions) that contain amino acid modifications (e.g., substitutions) at one or more amino acid positions (e.g., IgG4 isotypes containing the S228P mutation) may include.
[0108] In certain embodiments, the Fc region is mutated to increase its affinity for FcRn at pH 6.0, thereby increasing the antibody half-life. Antibodies with enhanced affinity for FcRn include substitutions of one or more of Fc region residues 252, 253, 254, 256, 428, 434, including so-called YTE mutations with substitutions M256Y / S254T / T252E. (Dall'Acqua et al., J Immunol. 169:5171-5180(2002)) or LS mutation M428L / N434S (Zalevsky et al., Nat Biotechnol. 28(2):157-159( 2010)).
[0109] In certain embodiments, the invention contemplates antibody variants that have some, but not all, effector functions, such that the half-life of the antibody in vivo is important; make it a desirable candidate for applications where its effector functions (such as complement activation and ADCC) are unnecessary or deleterious. In vitro and / or in vivo cytotoxicity assays can be performed to confirm reduction / depletion of CDC and / or ADCC activity. For example, Fc receptor (FcR) binding assays can be performed to ensure that the antibody lacks FcγR binding (and therefore likely lacks ADCC activity) but retains FcRn binding ability. NK cells, the primary cells for mediating ADCC, express only FcγRIII, whereas monocytes and microglia express FcγRI, FcγRII, and FcγRIII. FcR expression on hematopoietic cells is summarized in Table 3 on page 464 of Ravetch and Kinet, Annu. Rev. Immunol. 9:457-492 (1991). A non-limiting example of an in vitro assay for assessing ADCC activity of a molecule of interest is described in U.S. Pat. No. 5,500,362 (e.g., Hellstrom, I. et al. 7063 (1986)) and Hellstrom, I et al., Proc. Nat'l Acad. Sci. USA 82:1499-1502 (1985), No. 5,821,337 (Bruggemann, M. et al., j Exp.Med.166:1351-1361 (1987)).
[0110] Antibodies with reduced effector function include antibodies with substitutions of one or more of Fc region residues 234, 235, 238, 265, 269, 270, 297, 327, and 329 (U.S. Pat. No. 6,737,056). Certain antibody variants with improved or decreased binding to FcR are described. (See, eg, US Pat. No. 6,737,056, WO 2004 / 056312, and Shields et al., Biol. Chem. 9(2):6591-6604 (2001)). Such Fc variants include the so-called "DANA" Fc variants (US Pat. No. 7,332,581) with substitutions of residues 265 and 297 to alanine or residues 265 to alanine and 297 to glycine. Fc variants having substitutions at two or more of amino acid positions 265, 269, 270, 297, and 327, including so-called "DANG" Fc variants having . Alternatively, antibodies with reduced effector function include Fc region residues 234, 235, the so-called "PG-LALA" Fc variant with substitutions of residues 234 and 235 to alanine and 329 to glycine. , and antibodies having one or more substitutions of 329 (Lo, M. et al., Journal of Biochemistry, 292, 3900-3908). Other known mutations at positions 234, 235, and 321 can be used, the so-called TM variant containing mutations L234F / L235E / P331S in the CH2 domain (Oganesyan et al.Acta Cryst.D64,700- 704.(2008)). Antibodies derived from the human IgG4 isotype contain the mutations S228P / L235E to stabilize the hinge and reduce FgR binding (Schlothauer et al, PEDS, 29(10):457-466).
[0111] Other Fc variants include Fc region residues 238, 256, 265, 272, 286, 303, 305, 307, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, 382, 413 , 424, or 434, such as a substitution of Fc region residue 434 (US Pat. No. 7,371,826). See also Duncan & Winter, Nature 322:738-40 (1988), US Patent No. 5,648,260, US Patent No. 5,624,821.
[0112] The terms "specifically binds," "specific for," "immunoreactive," and "immunoreactive," as well as "antigen-binding specificity," when referring to an antibody, refer to a heterogeneous population of antigens (e.g. refers to a binding reaction with an antigen that is highly preferential for the antigen or a fragment thereof, so as to determine the presence of the antigen (e.g., proteins and other biological agents) in a sample. Therefore, under specified immunoassay conditions, a particular antibody will bind to a particular SARS-CoV-2 antigen and not in significant amounts to other antigens present in the sample. Specific binding to an antigen under such conditions may require antibodies that are selected for their specificity for a particular antigen. For example, an anti-SARS-CoV-2 antigen antibody can specifically bind to SARS-CoV-2 antigen and exhibit no comparable binding to other proteins present in the sample (e.g., no detectable binding). (not shown).
[0113] In some embodiments, antibodies of the present disclosure are directed against SARS-CoV-2 antigens (e.g., S1 subunit of SARS-CoV-2 spike (S) protein, receptor for S1 subunit of SARS-CoV-2 spike protein). body binding domain (RBD), S2 subunit of SARS-CoV-2 spike protein, SARS-CoV-2 envelope (E) protein, SARS-CoV-2 membrane (M) protein, or SARS-CoV-2 nucleocapsid (N ) protein), for example, about 10 5 M -1 Affinity or K a "specifically binds" to a SARS-CoV-2 antigen if it binds or associates with (i.e., the equilibrium binding constant for a particular binding interaction with units of 1 / M). In certain embodiments, the antibody has about 10 6 M -1 More than 10 7 M -1 More than 10 8 M -1 More than 10 9 M -1 More than 10 10 M -1 More than 10 11 M -1 More than 10 12 M -1 more than or about 10 13 M -1 more than K a binds to SARS-CoV-2. "High affinity" binding is defined as at least 10 7 M -1 , at least 10 8 M -1 , at least 10 9 M -1 , at least 10 10 M -1 , at least 10 11 M -1 , at least 10 12 M -1 , at least 10 13 M -1 , or larger K a It refers to joining with. Alternatively, the affinity may be measured in units of M (e.g., 10 -5 M~10 -13 The equilibrium dissociation constant (K D ) can be defined as In some embodiments, specific binding means that the antibody has about 10 -5 M or less, about 10 -6 M or less, about 10 -7 M or less, about 10 -8 M or less, about 10 -9 M or less, about 10 -10 M or less, about 10 -11 M or less, or about 10 -12 K less than or equal to M D meaning that it binds to SARS-CoV-2. The binding affinity of antibodies to SARS-CoV-2 antigens can be determined using conventional techniques, e.g. by competitive ELISA (enzyme-linked immunosorbent assay), by equilibrium dialysis, by surface plasmon resonance (SPR) technique. can be readily determined by radioimmunoassay, etc., by using the BIAcore2000 instrument (e.g., using the general procedures outlined by the manufacturer).
[0114] "Epitope" refers to the site on an antigen that an antibody binds to (e.g., the S1 subunit of the SARS-CoV-2 spike (S) protein, the receptor binding domain (RBD) of the S1 subunit of the SARS-CoV-2 spike protein) , the S2 subunit of the SARS-CoV-2 spike protein, the SARS-CoV-2 envelope (E) protein, the SARS-CoV-2 membrane (M) protein, and the SARS-CoV-2 nucleocapsid (N) protein. site on the CoV-2 antigen). Epitopes can be formed from both contiguous or non-contiguous amino acids juxtaposed by protein folding (eg, tertiary folding). Epitopes formed from contiguous amino acids are typically retained upon exposure to denaturing solvents, whereas epitopes formed by folding are typically lost upon treatment with denaturing solvents. Epitopes typically contain at least 3, more usually at least 5, or 8-10 amino acids in a linear or spatial configuration. Methods for determining the spatial structure of epitopes include, for example, X-ray crystallography and two-dimensional nuclear magnetic resonance. See, eg, Epitope Mapping Protocols in Methods in Molecular Biology, Vol. 66, Glenn E. Morris, Ed (1996). Several commercial laboratories offer epitope mapping services. An epitope bound by an antibody that is immunoreactive with a SARS-CoV-2 antigen can, for example, be present on the surface of SARS-CoV-2 or its antigen, such that such an epitope is immunoreactive with a SARS-CoV-2 antigen. -Considered to be accessible to CoV-2 surfaces, accessible to solvents, and / or exposed to SARS-CoV-2 surfaces.
[0115] According to some embodiments, the antibodies of the present disclosure are IgG antibodies. In certain embodiments, such antibodies are Variable heavy chain (V H ) polypeptide, which is encoded by the polynucleotide shown in SEQ ID NO: 473. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more , a variable heavy chain (V H ) polypeptide, Variable light chain (V L ) polypeptide, which is encoded by the polynucleotide shown in SEQ ID NO: 474. L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more , a variable light chain (V L ) polypeptide; The antibody has one or more, two or more, three or more, four or more, or five of the antibody complementarity determining regions (CDRs) encoded by the polynucleotides shown in SEQ ID NO: 473 and SEQ ID NO: 474. or comprising six such antibodies, Variable heavy chain (V H ) polypeptide encoded by the polynucleotide shown in SEQ ID NO: 475. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more , a variable heavy chain (V H ) polypeptide, Variable light chain (V L ) polypeptide encoded by the polynucleotide shown in SEQ ID NO: 476 L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more , a variable light chain (V L ) polypeptide; The antibody has one or more, two or more, three or more, four or more, or five of the antibody complementarity determining regions (CDRs) encoded by the polynucleotides shown in SEQ ID NO: 475 and SEQ ID NO: 476. or comprising six such antibodies, Variable heavy chain (V H ) polypeptide, which is encoded by the polynucleotide shown in SEQ ID NO: 477. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more , a variable heavy chain (V H ) polypeptide, Variable light chain (V L ) polypeptide, which is encoded by the polynucleotide shown in SEQ ID NO: 478. L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more , a variable light chain (V L ) polypeptide; The antibody has one or more, two or more, three or more, four or more, or five of the antibody complementarity determining regions (CDRs) encoded by the polynucleotides shown in SEQ ID NO: 477 and SEQ ID NO: 478. or comprising 6 or such antibodies, Variable heavy chain (V H ) polypeptide encoded by the polynucleotide shown in SEQ ID NO: 479 H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more , a variable heavy chain (V H ) polypeptide, Variable light chain (V L ) polypeptide encoded by the polynucleotide shown in SEQ ID NO: 480 L70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more , a variable light chain (V L ) polypeptide; The antibody has one or more, two or more, three or more, four or more, or five of the antibody complementarity determining regions (CDRs) encoded by the polynucleotides shown in SEQ ID NO: 479 and SEQ ID NO: 480. or comprising six such antibodies, Variable heavy chain (V H ) polypeptide, which is encoded by the polynucleotide shown in SEQ ID NO: 481. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more , a variable heavy chain (V H ) polypeptide, Variable light chain (V L ) polypeptide, which is encoded by the polynucleotide shown in SEQ ID NO: 482. L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more , a variable light chain (V L ) polypeptide; The antibody has one or more, two or more, three or more, four or more, or five of the antibody complementarity determining regions (CDRs) encoded by the polynucleotides shown in SEQ ID NO: 481 and SEQ ID NO: 482. or comprising six such antibodies, Variable heavy chain (V H ) polypeptide, which is encoded by the polynucleotide shown in SEQ ID NO: 483. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more , a variable heavy chain (V H ) polypeptide, Variable light chain (V L ) polypeptide, which is encoded by the polynucleotide shown in SEQ ID NO: 484. L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more , a variable light chain (V L ) polypeptide; The antibody has one or more, two or more, three or more, four or more, or five of the antibody complementarity determining regions (CDRs) encoded by the polynucleotides shown in SEQ ID NO: 483 and SEQ ID NO: 484. or comprising six such antibodies, Variable heavy chain (V H ) polypeptide, which is encoded by the polynucleotide shown in SEQ ID NO: 485. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more , a variable heavy chain (V H ) polypeptide, Variable light chain (V L ) polypeptide encoded by the polynucleotide shown in SEQ ID NO: 486 L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more , a variable light chain (V L ) polypeptide; The antibody has one or more, two or more, three or more, four or more, or five of the antibody complementarity determining regions (CDRs) encoded by the polynucleotides shown in SEQ ID NO: 485 and SEQ ID NO: 486. or comprising six such antibodies, Variable heavy chain (V H ) polypeptide, which is encoded by the polynucleotide shown in SEQ ID NO: 487. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more , a variable heavy chain (V H ) polypeptide, Variable light chain (V L ) polypeptide encoded by the polynucleotide shown in SEQ ID NO: 488. L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more , a variable light chain (V L ) polypeptide; The antibody has one or more, two or more, three or more, four or more, or five of the antibody complementarity determining regions (CDRs) encoded by the polynucleotides shown in SEQ ID NO: 487 and SEQ ID NO: 488. or comprising six such antibodies, Variable heavy chain (V H ) polypeptide encoded by the polynucleotide shown in SEQ ID NO: 489 H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more , a variable heavy chain (V H ) polypeptide, Variable light chain (V L ) polypeptide, which is encoded by the polynucleotide shown in SEQ ID NO: 490. L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more , a variable light chain (V L ) polypeptide; The antibody has one or more, two or more, three or more, four or more, or five of the antibody complementarity determining regions (CDRs) encoded by the polynucleotides shown in SEQ ID NO: 489 and SEQ ID NO: 490. or comprising six such antibodies, Variable heavy chain (V H ) polypeptide encoded by the polynucleotide shown in SEQ ID NO: 491 H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more , a variable heavy chain (V H ) polypeptide, Variable light chain (V L ) polypeptide, which is encoded by the polynucleotide shown in SEQ ID NO: 492. L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more , a variable light chain (V L ) polypeptide; The antibody has one or more, two or more, three or more, four or more, or five of the antibody complementarity determining regions (CDRs) encoded by the polynucleotides shown in SEQ ID NO: 491 and SEQ ID NO: 492. or comprising six such antibodies, Variable heavy chain (V H ) polypeptide, which is encoded by the polynucleotide shown in SEQ ID NO: 493. H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more , a variable heavy chain (V H ) polypeptide, Variable light chain (V L ) polypeptide, which is encoded by the polynucleotide shown in SEQ ID NO: 494. L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more , a variable light chain (V L ) polypeptide; The antibody has one or more, two or more, three or more, four or more, or five of the antibody complementarity determining regions (CDRs) encoded by the polynucleotides shown in SEQ ID NO: 493 and SEQ ID NO: 494. or 6, or such an antibody is Variable heavy chain (V H ) polypeptide encoded by the polynucleotide shown in SEQ ID NO: 495. H70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more , a variable heavy chain (V H ) polypeptide; Variable light chain (V L ) polypeptide encoded by the polynucleotide shown in SEQ ID NO: 496 L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more , a variable light chain (V L ) polypeptide; The antibody has one or more, two or more, three or more, four or more, or five of the antibody complementarity determining regions (CDRs) encoded by the polynucleotides shown in SEQ ID NO: 495 and SEQ ID NO: 496. or contains six.
[0116] In certain embodiments, SEQ ID NO:473 and SEQ ID NO:474, SEQ ID NO:475 and SEQ ID NO:476, SEQ ID NO:477 and SEQ ID NO:478, SEQ ID NO:479 and SEQ ID NO:480, SEQ ID NO:481 and SEQ ID NO:482, SEQ ID NO:483 and SEQ ID NO:484, SEQ ID NO:485 and SEQ ID NO:486, SEQ ID NO:487 and SEQ ID NO:488, SEQ ID NO:489 and SEQ ID NO:490, SEQ ID NO:491 and SEQ ID NO:492, SEQ ID NO:493 and SEQ ID NO:494, or SEQ ID NO:495 and Antibodies encoded by the polynucleotide set forth in SEQ ID NO: 496 are provided.
[0117] fusion protein Aspects of the disclosure further include fusion proteins. A fusion protein is a variable heavy chain (V H ) polypeptide, variable light chain (V L ) polypeptides, or both. "Heterologous," as used in the context of a nucleic acid or polypeptide, generally means that the nucleic acid or polypeptide has a different origin than that to which the nucleic acid or polypeptide is bound or linked (e.g., a molecule of a different sequence, means that the nucleic acid or polypeptide is not found in nature. For example, in a fusion protein, the light chain polypeptide and the reporter polypeptide (eg, GFP, luciferase, etc.) are said to be "heterologous" to each other. Similarly, CDRs from non-human antibodies and constant regions from human antibodies are said to be "heterologous" to each other.
[0118] In certain embodiments, the fusion proteins of the present disclosure include a heterologous sequence of amino acids fused to the C-terminus of an antibody chain. According to some embodiments, the antibody is a single chain antibody, eg, an scFv, as described elsewhere herein.
[0119] In certain embodiments, a fusion protein of the present disclosure is a chimeric antigen receptor (CAR) comprising a single chain antibody of the present disclosure, a transmembrane domain, and an intracellular signaling domain.
[0120] CARs of the present disclosure may include one or more linker sequences between the various domains. A "variable region linking sequence" is an amino acid sequence that connects the heavy chain variable region to the light chain variable region and provides a spacer function to accommodate the interaction of the two subbinding domains, so that the resulting polypeptide , retains the same specific binding affinity for the target molecule as an antibody containing the same light chain variable region and heavy chain variable region. A non-limiting example of a variable region linking sequence is the amino acid sequence GGGSGGGGSGGGS(G 4 S) 3 (SEQ ID NO: 497). In certain embodiments, a linker separates one or more heavy or light chain variable domains, hinge domains, transmembrane domains, costimulatory domains, and / or primary signaling domains. In certain embodiments, the CAR includes 1, 2, 3, 4, or 5 or more linkers. In certain embodiments, the length of the linker is from about 1 to about 25 amino acids, from about 5 to about 20 amino acids, or from about 10 to about 20 amino acids, or any intervening length of amino acids. In some embodiments, the linker is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or more amino acids in length.
[0121] In some embodiments, the antigen-binding domain of the CAR is followed by separation of the antigen-binding domain from the effector cell surface (e.g., the surface of a T cell expressing the CAR) for proper cell / cell contact, antigen binding, and / or or followed by one or more spacer domains that enable activation. The spacer domain (and any other spacer domains, linkers, etc. described herein) may be derived from either natural, synthetic, semi-synthetic, or recombinant sources. In certain embodiments, the spacer domain is a portion of an immunoglobulin, including, but not limited to, one or more heavy chain constant regions, such as CH2 and CH3. The spacer domain can include the amino acid sequence of a naturally occurring or modified immunoglobulin hinge region. In one embodiment, the spacer domain comprises CH2 and / or CH3 of IgG1, IgG4, or IgD. Exemplary spacer domains suitable for use in the CARs described herein include hinge regions derived from the extracellular regions of type 1 membrane proteins such as CD8α and CD4, which are derived from these molecules or variants thereof. may be the wild-type hinge region. In certain embodiments, the hinge domain comprises a CD8α hinge region. In some embodiments, the hinge is a PD-1 hinge or a CD152 hinge.
[0122] A "transmembrane domain" (Tm domain) is a portion of a CAR that fuses an extracellular binding portion with an intracellular signaling domain and anchors the CAR to the plasma membrane of a cell (eg, an immune effector cell). Tm domains can be derived from either natural, synthetic, semi-synthetic, or recombinant sources. In some embodiments, the Tm domain is a T cell receptor alpha or beta chain, CD35, CD3ζ, CD3γ, CD3δ, CD4, CD5, CD8α, CD9, CD16, CD22, CD27, CD28, CD33, CD37, Derived from CD45, CD64, CD80, CD86, CD134, CD137, CD152, CD154, or PD-1 (eg, containing at least transmembrane region(s) or a functional portion thereof).
[0123] In one embodiment, the CAR comprises a Tm domain derived from CD8α. In certain embodiments, the CAR has a Tm domain derived from CD8α, and connects the Tm domain and the intracellular signaling domain of the CAR, e.g., 1, 2, 3, 4, 5, 6, 7, 8, Contains short oligolinkers or polypeptide linkers of 9 or 10 amino acids in length. As such a linker, for example, a glycine-serine linker may be used.
[0124] The “intracellular signaling” domain of CAR is the term used to transmit signals from CAR binding to target molecules / antigens into the interior of immune effector cells to enhance effector cell functions, such as activation, cytokine production, proliferative activity, and / or or the portion of the CAR that is involved in eliciting cytotoxic activity, including the release of cytotoxic factors into CAR-bound target cells, or other cellular responses elicited upon target molecule / antigen binding to the extracellular CAR domain. point Accordingly, the term "intracellular signaling domain" refers to a portion of a protein that transmits effector function signals and causes the cell to perform specialized functions. To the extent that truncated portions of intracellular signaling domains are used, such truncated portions may be used in place of full-length intracellular signaling domains so long as they transmit effector function signals. The term intracellular signaling domain is meant to include any truncated portion of an intracellular signaling domain sufficient to transduce an effector function signal.
[0125] Signals generated through the T cell receptor (TCR) alone are insufficient for complete activation of T cells; secondary or costimulatory signals are also required. T cell activation therefore involves two distinct classes of intracellular signaling domains, primary signaling domains that initiate antigen-dependent primary activation through the TCR (e.g., TCR / CD3 complex), and antigen-independent mediated by co-stimulatory signaling domains that act to provide secondary or co-stimulatory signals. Accordingly, the CARs of the present disclosure may include intracellular signaling domains, including one or more "co-stimulatory signaling domains" and "primary signaling domains."
[0126] The primary signaling domain regulates the primary activation of the TCR complex in either a stimulatory or an inhibitory manner. A primary signaling domain that acts in a stimulatory manner may contain a signaling motif known as an immunoreceptor tyrosine-based activation motif (or "ITAM"). Non-limiting examples of ITAM-containing primary signaling domains suitable for use in the CARs of the present disclosure include those derived from FcRγ, FcRβ, CD3γ, CD3δ, CD3ε, CD3ζ, CD22, CD79α, CD79β, and CD66δ. It will be done. In certain embodiments, the CAR comprises a CD3ζ primary signaling domain and one or more costimulatory signaling domains. The intracellular primary signaling domain and the costimulatory signaling domain are operably linked to the carboxyl terminus of the transmembrane domain.
[0127] In some embodiments, the CAR includes one or more costimulatory signaling domains to enhance the efficacy and proliferation of immune effector cells (eg, T cells) that express the CAR. As used herein, the term "co-stimulatory signaling domain" or "co-stimulatory domain" refers to the intracellular signaling domain of a costimulatory molecule or active fragment thereof. Exemplary costimulatory molecules suitable for use in CARs contemplated in certain embodiments include TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, CARD11, CD2, CD7, CD27. , CD28, CD30, CD40, CD54 (ICAM), CD83, CD134 (OX40), CD137 (4-1BB), CD278 (ICOS), DAP10, LAT, KD2C, SLP76, TRIM, and ZAP70. In some embodiments, the CAR comprises one or more costimulatory signaling domains selected from the group consisting of 4-1BB (CD137), CD28, and CD134, and a CD3ζ primary signaling domain.
[0128] The CARs of the present disclosure include leader sequences, hinges, spacers, and / or linker domain(s), transmembrane domain(s), costimulatory domain(s), signal transduction domain(s) (e.g., CD3ζ Any of a variety of suitable domains may be included, including, but not limited to, domain(s), ribosome skipping element(s), restriction enzyme sequence(s), reporter protein domain, and the like.
[0129] In certain embodiments, a CAR of the present disclosure is a single chain antibody (e.g., any of the scFvs of the present disclosure) that binds to a SARS-CoV-2 antigen, from the group consisting of CD4, CD8α, CD154, and PD-1. a transmembrane domain from a selected polypeptide, one or more intracellular costimulatory signaling domains from a polypeptide selected from the group consisting of 4-1BB (CD137), CD28, and CD134, and FcRγ, FcRβ, The intracellular signaling domain is derived from a polypeptide selected from the group consisting of CD3γ, CD3δ, CD3ε, CD3ζ, CD22, CD79α, CD79β, and CD66δ. Such CARs may further include a spacer domain, eg, a CD8α hinge, between the antigen binding portion and the transmembrane domain.
[0130] According to some embodiments, from the N-terminus towards the C-terminus, the variable heavy chain (V H ) polypeptide, linker, antibody variable light chain (V L ), a CD8 hinge region (in some embodiments, an extended CD8 hinge region), a CD8 transmembrane domain, a 4-1BB costimulatory domain, and a CD3ζ signaling domain. According to certain embodiments, from the N-terminus towards the C-terminus, the variable light chain (V L ) Polypeptides, linkers, variable heavy chains of antibodies (V H ), a CD8 hinge region (in some embodiments, an extended CD8 hinge region), a CD8 transmembrane domain, a 4-1BB costimulatory domain, and a CD3ζ signaling domain. In certain embodiments, from the N-terminus towards the C-terminus, the variable heavy chain (V H ) polypeptide, linker, antibody variable light chain (V L ), a CD28 hinge region, a CD28 transmembrane domain, a 4-1BB costimulatory domain, and a CD3ζ signaling domain. According to some embodiments, from the N-terminus towards the C-terminus, the variable light chain (V L ) Polypeptides, linkers, variable heavy chains of antibodies (V H ), a CD28 hinge region, a CD28 transmembrane domain, a 4-1BB costimulatory domain, and a CD3ζ signaling domain. Any of the CARs in this disclosure may be V H A domain may be included at the N-terminus of the polypeptide. For example, a leader sequence (eg, GM-CSFR leader sequence) can be present at the N-terminus of a CAR of the present disclosure.
[0131] conjugate Conjugates are also provided. Conjugates include anti-SARS-CoV-2 antigen antibodies of the present disclosure or fusion proteins comprising such antibodies, and agents conjugated to the antibodies or fusion proteins. The term "conjugated" generally refers to a chemical bond, either covalent or non-covalent, usually covalent, that brings one molecule of interest into close association with a second molecule of interest. Point. In some embodiments, the agent is selected from a half-life extending moiety, a labeling agent, and a therapeutic agent. For half-life extension, for example, antibodies of the present disclosure can optionally be modified (eg, by PEGylation, hyperglycosylation, etc.) to provide improved pharmacokinetic profiles. Modifications that can extend serum half-life are of interest. A subject antibody can be "PEGylated" to contain one or more polyethylene glycol (PEG) moieties. Methods and reagents suitable for PEGylation of proteins are well known in the art and can be found in US Pat. No. 5,849,860. PEGs suitable for conjugation to proteins are generally soluble in water at room temperature and have the general formula R(O-CH 2 -CH 2 ) n O-R, where R is hydrogen or a protecting group such as an alkyl group or an alkanol group, and n is an integer from 1 to 1000. When R is a protecting group, it generally has 1 to 8 carbons. The PEG conjugated to the protein of interest can be linear. The PEG conjugated to the protein of interest may also be branched. Branched PEG derivatives such as those described in U.S. Pat. No. 5,643,575, "star PEG", and multi-arm PEG. Star PEGs have been described in the art, including, for example, US Pat. No. 6,046,305.
[0132] When the antibody of interest is isolated from a source, it may be conjugated to a moiety that facilitates purification, such as a member of a specific binding pair, e.g., biotin (a member of the biotin-avidin specific binding pair), a lectin, etc. can do. Antibodies can also be bound (eg, immobilized) to solid supports, including, but not limited to, polystyrene plates or beads, magnetic beads, test strips, membranes, and the like.
[0133] When antibodies are detected in an assay, they are labeled with a detectable label, such as a radioisotope (e.g. 125 I, 35 S), enzymes that produce detectable products (e.g., luciferase, β-galactosidase, horseradish peroxidase, alkaline phosphatase, etc.), fluorescent proteins, chromogenic proteins, dyes (e.g., fluorescein isothiocyanate, rhodamine, phycoerythrin, etc.) , a fluorescent emitting metal attached to the protein through a metal chelating group such as EDTA, e.g. 152 It may contain Eu or other metals of the lanthanide series, chemiluminescent compounds such as luminol, isoluminol, acridinium salts, etc., bioluminescent compounds such as luciferin, fluorescent proteins, etc. Indirect labels include antibodies specific for the protein of interest, which can be detected via a second antibody, and include members of specific binding pairs, such as biotin-avidin.
[0134] According to some embodiments, the agent is a labeling agent. "Labeling agent" (or "detectable label") means an antibody or fusion protein that is used to label an antibody or fusion protein so that it can be detected in the intended application (e.g., in vitro and / or in vivo studies and / or clinical applications). Refers to an agent that detectably labels a protein. Detectable labels of interest include radioisotopes (e.g., gamma emitters or positron emitters), enzymes that produce detectable products (e.g., horseradish peroxidase, alkaline phosphatase, luciferase, etc.), fluorescent proteins, Examples include paramagnetic atoms. In certain embodiments, the antibody or fusion protein is conjugated to a specific binding partner of the detectable label, e.g., biotin such that detection can occur via a detectable label, including avidin / streptavidin. conjugated.
[0135] In certain embodiments, the agent is associated with near-infrared (NIR) optical imaging, single-photon emission computed tomography (SPECT) ± CT imaging, positron emission tomography , PET) ± CT imaging, nuclear magnetic resonance (NMR) spectroscopy, and other in vivo imaging. Labeling agents that find use in such applications include, but are not limited to, fluorescent labels, radioactive isotopes, and the like. In certain embodiments, the labeling agent is a multimodal in vivo imaging agent that allows in vivo imaging using two or more imaging modalities (e.g., Thorp-Greenwood and Coogan (2011) Dalton Trans. 40: 6129-6143).
[0136] In certain embodiments, the labeling agent is an in vivo imaging agent that finds use in near-infrared (NIR) imaging applications. Such agents include, but are not limited to, Kodak X-SIGHT dyes, Pz247, DyLight 750 and 800 Fluors, Cy5.5 and 7 Fluors, Alexa Fluor 680 and 750 Dyes, IRDye 680 and 800CW Fluors. According to some embodiments, the labeling agent is an in vivo imaging agent that finds use in SPECT imaging applications, non-limiting examples of which include: 99m Tc, 111 In, 123 I, 201 Tl, and 133 An example is Xe. In certain embodiments, the labeling agent is an in vivo imaging agent that finds use in PET imaging applications, such as 11 C, 13 N, 15 O, 18 F, 64 Cu, 62 Cu, 124 I, 76 Br, 82 Rb, 68 Such as Ga.
[0137] Any of the agents described above used to modify the subject antibody or fusion protein can be linked to the antibody via a linker, such as a flexible linker. When present, the linker molecule is generally long enough to allow the antibody or fusion protein and the linked carrier some flexible movement between the antibody or fusion protein and the carrier. Linker molecules are generally about 6 to 50 atoms in length. The linker molecule may also be, for example, an arylacetylene, an ethylene glycol oligomer containing from 2 to 10 monomer units, a diamine, a diacid, an amino acid, or a combination thereof.
[0138] When the linker is a peptide, the linker contains from 1 amino acid (e.g., Gly) to 20 or more amino acids, from 4 amino acids to 10 amino acids, from 5 amino acids to 9 amino acids, from 6 amino acids to 8 amino acids, or from 7 amino acids to 8 amino acids, It can be of any suitable different length, such as 2 to 15 amino acids, 3 to 12 amino acids, and can be 1, 2, 3, 4, 5, 6, or 7 amino acids.
[0139] As a flexible linker, glycine polymer (G) n , glycine-serine polymers, glycine-alanine polymers, alanine-serine polymers, and other flexible linkers known in the art. Glycine and glycine-serine polymers can be used when relatively unstructured amino acids are desired and can function as neutral tethers between the components. Those skilled in the art will appreciate that the design of peptides conjugated to any of the elements described above can include all or It will be appreciated that partially flexible linkers can be included.
[0140] According to some embodiments, the antibody is conjugated to the drug via a non-cleavable linker. Non-cleavable linkers of interest include, but are not limited to, thioether linkers. Examples of thioether linkers that may be used include succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC) linkers.
[0141] In certain embodiments, the antibody is conjugated to the agent via a cleavable linker. According to some embodiments, the linker is stable at neutral pH (bloodstream pH 7.3-7.5), but weakly acidic endosomes (pH 5.0-6.5) and lysosomes (pH 4.5-7.5) of target cells. Chemically unstable linkers such as acid-cleavable linkers that undergo hydrolysis upon internalization to 5.0). Chemically unstable linkers include, but are not limited to, hydrazone-based linkers, oxime-based linkers, carbonate-based linkers, ester-based linkers, and the like. In certain embodiments, the linker is an enzyme that is stable in the bloodstream but undergoes enzymatic cleavage upon internalization into the target cell, e.g., by a lysosomal protease (such as a cathepsin or plasmin) in the lysosomes of the target cell. Enzyme-labile linkers, such as labile linkers. Enzyme-labile linkers include linkers containing peptide bonds, such as valine-citrulline (VC) linkers, maleimidocaproyl-valine-citruline-p-aminobenzyl, Examples include, but are not limited to, dipeptide-based linkers such as MC-vc-PAB) linkers, and valyl-alanyl-para-aminobenzyloxy (Val-Ala-PAB) linkers. Chemically labile linkers, enzymatically labile linkers, and non-cleavable linkers are known, for example Ducry & Stump (2010) Bioconjugate Chem. 21:5~13, Nolting, B. (2013) Methods Mol Biol. .1045:71-100, Tsuchikama and An (2018) Protein & Cell 9(1):33-46, and elsewhere.
[0142] A number of strategies are available for linking an agent to an antibody or fusion protein, either directly or indirectly through a linker. For example, a drug may be derivatized by covalently attaching a linker to the drug, the linker having a functional group that can react with a "chemical handle" on the antibody or fusion protein. The functional groups on the linker may vary and may be selected based on compatibility with the chemical handle on the antibody or fusion protein. According to one embodiment, a chemical handle on the antibody or fusion protein is provided by incorporating into the antibody or fusion protein a non-natural amino acid with a chemical handle. Unnatural amino acids that find use in preparing the conjugates of the present disclosure include azides, alkynes, alkenes, amino-oxy, hydrazines, aldehydes (e.g., formylglycine, e.g., SMARTag™ from Catalent Pharma Solutions). non-natural amino acids having functional groups selected from nitrone, nitrile oxide, cyclopropene, norbornene, isocyanide, aryl halide, and boronic acid functional groups. Unnatural amino acids that can be incorporated into the antibodies of the conjugates of the present disclosure and that can be selected to provide the desired functional group are known, e.g., Maza et al. (2015) Bioconjug. Chem.26(9):1884-9, Patterson et al.(2014)ACS Chem.Biol.9:592-605, Adumeau et al.(2016)Mol.Imaging Biol.(2):153-65, and Described elsewhere. Unnatural amino acids can be incorporated into antibodies via chemical synthesis or recombinant techniques (e.g., using a suitable orthogonal aminoacyl-tRNA synthetase-tRNA pair to incorporate unnatural amino acids during translation of the antibody in a host cell). obtain.
[0143] The functional groups of unnatural amino acids are azide, alkyne, alkene, amino-oxy, hydrazine, aldehyde, asaldehyde, nitrone, nitrile oxide, cyclopropene, norbornene, isocyanide, aryl halide, boric acid, diazo group, tetrazine, tetrazole, The functional group present in the antibody, which may be quadrocyclane, iodobenzene, or other suitable functional group, on the linker is selected to react with the functional group of the unnatural amino acid (and vice versa). similar). By way of example only, an unnatural amino acid with an azido group (such as 5-azido-L-norvaline) may be incorporated into the antibody, and the linker portion of the linker-sialic acid modulator moiety may include an alkyne functionality, such as As a result, the antibody and linker-sialic acid modulator moiety are covalently conjugated via an azide-alkyne cycloaddition. Conjugation can be performed using, for example, a copper-catalyzed azide-alkyne cycloaddition reaction.
[0144] In some embodiments, the chemical handle on the antibody does not include unnatural amino acids. Antibodies that do not contain unnatural amino acids can be used, for example, in substitution reactions with reactive leaving groups or other electrophilic moieties, such as nucleophilic functional groups of the antibody (N-terminal amines of lysine or primary amines, etc.). or any other nucleophilic amino acid residue) as a nucleophile. One example is to prepare a sialic acid modulator-linker or drug-linker moiety with an N-hydroxysuccinimidyl (NHS) ester, which can be used under aqueous conditions at high pH (approximately 10) or It involves reacting with the antibody in a polar organic solvent such as DMSO with the addition of a non-nucleophilic base such as N,N-diisopropylethylamine.
[0145] Specific techniques for linking linkers, agents, and / or antibodies or fusion proteins to each other are selected and used to conjugate the particular linkers, agents, and / or antibodies or fusion proteins, and the various components to each other. It is understood that this may vary depending on the functionality involved.
[0146] bispecific antibody Bispecific antibodies are also provided. According to some embodiments, the bispecific antibodies of the present disclosure include a first antigen-binding domain (e.g., Fab arm, scFv, etc.) that specifically binds a SARS-CoV-2 antigen; The antigen binding domain of 1 is the V of the antibodies of the present disclosure. H polypeptide and V L Contains polypeptides. In certain embodiments, bispecific antibodies include a second SARS-CoV-2 antigen that specifically binds to a SARS-CoV-2 antigen, e.g., the same or a different SARS-CoV-2 antigen that is bound by a first antigen-binding domain. antigen-binding domains (e.g., Fab arms, scFv, etc.). According to some embodiments, the bispecific antibody comprises a second antigen binding domain (eg, Fab arm, scFv, etc.) that specifically binds an antigen other than the SARS-CoV-2 antigen. Examples of antigens other than SARS-CoV-2 to which the second antigen-binding domain may specifically bind include cells physically associated with SARS-CoV-2 particles, e.g. These include, but are not limited to, cell surface antigens that are expressed on the surface of cells that carry the disease. In certain embodiments, the second antigen binding domain is capable of specifically binding an immune cell surface antigen. By way of example, an immune cell surface antigen may be a T cell surface antigen.
[0147] Bispecific antibodies of the present disclosure include antibodies having full-length antibody structures and bispecific antibody fragments. "Full-length" as used herein refers to an antibody having two full-length antibody heavy chains and two full-length antibody light chains. A full-length antibody heavy chain (HC) consists of the known variable heavy chain and constant domains VH, CH1, CH2, and CH3. A full-length antibody light chain (LC) consists of the known variable light chain and constant domains VL and CL. A full-length antibody may lack a C-terminal lysine on either one or both heavy chains. The term "Fab arm" refers to one heavy chain-light chain pair that specifically binds an antigen.
[0148] Full-length bispecific antibodies are produced using, for example, Fab arm exchange (or half molecule exchange) between two monospecific bivalent antibodies to introduce substitutions at the heavy chain CH3 interface in each half molecule. can be produced in vitro in a cell-free environment or using co-expression, by favoring heterodimerization of two antibody half molecules with distinct specificities. The Fab arm exchange reaction is the result of a disulfide bond isomerization reaction and dissociation-association of CH3 domains. Heavy chain disulfide bonds in the hinge region of the parent monospecific antibody are reduced. The resulting free cysteine of one of the parent monospecific antibodies forms an inter-heavy chain disulfide bond with the cysteine residue of the second parent monospecific antibody molecule, simultaneously with the CH3 domain of the parent antibody. is released and reformed by dissociation-association. The CH3 domain of the Fab arm can be engineered to favor heterodimerization over homodimerization. The resulting product is a bispecific antibody having two Fab arms or half molecules, each binding a different epitope.
[0149] Full-length bispecific antibodies may be generated using a "knob-in-hole" strategy (see, eg, International Application PCT WO 2006 / 028936). Briefly, selected amino acids that form the interface of the CHS domain in human IgG can be mutated at positions that affect CH3 domain interactions to promote heterodimer formation. An amino acid with a small side chain (hole) is introduced into the heavy chain of an antibody that specifically binds to a first antigen, and an amino acid with a large side chain (knob) specifically binds to a second antigen. Introduced into the heavy chain of the antibody. After co-expression of two antibodies, a heterodimer is formed as a result of the preferential interaction of the heavy chain with the "hole" and the heavy chain with the "knob." An exemplary CH3 substitution pair that forms a knob and hole is (expressed as a modified position in the first CH3 domain of the first heavy chain / modified position in the second CH3 domain of the second heavy chain) T366Y7F405A , T366W / F405W, F405W / Y407A, T394W / Y407T, T3945 / Y407A, T366W / T394S, F405W / T394S, and T366W / T366S_L368A_Y407V.
[0150] One CH3 surface can be Other methods, such as using electrostatic interactions to promote heavy chain heterodimerization by displacing charged residues on the surface and displacing negatively charged residues on the second CH3 surface, strategies may be used. In other strategies, heterodimerization involves the following substitutions (the first L351Y_F405A_Y407V (expressed as a modified position in the CH3 domain of the second heavy chain) A / T366A_K409F, L351Y_Y407A / T366V_K409F, Y407A / T366A_K409F, or It can be facilitated by substitution of T350V_L351Y_F405A_Y407V / T350V_T366L_K392L_T394W.
[0151] Single chain bispecific antibodies are also provided. In some embodiments, a single chain bispecific antibody of the present disclosure is a bispecific scFv. Details regarding bispecific scFvs can be found, for example, in Zhou et al. (2017) J Cancer8(18):3689-3696.
[0152] Methods of producing antibodies and fusion proteins Using the information provided herein, anti-SARS-CoV-2 antigen antibodies and fusion proteins of the present disclosure can be prepared using techniques known to those of skill in the art. For example, nucleic acid sequences encoding the amino acid sequences of antibodies of the present disclosure can be used to express antibodies. The polypeptide sequences provided herein (see, e.g., Table 1) can be used to determine suitable nucleic acid sequences encoding antibodies, which nucleic acid sequences can then be used to identify SARS-CoV- can be used to express one or more antibodies specific for 2. Nucleic acid sequence(s) can be optimized to reflect particular codon "choices" for various expression systems according to methods known to those skilled in the art.
[0153] Using the amino acid sequence information and / or polynucleotide sequence information provided herein, nucleic acids can be synthesized according to a number of standard methods known to those of skill in the art. Oligonucleotide synthesis is preferably performed on a commercially available solid phase oligonucleotide synthesizer or synthesized manually using, for example, the solid phase phosphoramidite triester method.
[0154] Once the nucleic acid encoding the antibody or fusion protein of interest has been synthesized, it can be amplified and / or cloned according to standard methods. Molecular cloning techniques to achieve these objectives are known in the art. A wide variety of cloning and in vitro amplification methods suitable for the construction of recombinant nucleic acids are known to those skilled in the art and are the subject of numerous textbooks and laboratory manuals.
[0155] Expression of natural or synthetic nucleic acids encoding antibodies of the present disclosure is accomplished by operably linking the antibody-encoding nucleic acids to a promoter (either constitutive or inducible) and incorporating the construct into an expression vector. This can be achieved by generating a recombinant expression vector. Vectors may be suitable for replication and integration in prokaryotes, eukaryotes, or both. A typical cloning vector contains functionally properly oriented transcription and translation terminators, initiation sequences, and a promoter useful for regulating the expression of the antibody-encoding nucleic acid. The vector optionally includes at least one independent terminator sequence, e.g., a sequence that allows replication of the cassette in both eukaryotic and prokaryotic systems, such as found in shuttle vectors, and Contains a general expression cassette containing selection markers for both biological systems.
[0156] To obtain high-level expression of a cloned nucleic acid, a strong promoter directing transcription, a ribosome binding site for translation initiation, and a transcription / translation terminator are each typically combined relative to each other. It is common to construct expression plasmids containing the protein-coding sequence in a functional orientation. Examples of suitable regulatory regions for this purpose in E. coli include the promoter and operator regions of the E. coli tryptophan biosynthetic pathway, phage lambda, P L ) and the L-arabinose (araBAD) operon. It is also useful to include a selection marker in the DNA vector transformed in E. coli. Examples of such markers include genes that specify resistance to ampicillin, tetracycline, or chloramphenicol. Expression systems for expressing antibodies are available using, for example, E. coli, Bacillus, and Salmonella. E. coli systems may also be used.
[0157] The antibody gene(s) also allows the addition of tags (e.g., FLAG, hexahistidine, etc.) to the C-terminus or N-terminus of the antibody (e.g., IgG, Fab, scFv, etc.) to facilitate purification. can be subcloned into an expression vector. Methods for transfecting and expressing genes in mammalian cells are known in the art. Transducing a cell with a nucleic acid can include, for example, incubating a lipid microparticle containing the nucleic acid with the cell, or incubating a viral vector containing the nucleic acid with a cell within the vector's host range. Culturing cells used in this disclosure, including cell lines and cultured cells from tissues (eg, tumors) or blood samples, is well known in the art.
[0158] Once the nucleic acid encoding the antibody of interest has been isolated and cloned, the nucleic acid can be expressed in a variety of recombinantly engineered cells known to those skilled in the art. Examples of such cells include bacteria, yeast, fungi, insects (eg, insects using baculovirus vectors), and mammalian cells.
[0159] Isolation and purification of the subject antibodies can be accomplished according to methods known in the art. For example, proteins can be purified by immunoaffinity purification (or using protein L or A), from lysates of cells genetically modified to express the protein constitutively and / or upon induction, or from synthetic reaction mixtures. (precipitation), washing to remove non-specifically bound material, and elution of specifically bound antibodies. Isolated antibodies can be further purified by dialysis and other methods commonly used in protein purification techniques. In one embodiment, antibodies can be isolated using metal chelate chromatography methods. Antibodies of the present disclosure may include modifications to facilitate isolation, as discussed above.
[0160] A subject antibody can be prepared in substantially pure or isolated form (eg, free of other polypeptides). A protein can be present in a composition that is enriched in polypeptides compared to other components that may be present (eg, other polypeptides or other host cell components). A purified antibody is defined such that the antibody is present in a composition that is substantially free of other expressed proteins, e.g., less than 90%, usually less than 60%, more usually less than 50% of the composition is free of other expressed proteins. It can be provided to be composed of proteins.
[0161] Antibodies produced by prokaryotic cells may require exposure to chaotropic agents for proper folding. During purification from E. coli, for example, the expressed protein may optionally be denatured and then renatured. This can be achieved, for example, by solubilizing bacterially produced antibodies in a chaotropic agent such as guanidine HCl. The antibodies are then regenerated either by slow dialysis or gel filtration. Alternatively, the nucleic acid encoding the antibody can be operably linked to a secretion signal sequence, such as pelB, so that the antibody is secreted into the periplasm in a correctly folded form.
[0162] The disclosure also provides cells that produce the antibodies of the disclosure, and suitable cells include eukaryotic cells, such as mammalian cells. The cells can be hybrid cells or "hybridomas" capable of regenerating antibodies (eg, monoclonal antibodies such as IgG) in vitro. For example, the present disclosure describes recombinant host cells (herein referred to as "genetically modified host cells") that have been genetically modified with one or more nucleic acids comprising nucleotide sequences encoding the heavy and / or light chains of the antibodies of the present disclosure. (also called).
[0163] Techniques for making recombinant DNA versions of the antigen binding region of antibody molecules that avoid the generation of hybridomas are also contemplated herein. The DNA is cloned into, for example, a bacterial expression system (eg, bacteriophage), a yeast expression system (eg, Saccharomyces or Pichia), an insect expression system, or a mammalian expression system. One example of a suitable technique uses a bacteriophage lambda vector system that has a leader sequence that allows the expressed antibody (eg, Fab or scFv) to be translocated into the periplasmic space (between the bacterial cell membrane and the cell wall) or secreted. Large numbers of functional fragments (eg, Fabs or scFvs) can be rapidly generated for those that bind tumor-associated antigens.
[0164] Antibodies that specifically bind SARS-CoV-2 are prepared using a wide variety of techniques known in the art, including the use of hybridoma, recombinant, phage display technology, or combinations thereof. be able to. For example, antibodies can be produced and isolated using phage display methods. Phage display is used for high-throughput screening of protein interactions. Phage may be used to display antigen binding domains expressed from repertoires or combinatorial antibody libraries (eg, human or murine). Phage expressing antigen binding domains that bind to SARS-CoV-2 are selected or identified with SARS-CoV-2, e.g., using labeled SARS-CoV-2 bound or captured to a solid surface or bead. be able to. The phages used in these methods are typically Fab, Fv (individual Fv regions from light or heavy chains), fused recombinantly to either phage gene III or gene VIII proteins; or a filamentous phage containing an fd and M13 binding domain expressed from a phage with a disulfide-stabilized Fv antibody domain. Exemplary methods are described, for example, in U.S. Pat. No. 5,969,108, Hoogenboom, H.R. and Chames, Immunol. Today 2000, 21:371, Nagy et al. Natl.Acad.Sci.USA 2001,98:2682, Lui et al., J.Mol.Biol.2002,315:1063, each of which is incorporated herein by reference. Several publications (e.g., Marks et al., Bio / Technology 1992, 10:779-783) discuss the production of high-affinity human antibodies by chain shuffling, as well as its use as a strategy for constructing large phage libraries. Combinatorial infection and in vivo recombination are described. In another embodiment, ribosome display can be used to replace bacteriophage as the display platform (e.g., Hanes et al.Biotechnol.2000,18:1287, Wilson et al., Proc. Natl. Acad. Sci. USA 2001, 98:3750, or Irving et al., J. Immunol. Methods 2001, 248:31). Cell surface libraries can be screened for antibodies (Boder et al., Proc. Natl. Acad. Sci. USA 2000, 97:10701, Daugherty et al., J. Immunol. Methods 2000, 243:211). Such a procedure provides an alternative to traditional hybridoma technology for the isolation and subsequent cloning of monoclonal antibodies.
[0165] After phage selection, the phage-derived antibody coding region is isolated and used to generate whole antibodies or any desired antigen-binding fragment, including human antibodies, mammalian cells, insect cells, plant cells, yeast, and bacteria. can be expressed in any desired host including. For example, Fv, scFv, Fab, F(ab’) 2 , and techniques for recombinantly producing Fab' fragments can be used using methods known in the art.
[0166] In certain embodiments, antibodies of the present disclosure may be used in individuals who have or have had a SARS-CoV-2 infection (e.g., have COVID-19 or have previously had a SARS-CoV-2 infection). sorting memory B cells obtained from a blood sample of an individual who had a (trademark)) and analyzing BCR-paired clonal strains and / or SHM variants within those strains to identify highly SARS-CoV-2-specific features. Selecting for potential and selecting top matched BCR candidates for antibody synthesis and functional characterization. Aspects of the present disclosure include methods of identifying anti-SARS-CoV-2 antigen antibodies by performing such steps.
[0167] Nucleic acids, expression vectors, and cells Considering the above section regarding methods of producing antibodies of the present disclosure, it will be understood that the present disclosure also provides nucleic acids, expression vectors, and cells.
[0168] In certain embodiments, the variable heavy chain (V H ) polypeptide, variable light chain (V L ) polypeptides, or both. According to some embodiments, the antibodies of the present disclosure have a variable heavy chain (V H ) polypeptides, such as antibodies 508, 767, 935, 937, 941, 980, 1085, 1213, 1227, 1231, 1238, 1439, 1589, 1671, 1679, 1814, 1815, 1823, 1826, 1851, 1856,1859,1864,1867,1870,1871,1872,1888,1915,1959,1963,1969,1984,2019,2020,2024,2025,2050,2075,2080,2432,2564,2598,2606,2 619, 2646, 2706, 2729, 2788, 2793, 2794, 2854, 2866, 2892, 3086, 3091, 3995, 4042, or 4441 V H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more , a variable heavy chain (V H ) polypeptide and variable light chain (V L ) polypeptide, which is an antibody 508, 767, 935, 937, 941, 980, 1085, 1213, 1227, 1231, 1238, 1439, 1589, 1671, 1679, 1814, 1815, 1823, 1826, 1851, 1856, 1859,1864,1867,1870,1871,1872,1888,1915,1959,1963,1969,1984,2019,2020,2024,2025,2050,2075,2080,2432,2564,2598,2606,2619,2 646, 2706, 2729, 2788, 2793, 2794, 2854, 2866, 2892, 3086, 3091, 3995, 4042, or 4441 V L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more , a variable light chain (V L ) polypeptide and V of the antibody containing respectively H polypeptide, V L Nucleic acids encoding polypeptides, or both, are provided, which antibodies include antibodies 508, 767, 935, 937, 941, 980, 1085, 1213, 1227, 1231, 1238, 1439, 1589, 1671, 1679 , 1814, 1815, 1823, 1826, 1851, 1856, 1859, 1864, 1867, 1870, 1871, 1872, 1888, 1915, 1959, 1963, 1969, 1984, 2019, 2020, 2024, 2025, 2050, 2075, 2080 of the complementarity determining regions (CDRs) of Including 1 or more, 2 or more, 3 or more, 4 or more, 5 or 6, respectively. A non-limiting example of such a nucleic acid is provided in Example 2 below. In certain embodiments, the nucleic acids of the present disclosure contain V of the polynucleotide sequence set forth in any one of SEQ ID NOs: 473-496 H code area or V L Contains code region. In certain embodiments, a nucleic acid of the present disclosure comprises a heavy chain coding region or a light chain coding region of a polynucleotide sequence set forth in any one of SEQ ID NOs: 473-496. According to some embodiments, the nucleic acid of the present disclosure comprises a polynucleotide sequence set forth in any one of SEQ ID NOs: 473-496, or a polynucleotide sequence set forth in any one of SEQ ID NOs: 473-496. , 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98 % or more, 99% or more, or 100% nucleotide sequence identity.
[0169] In certain embodiments, the variable heavy chain (V H ) polypeptide, variable light chain (V L ) polypeptides, or both, the antibody is a single chain antibody (eg, an scFv), and the nucleic acid encodes a single chain antibody.
[0170] Any of the nucleic acids of this disclosure can be operably linked to a heterologous expression control sequence, such as a heterologous promoter.
[0171] Expression vectors containing any of the nucleic acids of this disclosure are also provided.
[0172] Also provided are cells containing any of the disclosed nucleic acids and / or expression vectors. According to some embodiments, the cells of the present disclosure contain antibody V H V of polypeptides and antibodies L Contains a nucleic acid encoding a polypeptide. In certain such embodiments, the antibody is a single chain antibody (eg, an scFv) and the nucleic acid encodes a single chain antibody. According to some embodiments, the variable heavy chain (V H ) a first nucleic acid encoding a polypeptide and an antibody variable light chain (V L ) a second nucleic acid encoding a polypeptide. In certain embodiments, such cells include a first expression vector that includes a first nucleic acid and a second expression vector that includes a second nucleic acid.
[0173] According to some embodiments, the variable heavy chain (V H ) polypeptide, which is an antibody 508, 767, 935, 937, 941, 980, 1085, 1213, 1227, 1231, 1238, 1439, 1589, 1671, 1679, 1814, 1815, 1823, 1826, 1851, 1856, 1859,1864,1867,1870,1871,1872,1888,1915,1959,1963,1969,1984,2019,2020,2024,2025,2050,2075,2080,2432,2564,2598,2606,2619,2 646, 2706, 2729, 2788, 2793, 2794, 2854, 2866, 2892, 3086, 3091, 3995, 4042, or 4441 V H 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more , a variable heavy chain (V H ) polypeptide and variable light chain (V L ) polypeptide, which is an antibody 508, 767, 935, 937, 941, 980, 1085, 1213, 1227, 1231, 1238, 1439, 1589, 1671, 1679, 1814, 1815, 1823, 1826, 1851, 1856, 1859,1864,1867,1870,1871,1872,1888,1915,1959,1963,1969,1984,2019,2020,2024,2025,2050,2075,2080,2432,2564,2598,2606,2619,2 646, 2706, 2729, 2788, 2793, 2794, 2854, 2866, 2892, 3086, 3091, 3995, 4042, or 4441 V L 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more , a variable light chain (V L ) polypeptide and V of the antibody containing respectively H polypeptide, V L Nucleic acids encoding polypeptides, or both, are provided, which antibodies include antibodies 508, 767, 935, 937, 941, 980, 1085, 1213, 1227, 1231, 1238, 1439, 1589, 1671, 1679 , 1814, 1815, 1823, 1826, 1851, 1856, 1859, 1864, 1867, 1870, 1871, 1872, 1888, 1915, 1959, 1963, 1969, 1984, 2019, 2020, 2024, 2025, 2050, 2075, 2080 of the complementarity determining regions (CDRs) of Including 1 or more, 2 or more, 3 or more, 4 or more, 5 or 6, respectively. A non-limiting example of such a nucleic acid is provided in Example 2 below. In some embodiments, the cells of the present disclosure contain V of the polynucleotide sequence set forth in any one of SEQ ID NOs: 473-496. H code area or V LContains a nucleic acid that includes a coding region. In certain embodiments, a cell of the present disclosure comprises a nucleic acid comprising a heavy chain coding region or a light chain coding region of a polynucleotide sequence set forth in any one of SEQ ID NOs: 473-496. According to some embodiments, a cell of the present disclosure comprises a polynucleotide sequence set forth in any one of SEQ ID NOs: 473-496, or a polynucleotide sequence set forth in any one of SEQ ID NOs: 473-496. , 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, or 99% or more nucleotide sequence identity.
[0174] In certain embodiments, SEQ ID NO: 473 and SEQ ID NO: 474, SEQ ID NO: 475 and SEQ ID NO: 476, SEQ ID NO: 477 and SEQ ID NO: 478, SEQ ID NO: 479 and SEQ ID NO: 480, SEQ ID NO: 481 and SEQ ID NO: 482, SEQ ID NO: 483 and SEQ ID NO:484, SEQ ID NO:485 and SEQ ID NO:486, SEQ ID NO:487 and SEQ ID NO:488, SEQ ID NO:489 and SEQ ID NO:490, SEQ ID NO:491 and SEQ ID NO:492, SEQ ID NO:493 and SEQ ID NO:494, or SEQ ID NO:495 and A cell comprising a polynucleotide set forth in SEQ ID NO: 496 is provided.
[0175] Any of the cells of this disclosure may include a heterologous expression control sequence, eg, a nucleic acid(s) operably linked to a heterologous promoter.
[0176] A method of producing an antibody of the present disclosure, comprising: culturing a cell of the present disclosure under conditions suitable for the cell to express the antibody, wherein the antibody is produced. provided. Conditions suitable for cells to express antibodies can vary. Non-limiting examples of such conditions include a suitable container (e.g., a cell culture plate or well thereof) at a suitable temperature (e.g., 32°C to 42°C, such as 37°C) and pH (e.g., pH pH 7.0-7.7 (e.g. 7.4) in a suitable medium (e.g. cell culture medium such as DMEM, RPMI, MEM, IMDM, DMEM / F-12) with a suitable percentage of CO 2 For example, cells may be cultured in an environment having a concentration of 3% to 10%, such as 5%.
[0177] Composition The present disclosure also provides compositions. In certain embodiments, the compositions find use, for example, in practicing the methods of the present disclosure.
[0178] According to some embodiments, compositions of the present disclosure include antibodies of the present disclosure. For example, the antibody may be any of the antibodies described in the Antibodies section herein above, which is incorporated herein for purposes of brevity and will not be repeated. According to some embodiments, compositions of the present disclosure include conjugates of the present disclosure. In some embodiments, compositions of the present disclosure include fusion proteins of the present disclosure.
[0179] In certain embodiments, compositions of the present disclosure include antibodies present in a liquid medium. The liquid medium may be an aqueous liquid medium such as water or a buffer solution. Salts (e.g. NaCl, MgCl 2 , KCl, MgSO 4 ), buffers (Tris buffer, N-(2-hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid) (HEPES), 2-(N-morpholino)ethanesulfonic acid (MES), 2-( N-morpholino)ethanesulfonic acid sodium salt (MES), 3-(N-morpholino)propanesulfonic acid (MOPS), N-tris[hydroxymethyl]methyl-3-aminopropanesulfonic acid (TAPS), etc.), solubilization One or more additives are present in such compositions, such as detergents, detergents (e.g., nonionic detergents such as Tween-20), nuclease inhibitors, protease inhibitors, glycerol, chelating agents, etc. You may.
[0180] As summarized above, aspects of the present disclosure include pharmaceutical compositions. In some embodiments, a pharmaceutical composition of the present disclosure comprises an anti-SARS-CoV-2 antigen antibody of the present disclosure (or a conjugate or fusion protein comprising the same) and a pharmaceutically acceptable carrier. .
[0181] As will be appreciated, the pharmaceutical compositions of the present disclosure may include any of the agents and features described in the Antibodies and Methods section herein, which for purposes of brevity are omitted herein. incorporated into the book, but not repeated in detail.
[0182] In certain embodiments, the pharmaceutical compositions of the present disclosure are directed to an antibody that competes for binding to SARS-CoV-2 with an antibody comprising the six CDRs of the antibody designated herein as antibody 941, or the present invention. An antibody comprising the 6 CDRs of the antibody designated herein as antibody 941, or the V of the antibody designated herein as antibody 941 H and V L comprising a therapeutically effective amount of an antibody comprising. Antibodies may be part of the fusion proteins or conjugates of this disclosure.
[0183] According to some embodiments, the pharmaceutical compositions of the present disclosure include an antibody that competes for binding to SARS-CoV-2 with an antibody comprising six CDRs of antibody designated herein as antibody 980; or an antibody comprising the 6 CDRs of the antibody designated herein as antibody 980, or the V of the antibody designated herein as antibody 980. H and V L comprising a therapeutically effective amount of an antibody comprising. Antibodies may be part of the fusion proteins or conjugates of this disclosure.
[0184] In certain embodiments, the pharmaceutical compositions of the present disclosure are directed to an antibody that competes for binding to SARS-CoV-2 with an antibody comprising the six CDRs of the antibody designated herein as antibody 1589, or the present invention. An antibody comprising the 6 CDRs of the antibody designated herein as antibody 1589, or the V of the antibody designated herein as antibody 1589 H and V L comprising a therapeutically effective amount of an antibody comprising. Antibodies may be part of the fusion proteins or conjugates of this disclosure.
[0185] Any of the pharmaceutical compositions of the present disclosure may include a "cocktail" of two or more different antibodies, at least one of which is an antibody of the present disclosure. In certain embodiments, a pharmaceutical composition of the present disclosure comprises a therapeutically effective amount of a cocktail of two or more different antibodies, and at least two of the two or more different antibodies are antibodies of the present disclosure. . According to some embodiments, the pharmaceutical compositions of the present disclosure include antibodies of the present disclosure, e.g., antibodies 508, 767, 935, herein for binding to SARS-CoV-2 antigen(s). 937,941,980,1085,1213,1227,1231,1238,1439,1589,1671,1679,1814,1815,1823,1826,1851,1856,1859,1864,1867,1870,1871,1872,1888, 1915,1959,1963,1969,1984,2019,2020,2024,2025,2050,2075,2080,2432,2564,2598,2606,2619,2646,2706,2729,2788,2793,2794,2854,2 866, An antibody that competes with an antibody comprising the six CDRs of antibody designated 2892, 3086, 3091, 3995, 4042, and / or 4441, or herein antibody 508, 767, 935, 937, 941, 980, 1085 , 1213, 1227, 1231, 1238, 1439, 1589, 1671, 1679, 1814, 1815, 1823, 1826, 1851, 1856, 1859, 1864, 1867, 1870, 1871, 1872, 1888, 1915, 1959, 1963, 1969 , 1984, 2019, 2020, 2024, 2025, 2050, 2075, 2080, 2432, 2564, 2598, 2606, 2619, 2646, 2706, 2729, 2788, 2793, 2794, 2854, 2866, 2892, 3086, 3091, 3995 , 4042, and / or 4441, or herein antibodies 508, 767, 935, 937, 941, 980, 1085, 1213, 1227, 1231, 1238, 1439, 1589,1671,1679,1814,1815,1823,1826,1851,1856,1859,1864,1867,1870,1871,1872,1888,1915,1959,1963,1969,1984,2019,2020,2024,2 025, of antibodies designated as 2050, 2075, 2080, 2432, 2564, 2598, 2606, 2619, 2646, 2706, 2729, 2788, 2793, 2794, 2854, 2866, 2892, 3086, 3091, 3995, 4042, or 4441. V H and V L A cocktail of two or more, three or more, four or more, or five or more antibodies comprising. Antibodies can be present as fusion proteins or conjugates of the present disclosure.
[0186] In certain embodiments, the pharmaceutical compositions of the present disclosure provide antibodies comprising six CDRs of antibodies designated herein as antibodies 941 and 980 for binding to SARS-CoV-2 antigen(s). or an antibody comprising the six CDRs of antibodies designated herein as antibodies 941 and 980, or V of antibodies designated herein as antibodies 941 and 980. H and V L comprising a therapeutically effective amount of a cocktail comprising an antibody comprising: Antibodies can be present as fusion proteins or conjugates of the present disclosure.
[0187] According to some embodiments, the pharmaceutical compositions of the present disclosure compete for binding to SARS-CoV-2 with antibodies comprising the six CDRs of antibodies designated herein as antibodies 941 and 1589. antibody, or an antibody comprising the six CDRs of the antibody designated herein as antibodies 941 and 1589, or the V of the antibody designated herein as antibodies 941 and 1589 H and V L comprising a therapeutically effective amount of a cocktail comprising an antibody comprising: Antibodies can be present as fusion proteins or conjugates of the present disclosure.
[0188] In certain embodiments, the pharmaceutical compositions of the present disclosure provide an antibody that competes for binding to SARS-CoV-2 with an antibody comprising the six CDRs of antibodies designated herein as antibodies 980 and 1589; or an antibody comprising the 6 CDRs of antibodies designated herein as antibodies 980 and 1589, or V of antibodies designated herein as antibodies 980 and 1589. H and V L comprising a therapeutically effective amount of a cocktail comprising an antibody comprising: Antibodies can be present as fusion proteins or conjugates of the present disclosure.
[0189] One or more antibodies (including any of the conjugates or fusion proteins of the present disclosure) can be incorporated into a variety of formulations for therapeutic administration. More specifically, anti-SARS-CoV-2 antigen antibodies can be formulated into pharmaceutical compositions by combining with suitable pharmaceutically acceptable excipients or diluents, such as tablets, capsules, powders, etc. may be formulated into solid, semisolid, liquid, or gaseous form preparations, such as granules, ointments, solutions, injections, inhalants, and aerosols.
[0190] Preparations of drugs for administration to individuals (e.g., suitable for administration to humans) are generally sterile and, in addition, have a detectable fever that is contraindicated for administration to patients according to the chosen route of administration. It may be free of substances or other contaminants.
[0191] In pharmaceutical dosage forms, the drug(s) may be administered in the form of their pharmaceutically acceptable salts, or they may be combined alone or appropriately with other pharmaceutically active compounds. They can also be used together as well as in combination. The following methods and carriers / excipients are merely examples and are in no way limiting.
[0192] For oral formulations, the drug(s) may be added alone or with suitable excipients to make tablets, powders, granules, or capsules, such as conventional additions such as lactose, mannitol, cornstarch, or potato starch. binders such as microcrystalline cellulose, cellulose derivatives, acacia, corn starch, or gelatin; disintegrants such as corn starch, potato starch, or sodium carboxymethyl cellulose; lubricants such as talc or magnesium stearate; and, if necessary, dilution. It can be used in combination with agents, buffering agents, wetting agents, preservatives, and flavoring agents.
[0193] The drug(s) can be formulated for parenteral (eg, intravenous, intraarterial, intraosseous, intramuscular, intracerebral, intraventricular, intrathecal, subcutaneous, etc.) administration. In certain embodiments, the drug(s) are present in an aqueous or non-aqueous solvent such as vegetable oil or other similar oil, synthetic aliphatic acid glycerides, esters of higher aliphatic acids, or propylene glycol. Formulated for injection by dissolving, suspending, or emulsifying (optional), optionally containing conventional agents such as solubilizing agents, isotonic agents, suspending agents, emulsifying agents, stabilizing agents, and preservatives. It is formulated with additives.
[0194] Pharmaceutical compositions containing drug(s) contain drug(s) of desired purity in optional physiologically acceptable carriers, excipients, stabilizers, surfactants, buffers, and / or may be prepared by mixing with tonicity agents. Acceptable carriers, excipients, and / or stabilizers are non-toxic to recipients at the dosages and concentrations employed, and include buffering agents such as phosphates, citrates, and other organic acids. ;Antioxidants including ascorbic acid, glutathione, cysteine, methionine, and citric acid; (ethanol, benzyl alcohol, phenol, m-cresol, p-chloro-m-cresol, methyl or propylparaben, benzalkonium chloride; preservatives such as combinations of these); amino acids such as arginine, glycine, ornithine, lysine, histidine, glutamic acid, aspartic acid, isoleucine, leucine, alanine, phenylalanine, tyrosine, tryptophan, methionine, serine, proline, and combinations thereof; Monosaccharides, disaccharides, and other carbohydrates; low molecular weight (less than about 10 residues) polypeptides; proteins such as gelatin or serum albumin; chelating agents such as EDTA; trehalose, sucrose, lactose, glucose, mannose, maltose, galactose , sugars such as fructose, sorbose, raffinose, glucosamine, N-methylglucosamine, galactosamine, and neuraminic acid, and / or nonionic surfactants such as Tween, Brij Pluronics, Triton-X, or polyethylene glycol (PEG). include.
[0195] The pharmaceutical composition may be in liquid form, lyophilized form, or liquid form reconstituted from lyophilized form, with the lyophilized preparation being reconstituted with a sterile solution prior to administration. The standard procedure for reconstituting a lyophilized composition is to add back a volume of pure water (typically equal to the volume removed during lyophilization), but the antibacterial Solutions containing the agent can be used to produce pharmaceutical compositions for parenteral administration.
[0196] Aqueous formulations of the drug(s) may be prepared in a pH buffered solution, for example, at a pH ranging from about 4.0 to about 7.0, or from about 5.0 to about 6.0, or alternatively at a pH of about 5.5. Examples of buffers suitable for pH within this range include phosphate buffers, histidine buffers, citrate buffers, succinate buffers, acetate buffers, and other organic acid buffers. Buffer concentrations can be, for example, from about 1 mM to about 100 mM, or from about 5 mM to about 50 mM, depending on the buffer and the desired tonicity of the formulation.
[0197] Tonicity agents may be included to adjust the tonicity of the formulation. Examples of tonicity agents include sodium chloride, potassium chloride, glycerin, and any component from the group of amino acids, sugars, and combinations thereof. In some embodiments, the aqueous formulation is an isotonic solution, although hypertonic or hypotonic solutions may be suitable. The term "isotonic" refers to a solution that has the same tonicity as some other solution to which it is compared, such as saline or serum. The tonicity agent may be used in an amount of about 5mM to about 350mM, for example, 100mM to 350mM.
[0198] Surfactants may also be added to the formulation to reduce agglomeration and / or minimize particulate formation and / or reduce adsorption in the formulation. Exemplary surfactants include polyoxyethylene sorbitan fatty acid ester (Tween), polyoxyethylene alkyl ether (Brij), alkylphenyl polyoxyethylene ether (Triton-X), polyoxyethylene-polyoxypropylene copolymer (Poloxamer , Pluronic), and sodium dodecyl sulfate (SDS). Examples of suitable polyoxyethylene sorbitan-fatty acid esters are polysorbate 20 (sold under the trademark Tween 20™) and polysorbate 80 (sold under the trademark Tween 80™). Examples of suitable polyethylene-polypropylene copolymers are those sold under the names Pluronic® F68 or Poloxamer 188®. Examples of suitable polyoxyethylene alkyl ethers are those sold under the trademark Brij(TM). Exemplary concentrations of surfactants can range from about 0.001% to about 1% w / v.
[0199] A lyoprotectant may also be added to protect the antibody and / or T cell activator from destabilizing conditions during the lyophilization process. For example, known lyoprotectants include sugars (including glucose and sucrose), polyols (including mannitol, sorbitol, and glycerol), and amino acids (including alanine, glycine, and glutamic acid). The lyoprotectant may be included in an amount of about 10mM to 500nM.
[0200] In some embodiments, the pharmaceutical composition comprises an antibody and / or a T cell activator, and any of the ingredients identified above (e.g., surfactants, buffers, stabilizers, tonicity agents). Contains one or more preservatives such as ethanol, benzyl alcohol, phenol, m-cresol, p-chloro-m-cresol, methylparaben or propylparaben, benzalkonium chloride, and combinations thereof Not included in In other embodiments, preservatives are included in the formulation at concentrations ranging from, for example, about 0.001 to about 2% (w / v).
[0201] Method Aspects of the present disclosure include methods comprising administering an anti-SARS-CoV-2 antigen antibody (or conjugate or fusion protein comprising the same) of the present disclosure to an individual in need thereof. In certain embodiments, a method of treating an individual who has or is suspected of having a SARS-CoV-2 infection, comprising: a therapeutically effective amount of any of the antibodies, fusion proteins, or conjugates of the present disclosure. A method is provided comprising administering to an individual. In certain embodiments, a method of treating an individual suspected of having a SARS-CoV-2 infection, comprising administering to the individual a therapeutically effective amount of any of the antibodies, fusion proteins, or conjugates of the present disclosure. A therapeutically effective amount of the antibody, fusion protein, or conjugate is provided, for example, when the individual is exposed to the SARS-CoV-2 virus. Administered prophylactically to prevent experiencing one or more symptoms (eg, one or more symptoms of COVID-19). In some embodiments, the individual who is not suspected of having a SARS-CoV-2 infection is an immunocompromised individual. Non-limiting examples of immunocompromised individuals include individuals with HIV / AIDS, cancer, patients taking one or more immunosuppressive drugs (e.g., transplant patients), and those with genetics that affect the immune system. Examples include individuals with sexually transmitted diseases (eg, congenital agammaglobulinemia, congenital IgA deficiency, etc.).
[0202] Anti-SARS-CoV-2 antibodies, fusion proteins, or conjugates can be administered to any of a variety of subjects. In certain embodiments, the individual is a "mammal" or "mammal," and these terms include carnivores (e.g., dogs and cats), rodents (e.g., mice, guinea pigs, and rats), and primates. It is widely used to describe organisms within the class Mammalia, including species (eg, humans, chimpanzees, and monkeys). In some embodiments, the individual is a human. In certain embodiments, the individual is an animal model of SARS-CoV-2 infection (eg, a mouse model, a primate model, etc.), eg, an animal model of COVID-19.
[0203] The anti-SARS-CoV-2 antibody, fusion protein, or conjugate is administered in a therapeutically effective amount. "Therapeutically effective amount" means a dose sufficient to produce a desired result, such as prevention or reduction of symptoms of SARS-CoV-2 infection (e.g., symptoms of COVID-19) as compared to a control. Means an amount sufficient to produce a beneficial or desired therapeutic (including prophylactic) result. In some embodiments, a therapeutically effective amount is for viral load, hypoxia (e.g., oxygen saturation less than 95%, as measured by pulse oximetry), pneumonia, acute respiratory distress syndrome, pulmonary microcirculation. sufficient to delay the progression of, or reduce the symptoms of, one or more symptoms of SARS-CoV-2 infection (e.g., one or more COVID-19 symptoms), such as thrombosis in be. According to some embodiments, a therapeutically effective amount reduces one or more of such symptoms as compared to the absence of administration of the anti-SARS-CoV-2 antibody, fusion protein, or conjugate. delay the progress of one or more of or reduce these symptoms. An effective amount can be administered in one or more doses.
[0204] The method comprises combining an anti-SARS-CoV-2 antigen antibody (or fusion protein or conjugate) of the present disclosure with a second agent (e.g., a second anti-SARS-CoV-2 antigen antibody (or fusion protein or conjugate) ) or administering a second drug approved for the treatment of SARS-CoV-2 infection, e.g., COVID-19, non-limiting examples thereof include 2 polymerase inhibitors, e.g. remdesivir, the anti-SARS-CoV-2 antigen antibody and the second agent are administered simultaneously (e.g., in the same formulation or in separate formulations), sequentially, or both. For example, according to certain embodiments, the second agent is administered prior to the administration of the anti-SARS-CoV-2 antigen antibody, concurrently with the administration of the anti-SARS-CoV-2 antigen antibody, or both. In some embodiments, the anti-SARS-CoV-2 antigen antibody is administered to the individual prior to administration of the second agent, concurrently with administration of the second agent, or both. .
[0205] In certain embodiments, one or more agents are administered according to a dosage regimen approved for individual use. In some embodiments, administration of the anti-SARS-CoV-2 antigen antibody is compared to that utilized when the second agent is administered without administration of the anti-SARS-CoV-2 antigen antibody. allows the second agent to be administered according to a dosing regimen that includes one or more lower and / or less frequent doses and / or a reduced number of cycles. In some embodiments, the administration of the second agent is one compared to that utilized when the anti-SARS-CoV-2 antigen antibody is administered without administration of the second agent. The anti-SARS-CoV-2 antigen antibody may be administered according to a dosing regimen that includes lower and / or less frequent doses and / or a reduced number of cycles.
[0206] As described above, in certain embodiments, one or more doses of an anti-SARS-CoV-2 antigen antibody and a second agent are administered simultaneously, and in some such embodiments, such agent may be administered in the same pharmaceutical composition. However, in some embodiments, the anti-SARS-CoV-2 antigen antibody and the second agent are administered to the individual in different compositions and / or at different times. For example, an anti-SARS-CoV-2 antigen antibody may be administered prior to administration of a second agent (eg, in a particular cycle). Alternatively, the second agent may be administered prior to (eg, in a particular cycle) administering the anti-SARS-CoV-2 antigen antibody. The second drug administered is at least 1 hour, 3 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, or up to 5 days after the administration of the first drug. may be administered over a period of time starting after.
[0207] In some embodiments, administration of one agent is specifically timed with respect to administration of another agent. For example, in some embodiments, the first agent is administered for a specific effect that is observed (or based on, e.g., a population study that shows a correlation between a given dosing regimen and a specific effect of interest). expected to be observed).
[0208] In certain embodiments, the desired relative dosing schedule of agents to be administered in combination can be evaluated or determined empirically using, for example, ex vivo, in vivo, and / or in vitro models. In some embodiments, such evaluation or empirical determination is performed in vivo in a patient population (eg, so that a correlation is established), or alternatively, in a particular subject of interest.
[0209] In some embodiments, the anti-SARS-CoV-2 antigen antibody and the second agent are administered according to an intermittent dosing regimen that includes at least two cycles. When two or more drugs are administered in combination, each administered on such an intermittent, periodic schedule, the individual doses of the different drugs may be combined with each other. In certain embodiments, one or more doses of the second agent are administered a period of time after the dose of the first agent. In some embodiments, each dose of the second agent is administered a period of time after the dose of the first agent. In certain embodiments, each dose of the first agent is followed after a period of time by a dose of the second agent. In some embodiments, the two or more doses of the first agent are administered between at least one pair of doses of the second agent, and in certain embodiments, the two or more doses of the second agent are , administered during at least one pair of doses of the first agent. In some embodiments, different doses of the same agent are separated by a common time interval, and in some embodiments, the time interval between different doses of the same agent varies. In certain aspects, different doses of different agents are separated from each other by a common time interval, and in some embodiments, different doses of different agents are separated from each other by different time intervals.
[0210] One exemplary protocol for combining two intermittent, periodic dosing regimens (e.g., to enhance the efficacy of anti-SARS-CoV-2 antigen antibodies) includes (a) administering a therapeutically effective amount of the first (b) a first rest period; (c) a therapeutically effective amount of a second agent; and, optionally, a third period during which a third agent is administered to the individual. and (d) a second rest period.
[0211] In some embodiments, the first rest period and the second rest period may correspond to the same number of hours or days. Alternatively, in some embodiments, the first rest period and the second rest period are different, with the first rest period being longer than the second rest period, or vice versa. In some embodiments, each rest period corresponds to 120 hours, 96 hours, 72 hours, 48 hours, 24 hours, 12 hours, 6 hours, 30 hours, 1 hour, or less. In some embodiments, when the second rest period is longer than the first rest period, it is a number of days or weeks rather than hours (e.g., 1 day, 3 days, 5 days, 1 week, 2 weeks, 4 weeks or more).
[0212] If the length of the first rest period is determined by the presence or occurrence of a particular biological or therapeutic event, the length of the second rest period may be determined separately or in combination based on different factors. can be determined. Exemplary such factors include the identity and / or properties of the first agent (e.g., pharmacokinetic properties) and / or one or more characteristics of the patient's response to treatment with the first agent. may be included. In some embodiments, the length of one or both rest periods takes into account the pharmacokinetic properties (e.g., assessed via plasma concentration levels) of one or the other (or both) of the administered agents. can be adjusted accordingly. For example, the relevant rest period is optionally one of the individual's response when the plasma concentration of the relevant drug is less than about 1 μg / mL, 0.1 μg / mL, 0.01 μg / mL, or 0.001 μg / mL. It may be considered complete upon evaluation of one or more characteristics or other considerations.
[0213] In certain embodiments, the number of cycles in which a particular agent is administered can be determined empirically. Also, in some embodiments, the precise schedule followed (e.g., the number of doses, the spacing of doses (e.g., relative to each other or to another event, such as administration of another treatment), the amount of doses, etc. etc.) may be different for one or more cycles compared to one or more other cycles.
[0214] The anti-SARS-CoV-2 antigen antibody, and if administered, the second agent, may also be administered orally, parenterally (e.g., intravenously, intraarterially, subcutaneously, intramuscularly, or intradurally). The administration may be administered via a route of administration independently selected from (by external injection), topical administration, or intranasal administration. According to certain embodiments, the anti-SARS-CoV-2 antigen antibody is administered parenterally.
[0215] As mentioned above, aspects of the present disclosure include methods for treating an individual who has or is suspected of having a SARS-CoV-2 infection, eg, COVID-19. Treatment means at least the prevention or amelioration of one or more symptoms associated with a SARS-CoV-2 infection (e.g., COVID-19) in an individual, where amelioration refers to a parameter associated with a SARS-CoV-2 infection , for example, is used in a broad sense to refer to at least a reduction in the magnitude of symptoms. Non-limiting examples of such conditions include viral load, hypoxia (e.g., oxygen saturation less than 95%, as measured by pulse oximetry), pneumonia, acute respiratory distress syndrome, pulmonary micro- one or more of the following: thrombosis in the circulation; Therefore, treatment also reduces the risk of SARS-CoV-2 infection, or at least one or more symptoms associated therewith, such that the individual no longer suffers from SARS-CoV-2 infection, or at least the symptoms that characterize SARS-CoV-2 infection. includes situations where the occurrence is completely suppressed, eg, prevented from occurring, or stopped, eg, terminated.
[0216] In certain embodiments, the method of treatment comprises an antibody that competes for binding to SARS-CoV-2 with an antibody comprising the six CDRs of the antibody designated herein as antibody 941, or as used herein with the antibody 941. An antibody comprising the 6 CDRs of antibody designated as antibody 941, or V of the antibody designated herein as antibody 941 H and V L administering a therapeutically effective amount of an antibody comprising: Antibodies can be present as fusion proteins or conjugates of the present disclosure.
[0217] According to some embodiments, the method of treatment comprises an antibody that competes for binding to SARS-CoV-2 with an antibody comprising the six CDRs of antibody designated herein as antibody 980, or as described herein. or V of the antibody designated herein as antibody 980. H and V L administering a therapeutically effective amount of an antibody comprising: Antibodies can be present as fusion proteins or conjugates of the present disclosure.
[0218] In certain embodiments, the method of treatment comprises an antibody that competes for binding to SARS-CoV-2 with an antibody comprising the six CDRs of the antibody designated herein as antibody 1589; An antibody comprising the 6 CDRs of antibody designated as antibody 1589 or V of antibody designated herein as antibody 1589 H and V L administering a therapeutically effective amount of an antibody comprising: Antibodies can be present as fusion proteins or conjugates of the present disclosure.
[0219] Any of the methods of treatment of the present disclosure may involve administering to an individual a therapeutically effective amount of a "cocktail" of two or more antibodies, at least one of which is an antibody of the present disclosure. In certain embodiments, the method of treatment comprises administering to an individual a therapeutically effective amount of a cocktail of two or more antibodies, at least two of which are antibodies of the present disclosure. According to some embodiments, methods of treatment include antibodies of the disclosure, e.g., antibodies 508, 767, 935, 937, 941, 980, 1085, 1213 herein for binding to SARS-CoV-2. , 1227, 1231, 1238, 1439, 1589, 1671, 1679, 1814, 1815, 1823, 1826, 1851, 1856, 1859, 1864, 1867, 1870, 1871, 1872, 1888, 1915, 1959, 1963, 1969, 1984 , 2019, 2020, 2024, 2025, 2050, 2075, 2080, 2432, 2564, 2598, 2606, 2619, 2646, 2706, 2729, 2788, 2793, 2794, 2854, 2866, 2892, 3086, 3091, 3995, 4042 , and / or an antibody that competes with an antibody comprising the six CDRs of antibody designated 4441, or herein antibodies 508, 767, 935, 937, 941, 980, 1085, 1213, 1227, 1231, 1238, 1439,1589,1671,1679,1814,1815,1823,1826,1851,1856,1859,1864,1867,1870,1871,1872,1888,1915,1959,1963,1969,1984,2019,2020,2 024, Designated as 2025, 2050, 2075, 2080, 2432, 2564, 2598, 2606, 2619, 2646, 2706, 2729, 2788, 2793, 2794, 2854, 2866, 2892, 3086, 3091, 3995, 4042, and / or 4441 or herein antibodies comprising the six CDRs of an antibody that is , 1823, 1826, 1851, 1856, 1859, 1864, 1867, 1870, 1871, 1872, 1888, 1915, 1959, 1963, 1969, 1984, 2019, 2020, 2024, 2025, 2050, 2075, 2080, 2432, 2564 , 2598, 2606, 2619, 2646, 2706, 2729, 2788, 2793, 2794, 2854, 2866, 2892, 3086, 3091, 3995, 4042, and / or 4441. H and V L 2 or more, 3 or more, 4 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 of the antibodies containing, or a cocktail of each of these antibodies. and administering a therapeutically effective amount. Antibodies can be present as fusion proteins or conjugates of the present disclosure.
[0220] In certain embodiments, the method of treatment comprises an antibody that competes for binding to SARS-CoV-2 with an antibody comprising the six CDRs of antibodies designated herein as antibodies 941 and 980; or V of the antibody designated herein as antibodies 941 and 980. H and V L administering a therapeutically effective amount of a cocktail comprising an antibody comprising: Antibodies can be present as fusion proteins or conjugates of the present disclosure.
[0221] According to some embodiments, the method of treatment comprises using an antibody that competes for binding to SARS-CoV-2 with an antibody comprising the six CDRs of antibodies designated herein as antibodies 941 and 1589; An antibody comprising the 6 CDRs of antibodies designated herein as antibodies 941 and 1589, or V of antibodies designated herein as antibodies 941 and 1589 H and V L administering a therapeutically effective amount of a cocktail comprising an antibody comprising: Antibodies can be present as fusion proteins or conjugates of the present disclosure.
[0222] In certain embodiments, the method of treatment comprises an antibody that competes for binding to SARS-CoV-2 with an antibody comprising the six CDRs of antibodies designated herein as antibodies 980 and 1589; or V of the antibody designated herein as antibodies 980 and 1589. H and V L administering a therapeutically effective amount of a cocktail comprising an antibody comprising: Antibodies can be present as fusion proteins or conjugates of the present disclosure.
[0223] When a cocktail of antibodies is administered, the antibodies may be present in separate pharmaceutical compositions or may be administered in a single pharmaceutical composition.
[0224] kit As summarized above, the present disclosure provides kits. Kits find use, for example, in practicing the methods of the present disclosure. In some embodiments, the subject kit comprises any of the anti-SARS-CoV-2 antibodies, fusion proteins, or conjugates of the present disclosure (e.g., anti-SARS-CoV-2 as described elsewhere herein). 2 antibodies, fusion proteins, or conjugates - including any desired combinations thereof). In some embodiments, kits are provided that include any of the pharmaceutical compositions described herein, including any of the pharmaceutical compositions described above in the composition section of this disclosure. The kits of the present disclosure provide a method for administering a pharmaceutical composition to an individual in need thereof, including, but not limited to, an individual who has or is suspected of having a SARS-CoV-2 infection, e.g., COVID-19. may include instructions for administering the product.
[0225] A subject kit may contain an amount of the composition presented in unit dose, eg, ampoule, or multi-dose format. Accordingly, in certain embodiments, the kits contain any of the anti-SARS-CoV-2 antibodies, fusion proteins, conjugates, or cells of the present disclosure (e.g., anti-SARS-CoV-2 as described elsewhere herein). - CoV-2 antibodies, fusion proteins, conjugates, or cells). The term "unit dose" as used herein refers to physically discrete units suitable as unit doses for human and animal subjects, each unit containing enough dosage to produce a desired effect. Contains a predetermined amount of the composition, calculated in a given amount. The amount of the unit dose depends on various factors such as the specific anti-SARS-CoV-2 antigen antibody used, the effect to be achieved, and the pharmacodynamics associated with the anti-SARS-CoV-2 antigen antibody in the individual. do. In yet other embodiments, the kit may contain single multiple doses of the composition.
[0226] As will be appreciated, the kits of the present disclosure may include any of the agents and features described above in the sections regarding subject antibodies, methods, and compositions, which are not described herein for purposes of brevity. Not repeated in detail.
[0227] The components of the kit may be present in separate containers or multiple components may be present in a single container. Suitable containers include a single tube (eg, a vial), an ampoule, one or more wells of a plate (eg, 96 well plate, 384 well plate, etc.), and the like.
[0228] Instructions included in the kit (eg, instructions for use (IFU)) may be recorded on a suitable recording medium. For example, the instructions may be printed on a substrate such as paper or plastic. Accordingly, instructions may be present as a package insert with the kit, such as on the labeling of the container of the kit or its components (ie, associated with the packaging or sub-packaging). In other embodiments, the instructions are present as an electronic storage data file residing on a suitable computer readable storage medium, such as a portable flash drive, DVD, CD-ROM, diskette, or the like. In yet other embodiments, actual instructions are not present in the kit, and a means is provided for obtaining the instructions from a remote source, eg, via the Internet. An example of this embodiment is a kit that includes a web address where the instructions can be viewed and / or downloaded. Like the instructions, the means for obtaining the instructions are recorded on a suitable substrate.
[0229] Notwithstanding the appended claims, the present disclosure is also defined by the following embodiments.
[0230] Embodiment 1. An antibody that specifically binds to a SARS-CoV-2 antigen and competes for binding to the SARS-CoV-2 antigen with an antibody comprising: Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 1 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 5 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 9 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 13 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 17 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 21 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 25 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 29 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 33 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 37 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 41 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 45 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 49 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 53 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 57 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (VL ) a polypeptide, V shown in SEQ ID NO: 61 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 65 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 69 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 73 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 77 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 81 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 85 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, or Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 89 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 93 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 97 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 101 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 105 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 109 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 113 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 117 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 121 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 125 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 129 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 133 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 137 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 141 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 145 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 149 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 153 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 157 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 161 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 165 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 169 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 173 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 177 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 181 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 185 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 189 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 193 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 197 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 201 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 205 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 209 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 213 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 217 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 221 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 225 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 229 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 233 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 237 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 241 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 245 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 249 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 253 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 257 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 261 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 265 H V of H CDR1,V H CDR2, and VH Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 269 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 273 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 277 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 281 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 285 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 289 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 293 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 297 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 301 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 305 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 309 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 313 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 317 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 321 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 325 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 329 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 333 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 337 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 341 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 345 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 349 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 353 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 357 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 361 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 365 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 369 H V ofH CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 373 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 377 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 381 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 385 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 389 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 393 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 397 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 401 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 405 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 409 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 413 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 417 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 421 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 425 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 429 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 433 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 437 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 441 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 445 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 449 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 453 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 457 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 461 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, or Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 465 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 469 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide.
[0231] Embodiment 2. The antibody is Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 1 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 5 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 9 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 13 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 17 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 21 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 25 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 29 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 33 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 37 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 41 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 45 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 49 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 53 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 57 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 61 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 65 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 69 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 73 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 77 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 81 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 85 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, or Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 89 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 93 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 97 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 101 L V of L CDR1,V L CDR2, and V LVariable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 105 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 109 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 113 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 117 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 121 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 125 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 129 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 133 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 137 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 141 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 145 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 149 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 153 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 157 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 161 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 165 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 169 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 173 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 177 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 181 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 185 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 189 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 193 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 197 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 201 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 205 L V of LCDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 209 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 213 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 217 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 221 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 225 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 229 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 233 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 237 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 241 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 245 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 249 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 253 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 257 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 261 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 265 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 269 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 273 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 277 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 281 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 285 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 289 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 293 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 297 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 301 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 305 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 309 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 313 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 317 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 321 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 325 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 329 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 333 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 337 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 341 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 345 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 349 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 353 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 357 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 361 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 365 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 369 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 373 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 377 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 381 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 385 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 389 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 393 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 397 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 401 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 405 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 409 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (VL ) a polypeptide, V shown in SEQ ID NO: 413 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 417 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 421 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 425 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 429 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 433 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 437 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 441 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 445 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 449 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 453 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 457 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 461 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide, or Variable heavy chain (V H ) a polypeptide, V shown in SEQ ID NO: 465 H V of H CDR1,V H CDR2, and V H Variable heavy chain (V H ) polypeptide, and Variable light chain (V L ) a polypeptide, V shown in SEQ ID NO: 469 L V of L CDR1,V L CDR2, and V L Variable light chain (V L ) polypeptide.
[0232] Embodiment 3. The antibody is 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 1 A variable heavy chain (V H ) polypeptide; 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 5 A variable light chain (V L ) The antibody according to Embodiment 1 or 2, comprising a polypeptide. Embodiment 4. The antibody is 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 9 A variable heavy chain (V H ) polypeptide; 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 13 A variable light chain (V L ) The antibody according to Embodiment 1 or 2, comprising a polypeptide. Embodiment 5. The antibody is 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 17 A variable heavy chain (V H ) polypeptide; 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 21 A variable light chain (V L ) The antibody according to Embodiment 1 or 2, comprising a polypeptide. Embodiment 6. The antibody is 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 25 A variable heavy chain (V H ) polypeptide; 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 29 A variable light chain (V L ) The antibody according to Embodiment 1 or 2, comprising a polypeptide. Embodiment 7. The antibody is 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 33 A variable heavy chain (V H ) polypeptide, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 37 A variable light chain (V L ) The antibody according to Embodiment 1 or 2, comprising a polypeptide. Embodiment 8. The antibody is 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 41 A variable heavy chain (V H ) polypeptide, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 45 A variable light chain (V L ) The antibody according to Embodiment 1 or 2, comprising a polypeptide. Embodiment 9. The antibody is 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 49 A variable heavy chain (V H ) polypeptide, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 53 Variable light chain (V L ) The antibody according to Embodiment 1 or 2, comprising a polypeptide. Embodiment 10. The antibody is 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 57 A variable heavy chain (V H ) polypeptide, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 61 A variable light chain (V L ) The antibody according to Embodiment 1 or 2, comprising a polypeptide.
[0233] Embodiment 11. The antibody is 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 65 A variable heavy chain (V H ) polypeptide, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 69 A variable light chain (V L ) The antibody according to Embodiment 1 or 2, comprising a polypeptide. Embodiment 12. The antibody is 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 73 A variable heavy chain (V H ) polypeptide, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 77 A variable light chain (V L ) The antibody according to Embodiment 1 or 2, comprising a polypeptide. Embodiment 13. The antibody is 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 81 A variable heavy chain (V H ) polypeptide, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 85 A variable light chain (V L ) The antibody according to Embodiment 1 or 2, comprising a polypeptide. Embodiment 14. The antibody is 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 89 A variable heavy chain (V H ) polypeptide, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 93 A variable light chain (V L ) The antibody according to Embodiment 1 or 2, comprising a polypeptide. Embodiment 15. The antibody is 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 97 A variable heavy chain (V H ) polypeptide, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 101 A variable light chain (V L ) The antibody according to Embodiment 1 or 2, comprising a polypeptide. Embodiment 16. The antibody is 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 105 A variable heavy chain (V H ) polypeptide, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 109 Variable light chain (V L ) The antibody according to Embodiment 1 or 2, comprising a polypeptide. Embodiment 17. The antibody is 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 113 A variable heavy chain (V H ) polypeptide, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 117 A variable light chain (V L ) The antibody according to Embodiment 1 or 2, comprising a polypeptide. Embodiment 18. The antibody is 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 121 A variable heavy chain (V H ) polypeptide, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 125 A variable light chain (V L ) The antibody according to Embodiment 1 or 2, comprising a polypeptide. Embodiment 19. The antibody is 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 129 Variable heavy chain (V H ) polypeptide; 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 133 Variable light chain (V L ) The antibody according to Embodiment 1 or 2, comprising a polypeptide. Embodiment 20. The antibody is 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 137 A variable heavy chain (V H ) polypeptide; 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 141 A variable light chain (V L ) The antibody according to Embodiment 1 or 2, comprising a polypeptide. Embodiment 21. The antibody is 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 145 A variable heavy chain (V H ) polypeptide; 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 149 A variable light chain (V L ) The antibody according to Embodiment 1 or 2, comprising a polypeptide. Embodiment 22. The antibody is 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 153 A variable heavy chain (V H ) polypeptide; 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 157 A variable light chain (V L ) The antibody according to Embodiment 1 or 2, comprising a polypeptide. Embodiment 23. The antibody is 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 161 A variable heavy chain (V H ) polypeptide; 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 165 A variable light chain (V L ) The antibody according to Embodiment 1 or 2, comprising a polypeptide. Embodiment 24. The antibody is 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 169 A variable heavy chain (V H ) polypeptide; 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 173 A variable light chain (V L ) The antibody according to Embodiment 1 or 2, comprising a polypeptide. Embodiment 25. The antibody is 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 177 A variable heavy chain (V H ) polypeptide; 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 181 A variable light chain (V L ) The antibody according to Embodiment 1 or 2, comprising a polypeptide. Embodiment 26. The antibody is 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 185 A variable heavy chain (V H ) polypeptide; 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 189 Variable light chain (V L ) The antibody according to Embodiment 1 or 2, comprising a polypeptide. Embodiment 27. The antibody is 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 193 A variable heavy chain (V H ) polypeptide; 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 197 A variable light chain (V L ) The antibody according to Embodiment 1 or 2, comprising a polypeptide. Embodiment 28. The antibody is 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 201 A variable heavy chain (V H ) polypeptide; 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 205 A variable light chain (V L ) The antibody according to Embodiment 1 or 2, comprising a polypeptide. Embodiment 29. The antibody is 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 209 A variable heavy chain (V H ) polypeptide; 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 213 A variable light chain (V L ) The antibody according to Embodiment 1 or 2, comprising a polypeptide. Embodiment 30. The antibody is 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 217 A variable heavy chain (V H ) polypeptide; 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 221 A variable light chain (V L ) The antibody according to Embodiment 1 or 2, comprising a polypeptide.
[0234] Embodiment 31. The antibody is 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 225 A variable heavy chain (V H ) polypeptide, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 229 A variable light chain (V L ) The antibody according to Embodiment 1 or 2, comprising a polypeptide. Embodiment 32. The antibody is 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 233 A variable heavy chain (V H ) polypeptide, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 237 A variable light chain (V L ) The antibody according to Embodiment 1 or 2, comprising a polypeptide. Embodiment 33. The antibody is 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 241 A variable heavy chain (V H ) polypeptide, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 245 A variable light chain (V L ) The antibody according to Embodiment 1 or 2, comprising a polypeptide. Embodiment 34. The antibody is 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 249 A variable heavy chain (V H ) polypeptide, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 253 A variable light chain (V L ) The antibody according to Embodiment 1 or 2, comprising a polypeptide. Embodiment 35. The antibody is 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 257 A variable heavy chain (V H ) polypeptide, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 261 A variable light chain (V L ) The antibody according to Embodiment 1 or 2, comprising a polypeptide. Embodiment 36. The antibody is 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 265 A variable heavy chain (V H ) polypeptide, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 269 A variable light chain (V L ) The antibody according to Embodiment 1 or 2, comprising a polypeptide. Embodiment 37. The antibody is 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 273 A variable heavy chain (V H ) polypeptide, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 277 A variable light chain (V L ) The antibody according to Embodiment 1 or 2, comprising a polypeptide. Embodiment 38. The antibody is 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 281 A variable heavy chain (V H ) polypeptide, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 285 A variable light chain (V L ) The antibody according to Embodiment 1 or 2, comprising a polypeptide. Embodiment 39. The antibody comprises: 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 289 A variable heavy chain (V H ) polypeptide, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 293 A variable light chain (V L ) The antibody according to Embodiment 1 or 2, comprising a polypeptide. Embodiment 40. The antibody is 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 297 A variable heavy chain (V H ) polypeptide, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 301 A variable light chain (V L ) The antibody according to Embodiment 1 or 2, comprising a polypeptide. Embodiment 41. The antibody is 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 305. A variable heavy chain (V H ) polypeptide, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 309 A variable light chain (V L) The antibody according to Embodiment 1 or 2, comprising a polypeptide. Embodiment 42. The antibody is 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 313 A variable heavy chain (V H ) polypeptide, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 317 A variable light chain (V L ) The antibody according to Embodiment 1 or 2, comprising a polypeptide. Embodiment 43. The antibody is 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 321 A variable heavy chain (V H ) polypeptide, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 325 A variable light chain (V L ) The antibody according to Embodiment 1 or 2, comprising a polypeptide. Embodiment 44. The antibody is 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 329 A variable heavy chain (V H ) polypeptide, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 333 A variable light chain (V L ) The antibody according to Embodiment 1 or 2, comprising a polypeptide. Embodiment 45. The antibody comprises: 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 337 A variable heavy chain (V H ) polypeptide, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 341 A variable light chain (V L ) The antibody according to Embodiment 1 or 2, comprising a polypeptide. Embodiment 46. The antibody comprises: 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 345 A variable heavy chain (V H ) polypeptide, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 349 A variable light chain (V L ) The antibody according to Embodiment 1 or 2, comprising a polypeptide. Embodiment 47. The antibody is 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 353 A variable heavy chain (V H ) polypeptide, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 357 A variable light chain (V L ) The antibody according to Embodiment 1 or 2, comprising a polypeptide. Embodiment 48. The antibody is 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 361 A variable heavy chain (V H ) polypeptide, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 365 A variable light chain (V L ) The antibody according to Embodiment 1 or 2, comprising a polypeptide. Embodiment 49. The antibody comprises: 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 369 A variable heavy chain (V H ) polypeptide, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 373 A variable light chain (V L ) The antibody according to Embodiment 1 or 2, comprising a polypeptide. Embodiment 50. The antibody comprises: 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 377 A variable heavy chain (V H ) polypeptide, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 381 A variable light chain (V L ) The antibody according to Embodiment 1 or 2, comprising a polypeptide.
[0235] Embodiment 51. The antibody is 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 385. A variable heavy chain (V H ) polypeptide, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 389 A variable light chain (V L ) The antibody according to Embodiment 1 or 2, comprising a polypeptide. Embodiment 52. The antibody comprises: 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 393 A variable heavy chain (V H ) polypeptide, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 397 A variable light chain (V L ) The antibody according to Embodiment 1 or 2, comprising a polypeptide. Embodiment 53. The antibody comprises: 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 401 A variable heavy chain (V H ) polypeptide; 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 405 A variable light chain (V L ) The antibody according to Embodiment 1 or 2, comprising a polypeptide. Embodiment 54. The antibody comprises: 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 409 A variable heavy chain (V H ) polypeptide; 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 413 A variable light chain (V L ) The antibody according to Embodiment 1 or 2, comprising a polypeptide. Embodiment 55. The antibody comprises: 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% with respect to the amino acid sequence shown in SEQ ID NO: 417 A variable heavy chain (V H ) polypeptide; 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% o...
Claims
1. An antibody that specifically binds to a SARS-CoV-2 antigen, An antibody that comprises, or that competes for binding to the SARS-CoV-2 antigen with, an antibody comprising: A variable heavy (VH) chain polypeptide comprising: a variable heavy chain (VH) polypeptide comprising the VH CDR1, VH CDR2, and VH CDR3 of the VH set forth in SEQ ID NO:209; and A variable light chain (VL) polypeptide comprising: a variable light chain (V L ) polypeptide comprising the V L CDR1, V L CDR2, and V L CDR3 of V L set forth in SEQ ID NO:213; A variable heavy (VH) chain polypeptide comprising: a variable heavy chain (VH) polypeptide comprising the VH CDR1, VH CDR2, and VH CDR3 of the VH set forth in SEQ ID NO:425; and A variable light chain (VL) polypeptide comprising: a variable light chain (V L ) polypeptide comprising the V L CDR1, V L CDR2, and V L CDR3 of V L set forth in SEQ ID NO:429; A variable heavy (VH) chain polypeptide comprising: a variable heavy chain (VH) polypeptide comprising the VH CDR1, VH CDR2, and VH CDR3 of the VH set forth in SEQ ID NO: 121; and A variable light chain (VL) polypeptide comprising: a variable light chain (V L ) polypeptide comprising the V L CDR1, V L CDR2, and V L CDR3 of V L set forth in SEQ ID NO: 125; A variable heavy (VH) chain polypeptide comprising: a variable heavy chain (VH) polypeptide comprising the VH CDR1, VH CDR2, and VH CDR3 of the VH set forth in SEQ ID NO:345; and A variable light chain (VL) polypeptide comprising: a variable light chain (V L ) polypeptide comprising the V L CDR1, V L CDR2, and V L CDR3 of V L set forth in SEQ ID NO:349; A variable heavy (VH) chain polypeptide comprising: a variable heavy chain (VH) polypeptide comprising the VH CDR1, VH CDR2, and VH CDR3 of the VH set forth in SEQ ID NO:97; and A variable light chain (VL) polypeptide comprising: a variable light chain (V L ) polypeptide comprising the V L CDR1, V L CDR2, and V L CDR3 of V L set forth in SEQ ID NO: 101; Variable heavy chain (V H ) a polypeptide comprising: V shown in SEQ ID NO: 1 H V of H CDR1, V H CDR2, and V H The variable heavy chain (V H ) polypeptides, and Variable light chain (V L ) a polypeptide comprising: V shown in SEQ ID NO: 5 L V of L CDR1, V L CDR2, and V L A variable light chain (V L ) polypeptide; Variable heavy chain (V H ) a polypeptide comprising: V shown in SEQ ID NO: 9 H V of H CDR1, V H CDR2, and V H The variable heavy chain (V H ) polypeptides, and Variable light chain (V L ) a polypeptide comprising: V shown in SEQ ID NO: 13 L V of L CDR1, V L CDR2, and V L A variable light chain (V L ) polypeptide; Variable heavy chain (V H ) a polypeptide comprising: V shown in SEQ ID NO: 17 H V of H CDR1, V H CDR2, and V H The variable heavy chain (V H ) polypeptides, and Variable light chain (V L ) a polypeptide comprising: V shown in SEQ ID NO: 21 L V of L CDR1, V L CDR2, and V L A variable light chain (V L ) polypeptide; Variable heavy chain (V H ) a polypeptide comprising: V shown in SEQ ID NO: 25 H V of H CDR1, V H CDR2, and V H The variable heavy chain (V H ) polypeptides, and Variable light chain (V L ) a polypeptide comprising: V shown in SEQ ID NO: 29 L V of L CDR1, V L CDR2, and V L A variable light chain (V L ) polypeptide; Variable heavy chain (V H ) a polypeptide comprising: V shown in SEQ ID NO: 33 H V of H CDR1, V H CDR2, and V H The variable heavy chain (V H ) polypeptides, and Variable light chain (V L ) a polypeptide comprising: V shown in SEQ ID NO: 37 L V of L CDR1, V L CDR2, and V L A variable light chain (V L ) polypeptide; Variable heavy chain (V H ) a polypeptide comprising: V shown in SEQ ID NO: 41 H V of H CDR1, V H CDR2, and V H The variable heavy chain (V H ) polypeptides, and Variable light chain (V L ) a polypeptide comprising: V shown in SEQ ID NO: 45 L V of L CDR1, V L CDR2, and V L A variable light chain (V L ) polypeptide; Variable heavy chain (V H ) a polypeptide comprising: V shown in SEQ ID NO: 49 H V of H CDR1, V H CDR2, and V H The variable heavy chain (V H ) polypeptides, and Variable light chain (V L ) a polypeptide comprising: V shown in SEQ ID NO: 53 L V of L CDR1, V L CDR2, and V L A variable light chain (V L ) polypeptide; Variable heavy chain (V H ) a polypeptide comprising: V shown in SEQ ID NO: 57 H V of H CDR1, V H CDR2, and V H The variable heavy chain (V H ) polypeptides, and Variable light chain (V L ) a polypeptide comprising: V shown in SEQ ID NO: 61 L V of L CDR1, V L CDR2, and V L A variable light chain (V L ) polypeptide; Variable heavy chain (V H ) a polypeptide comprising: V shown in SEQ ID NO: 65 H V of H CDR1, V H CDR2, and V H The variable heavy chain (V H ) polypeptides, and Variable light chain (V L ) a polypeptide comprising: V shown in SEQ ID NO: 69 L V of L CDR1, V L CDR2, and V L A variable light chain (V L ) polypeptide; Variable heavy chain (V H ) a polypeptide comprising: V shown in SEQ ID NO: 73 H V of H CDR1, V H CDR2, and V H The variable heavy chain (V H ) polypeptides, and Variable light chain (V L ) a polypeptide comprising: V shown in SEQ ID NO: 77 L V of L CDR1, V L CDR2, and V L A variable light chain (V L ) polypeptide; Variable heavy chain (V H ) a polypeptide comprising: V shown in SEQ ID NO: 81 H V of H CDR1, V H CDR2, and V H The variable heavy chain (V H ) polypeptides, and Variable light chain (V L ) a polypeptide comprising: V shown in SEQ ID NO: 85 L V of L CDR1, V L CDR2, and V L A variable light chain (V L ) polypeptide; or Variable heavy chain (V H ) a polypeptide comprising: V shown in SEQ ID NO: 89 H V of H CDR1, V H CDR2, and V H The variable heavy chain (V H ) polypeptides, and Variable light chain (V L ) a polypeptide comprising: V shown in SEQ ID NO: 93 L V of L CDR1, V L CDR2, and V L A variable light chain (V L ) polypeptide; Variable heavy chain (V H ) a polypeptide comprising: V shown in SEQ ID NO: 105 H V of H CDR1, V H CDR2, and V H The variable heavy chain (V H ) polypeptides, and Variable light chain (V L ) a polypeptide comprising: V shown in SEQ ID NO: 109 L V of L CDR1, V L CDR2, and V L A variable light chain (V L ) polypeptide; Variable heavy chain (V H ) a polypeptide comprising: V shown in SEQ ID NO: 113 H V of H CDR1, V H CDR2, and V H The variable heavy chain (V H ) polypeptides, and Variable light chain (V L ) a polypeptide comprising: V shown in SEQ ID NO: 117 L V of L CDR1, V L CDR2, and V L A variable light chain (V L ) polypeptide; Variable heavy chain (V H ) a polypeptide comprising: V shown in SEQ ID NO: 129 H V of H CDR1, V H CDR2, and V H The variable heavy chain (V H ) polypeptides, and Variable light chain (V L ) a polypeptide comprising: V shown in SEQ ID NO: 133 L V of L CDR1, V L CDR2, and V L A variable light chain (V L ) polypeptide; Variable heavy chain (V H ) a polypeptide comprising: V shown in SEQ ID NO: 137 H V of H CDR1, V H CDR2, and V H The variable heavy chain (V H ) polypeptides, and Variable light chain (V L ) a polypeptide comprising: V shown in SEQ ID NO: 141 L V of L CDR1, V L CDR2, and V L A variable light chain (V L ) polypeptide; Variable heavy chain (V H ) a polypeptide comprising: V shown in SEQ ID NO: 145 H V of H CDR1, V H CDR2, and V H The variable heavy chain (V H ) polypeptides, and Variable light chain (V L ) a polypeptide comprising: V shown in SEQ ID NO: 149 L V of L CDR1, V L CDR2, and V L A variable light chain (V L ) polypeptide; Variable heavy chain (V H ) a polypeptide comprising: V shown in SEQ ID NO: 153 H V of H CDR1, V H CDR2, and V H The variable heavy chain (V H ) polypeptides, and Variable light chain (V L ) a polypeptide comprising: V shown in SEQ ID NO: 157 L V of L CDR1, V L CDR2, and V L A variable light chain (V L ) polypeptide; Variable heavy chain (V H ) a polypeptide comprising: V shown in SEQ ID NO: 161 H V of H CDR1, V H CDR2, and V H The variable heavy chain (V H ) polypeptides, and Variable light chain (V L ) a polypeptide comprising: V shown in SEQ ID NO: 165 L V of L CDR1, V L CDR2, and V L A variable light chain (V L ) polypeptide; Variable heavy chain (V H ) a polypeptide comprising: V shown in SEQ ID NO: 169 H V of H CDR1, V H CDR2, and V H The variable heavy chain (V H ) polypeptides, and Variable light chain (V L ) a polypeptide comprising: V shown in SEQ ID NO: 173 L V of L CDR1, V L CDR2, and V L A variable light chain (V L ) polypeptide; Variable heavy chain (V H ) a polypeptide comprising: V shown in SEQ ID NO: 177 H V of H CDR1, V H CDR2, and V H The variable heavy chain (V H ) polypeptides, and Variable light chain (V L ) a polypeptide comprising: V shown in SEQ ID NO: 181 L V of L CDR1, V L CDR2, and V L A variable light chain (V L ) polypeptide; Variable heavy chain (V H ) a polypeptide comprising: V shown in SEQ ID NO: 185 H V of H CDR1, V H CDR2, and V H The variable heavy chain (V H ) polypeptides, and Variable light chain (V L ) a polypeptide comprising: V shown in SEQ ID NO: 189 L V of L CDR1, V L CDR2, and V L A variable light chain (V L ) polypeptide; Variable heavy chain (V H ) a polypeptide comprising: V shown in SEQ ID NO: 193 H V of H CDR1, V H CDR2, and V H The variable heavy chain (V H ) polypeptides, and Variable light chain (V L ) a polypeptide comprising: V shown in SEQ ID NO: 197 L V of L CDR1, V L CDR2, and V L A variable light chain (V L ) polypeptide; Variable heavy chain (V H ) a polypeptide comprising: V shown in SEQ ID NO: 201 H V of H CDR1, V H CDR2, and V H The variable heavy chain (V H ) polypeptides, and Variable light chain (V L ) a polypeptide comprising: V shown in SEQ ID NO: 205 L V of L CDR1, V L CDR2, and V L A variable light chain (V L ) polypeptide; Variable heavy chain (V H ) a polypeptide comprising: V shown in SEQ ID NO: 217 H V of H CDR1, V H CDR2, and V H The variable heavy chain (V H ) polypeptides, and Variable light chain (V L ) a polypeptide comprising: V shown in SEQ ID NO: 221 L V of L CDR1, V L CDR2, and V L A variable light chain (V L ) polypeptide; Variable heavy chain (V H ) a polypeptide comprising: V shown in SEQ ID NO: 225 H V of H CDR1, V H CDR2, and V H The variable heavy chain (V H ) polypeptides, and Variable light chain (V L ) a polypeptide comprising: V shown in SEQ ID NO: 229 L V of L CDR1, V L CDR2, and V L A variable light chain (V L ) polypeptide; Variable heavy chain (V H ) a polypeptide comprising: V shown in SEQ ID NO: 233 H V of H CDR1, V H CDR2, and V H The variable heavy chain (V H ) polypeptides, and Variable light chain (V L ) a polypeptide comprising: V shown in SEQ ID NO: 237 L V of L CDR1, V L CDR2, and V L A variable light chain (V L ) polypeptide; Variable heavy chain (V H ) a polypeptide comprising: V shown in SEQ ID NO: 241 H V of H CDR1, V H CDR2, and V H The variable heavy chain (V H ) polypeptides, and Variable light chain (V L ) a polypeptide comprising: V shown in SEQ ID NO: 245 L V of L CDR1, V L CDR2, and V L A variable light chain (V L ) polypeptide; Variable heavy chain (V H ) a polypeptide comprising: V shown in SEQ ID NO: 249 H V of H CDR1, V H CDR2, and V H The variable heavy chain (V H ) polypeptides, and Variable light chain (V L ) a polypeptide comprising: V shown in SEQ ID NO: 253 L V of L CDR1, V L CDR2, and V L A variable light chain (V L ) polypeptide; Variable heavy chain (V H ) a polypeptide comprising: V shown in SEQ ID NO: 257 H V of H CDR1, V H CDR2, and V H The variable heavy chain (V H ) polypeptides, and Variable light chain (V L ) a polypeptide comprising: V shown in SEQ ID NO: 261 L V of L CDR1, V L CDR2, and V L A variable light chain (V L ) polypeptide; Variable heavy chain (V H ) a polypeptide comprising: V shown in SEQ ID NO: 265 H V of H CDR1, V H CDR2, and V H The variable heavy chain (V H ) polypeptides, and Variable light chain (V L ) a polypeptide comprising: V shown in SEQ ID NO: 269 L V of L CDR1, V L CDR2, and V L A variable light chain (V L ) polypeptide; Variable heavy chain (V H ) a polypeptide comprising: V shown in SEQ ID NO: 273 H V of H CDR1, V H CDR2, and V H The variable heavy chain (V H ) polypeptides, and Variable light chain (V L ) a polypeptide comprising: V shown in SEQ ID NO: 277 L V of L CDR1, V L CDR2, and V L A variable light chain (V L ) polypeptide; Variable heavy chain (V H ) a polypeptide comprising: V shown in SEQ ID NO: 281 H V of H CDR1, V H CDR2, and V H The variable heavy chain (V H ) polypeptides, and Variable light chain (V L ) a polypeptide comprising: V shown in SEQ ID NO: 285 L V of L CDR1, V L CDR2, and V L A variable light chain (V L ) polypeptide; Variable heavy chain (V H ) a polypeptide comprising: V shown in SEQ ID NO: 289 H V of H CDR1, V H CDR2, and V H The variable heavy chain (V H ) polypeptides, and Variable light chain (V L ) a polypeptide comprising: V shown in SEQ ID NO: 293 L V of L CDR1, V L CDR2, and V L A variable light chain (V L ) polypeptide; Variable heavy chain (V H ) a polypeptide comprising: V shown in SEQ ID NO: 297 H V of H CDR1, V H CDR2, and V H The variable heavy chain (V H ) polypeptides, and Variable light chain (V L ) a polypeptide comprising: V shown in SEQ ID NO: 301 L V of L CDR1, V L CDR2, and V L A variable light chain (V L ) polypeptide; Variable heavy chain (V H ) a polypeptide comprising: V shown in SEQ ID NO: 305 H V of H CDR1, V H CDR2, and V H The variable heavy chain (V H ) polypeptides, and Variable light chain (V L ) a polypeptide comprising: V shown in SEQ ID NO: 309 L V of L CDR1, V L CDR2, and V L A variable light chain (V L ) polypeptide; Variable heavy chain (V H ) a polypeptide comprising: V shown in SEQ ID NO: 313 H V of H CDR1, V H CDR2, and V H The variable heavy chain (V H ) polypeptides, and Variable light chain (V L ) a polypeptide comprising: V shown in SEQ ID NO: 317 L V of L CDR1, V L CDR2, and V L A variable light chain (V L ) polypeptide; Variable heavy chain (V H ) a polypeptide comprising: V shown in SEQ ID NO: 321 H V of H CDR1, V H CDR2, and V H The variable heavy chain (V H ) polypeptides, and Variable light chain (V L ) a polypeptide comprising: V shown in SEQ ID NO: 325 L V of L CDR1, V L CDR2, and V L A variable light chain (V L ) polypeptide; Variable heavy chain (V H ) a polypeptide comprising: V shown in SEQ ID NO: 329 H V of H CDR1, V H CDR2, and V H The variable heavy chain (V H ) polypeptides, and Variable light chain (V L ) a polypeptide comprising: V shown in SEQ ID NO: 333 L V of L CDR1, V L CDR2, and V L A variable light chain (V L ) polypeptide; Variable heavy chain (V H ) a polypeptide comprising: V shown in SEQ ID NO: 337 H V of H CDR1, V H CDR2, and V H The variable heavy chain (V H ) polypeptides, and Variable light chain (V L ) a polypeptide comprising: V shown in SEQ ID NO: 341 L V of L CDR1, V L CDR2, and V L A variable light chain (V L ) polypeptide; Variable heavy chain (V H ) a polypeptide comprising: V shown in SEQ ID NO: 353 H V of H CDR1, V H CDR2, and V H The variable heavy chain (V H ) polypeptides, and Variable light chain (V L ) a polypeptide comprising: V shown in SEQ ID NO: 357 L V of L CDR1, V L CDR2, and V L A variable light chain (V L ) polypeptide; Variable heavy chain (V H ) a polypeptide comprising: V shown in SEQ ID NO: 361 H V of H CDR1, V H CDR2, and V H The variable heavy chain (V H ) polypeptides, and Variable light chain (V L ) a polypeptide comprising: V shown in SEQ ID NO: 365 L V of L CDR1, V L CDR2, and V L A variable light chain (V L ) polypeptide; Variable heavy chain (V H ) a polypeptide comprising: V shown in SEQ ID NO: 369 H V of H CDR1, V H CDR2, and V H The variable heavy chain (V H ) polypeptides, and Variable light chain (V L ) a polypeptide comprising: V shown in SEQ ID NO: 373 L V of L CDR1, V L CDR2, and V L A variable light chain (V L ) polypeptide; Variable heavy chain (V H ) a polypeptide comprising: V shown in SEQ ID NO: 377 H V of H CDR1, V H CDR2, and V H The variable heavy chain (V H ) polypeptides, and Variable light chain (V L ) a polypeptide comprising: V shown in SEQ ID NO: 381 L V of L CDR1, V L CDR2, and V L A variable light chain (V L ) polypeptide; Variable heavy chain (V H ) a polypeptide comprising: V shown in SEQ ID NO: 385 H V of H CDR1, V H CDR2, and V H The variable heavy chain (V H ) polypeptides, and Variable light chain (V L ) a polypeptide comprising: V shown in SEQ ID NO: 389 L V of L CDR1, V L CDR2, and V L A variable light chain (V L ) polypeptide; Variable heavy chain (V H ) a polypeptide comprising: V shown in SEQ ID NO: 393 H V of H CDR1, V H CDR2, and V H The variable heavy chain (V H ) polypeptides, and Variable light chain (V L ) a polypeptide comprising: V shown in SEQ ID NO: 397 L V of L CDR1, V L CDR2, and V L A variable light chain (V L ) polypeptide; Variable heavy chain (V H ) a polypeptide comprising: V shown in SEQ ID NO: 401 H V of H CDR1, V H CDR2, and V H The variable heavy chain (V H ) polypeptides, and Variable light chain (V L ) a polypeptide comprising: V shown in SEQ ID NO: 405 L V of L CDR1, V L CDR2, and V L A variable light chain (V L ) polypeptide; Variable heavy chain (V H ) a polypeptide comprising: V shown in SEQ ID NO: 409 H V of H CDR1, V H CDR2, and V H The variable heavy chain (V H ) polypeptides, and Variable light chain (V L ) a polypeptide comprising: V shown in SEQ ID NO: 413 L V of L CDR1, V L CDR2, and V L A variable light chain (V L ) polypeptide; Variable heavy chain (V H ) a polypeptide comprising: V shown in SEQ ID NO: 417 H V of H CDR1, V H CDR2, and V H The variable heavy chain (V H ) polypeptides, and Variable light chain (V L ) a polypeptide comprising: V shown in SEQ ID NO: 421 L V of L CDR1, V L CDR2, and V L A variable light chain (V L ) polypeptide; Variable heavy chain (V H ) a polypeptide comprising: V shown in SEQ ID NO: 433 H V of H CDR1, V H CDR2, and V H The variable heavy chain (V H ) polypeptides, and Variable light chain (V L ) a polypeptide comprising: V shown in SEQ ID NO: 437 L V of L CDR1, V L CDR2, and V L A variable light chain (V L ) polypeptide; Variable heavy chain (V H ) a polypeptide comprising: V shown in SEQ ID NO: 441 H V of H CDR1, V H CDR2, and V H The variable heavy chain (V H ) polypeptides, and Variable light chain (V L ) a polypeptide comprising: V shown in SEQ ID NO: 445 L V of L CDR1, V L CDR2, and V L A variable light chain (V L ) polypeptide; Variable heavy chain (V H ) a polypeptide comprising: V shown in SEQ ID NO: 449 H V of H CDR1, V H CDR2, and V H The variable heavy chain (V H ) polypeptides, and Variable light chain (V L ) a polypeptide comprising: V shown in SEQ ID NO: 453 L V of L CDR1, V L CDR2, and V L A variable light chain (V L ) polypeptide; Variable heavy chain (V H ) a polypeptide comprising: V shown in SEQ ID NO: 457 H V of H CDR1, V H CDR2, and V H The variable heavy chain (V H ) polypeptides, and Variable light chain (V L ) a polypeptide comprising: V shown in SEQ ID NO: 461 L V of L CDR1, V L CDR2, and V L A variable light chain (V L ) polypeptide; or Variable heavy chain (V H ) a polypeptide comprising: V shown in SEQ ID NO: 465 H V of H CDR1, V H CDR2, and V H The variable heavy chain (V H ) polypeptides, and Variable light chain (V L ) a polypeptide comprising: V shown in SEQ ID NO: 469 L V of L CDR1, V L CDR2, and V L A variable light chain (V L ) polypeptide.
2. A variable heavy chain (V) comprising an amino acid sequence having 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, or 100% identity to the amino acid sequence set forth in SEQ ID NO:
209. H ) a polypeptide; A variable light chain (V) comprising an amino acid sequence having 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, or 100% identity to the amino acid sequence set forth in SEQ ID NO:
213. L ) polypeptide; a variable heavy chain (VH) polypeptide comprising an amino acid sequence having 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, or 100% identity to the amino acid sequence set forth in SEQ ID NO:425; a variable light chain (VL) polypeptide comprising an amino acid sequence having 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, or 100% identity to the amino acid sequence set forth in SEQ ID NO:429; a variable heavy chain (VH) polypeptide comprising an amino acid sequence having 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, or 100% identity to the amino acid sequence set forth in SEQ ID NO: 121; a variable light chain (VL) polypeptide comprising an amino acid sequence having 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, or 100% identity to the amino acid sequence set forth in SEQ ID NO: 125; a variable heavy chain (VH) polypeptide comprising an amino acid sequence having 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, or 100% identity to the amino acid sequence set forth in SEQ ID NO:345; a variable light chain (VL) polypeptide comprising an amino acid sequence having 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, or 100% identity to the amino acid sequence set forth in SEQ ID NO:349; or a variable heavy chain (VH) polypeptide comprising an amino acid sequence having 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, or 100% identity to the amino acid sequence set forth in SEQ ID NO:97; A variable light chain (VL) polypeptide comprising an amino acid sequence having 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, or 100% identity to the amino acid sequence set forth in SEQ ID NO:
101. The antibody of claim 1, comprising:
3. The antibody of claim 1 or 2, which is selected from the group consisting of IgG, Fv, single-chain antibody, scFv, Fab, F(ab')2, or Fab'.
4. The antibody of any one of claims 1 to 3, which is a Fab or single-chain antibody.
5. A bispecific antibody comprising a first antigen-binding domain that specifically binds to SARS-CoV-2, wherein the first antigen-binding domain is a V antigen-binding domain as defined in claim 1 or 2. H Polypeptides and V L The antibody according to any one of claims 1 to 4, comprising a pair with a polypeptide.
6. A fusion protein comprising: A fusion protein comprising a chain of the antibody of claim 1 or 2 fused to a heterologous sequence of amino acids.
7. A conjugate comprising: The antibody according to claim 1 or 2 or the fusion protein according to claim 6, a drug conjugated to said antibody or said fusion protein.
8. The conjugate of claim 7 , wherein the agent is a detectable label or a half-life extending moiety.
9. The variable heavy chain (V) of the antibody according to any one of claims 1 to 4 H ) polypeptide, variable light chain (V L ) a nucleic acid encoding a polypeptide, or both.
10. The variable heavy chain (V) of the antibody according to any one of claims 1 to 4 H a first nucleic acid encoding a polypeptide; The variable light chain (V L a second nucleic acid encoding the polypeptide; or A nucleic acid encoding the variable heavy chain (V H ) and variable light chain (V L ) polypeptides of the antibody of any one of claims 1 to 4, cell.
11. 11. A method of producing an antibody according to any one of claims 1 to 4, comprising culturing a cell according to claim 10 under conditions suitable for said cell to express said antibody, wherein said antibody is produced.
12. 1. A pharmaceutical composition comprising: The antibody according to any one of claims 1 to 4, and a pharmaceutically acceptable carrier.
13. A composition comprising the antibody of any one of claims 1 to 4, the fusion protein of claim 6, or the conjugate of claim 7, A composition for use in a method comprising administering a therapeutically effective amount of said antibody, fusion protein, or conjugate to an individual in need thereof.
14. 14. The composition of claim 13, wherein the individual has a SARS-CoV-2 infection and the method is effective in neutralizing the SARS-CoV-2 infection in the individual.
15. The composition of claim 13, wherein the individual does not have a SARS-CoV-2 infection, and optionally the individual is immunocompromised.
